Search Result
Results for "
type
" in MCE Product Catalog:
1553
Inhibitors & Agonists
31
Biochemical Assay Reagents
101
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
-
- HY-150044
-
|
Type II topoisomerase inhibitor 1
|
DNA/RNA Synthesis
Topoisomerase
Bacterial
|
Infection
|
|
Type II topoisomerase inhibitor 1 is a potent and selective E. coli DNA gyrase inhibitor (IC50: 1.7 nM), and forms hydrogen bonds with Asp73 residue. Type II topoisomerase inhibitor 1 inhibits topoisomerase IV activity (IC50: 0.98 μM). Type II topoisomerase inhibitor 1 can be used in the research of antibacterial area.
|
-
- HY-146807
-
|
Type II TRK inhibitor 1
|
Trk Receptor
|
Cancer
|
|
Type II TRK inhibitor 1 is a potent TRK inhibitor, which inhibits various TRK fusion protein variants and wild type. Type II TRK inhibitor 1 exhibits antiproliferative activity against Ba/F3 cells harboring CD74-TRKA G667C and ETV6-TRKC G696C fusion proteins with IC50s of 6 nM and 1.7 nM, respectively.
|
-
- HY-146356
-
-
- HY-N10510
-
|
Blood group A antigen tetraose type 5
A-Tetrasaccharide
|
Others
|
Others
|
|
Blood group A antigen tetraose type 5 (A-Tetrasaccharide) is a tetrasaccharide and a blood group specific oligosaccharide, inhibits the binding of anti-A antibody to blood group A substance. Blood group A antigen tetraose type 5 can be isolated from polar bear milk samples.
|
-
- HY-P1815
-
-
- HY-100310
-
-
- HY-114132
-
|
Botulinum toxin type B
|
Histone Acetyltransferase
|
Neurological Disease
|
|
Botulinum toxin type B is an antigen-specific botulinum toxin. Botulinum toxin type B can be used in the study of neck dystonia. Botulinum toxin is an exotoxin produced by the anaerobic bacterium Clostridium botulinum. Botulinum toxin works by inhibiting the release of Acetylcholine from the neuromuscular junction, resulting in relaxation paralysis or muscle weakening of the injected muscle.
|
-
- HY-10035
-
|
TTA-P2
T-type calcium channel inhibitor
|
Calcium Channel
|
Neurological Disease
|
|
TTA-P2 (T-Type calcium channel inhibitor) is a potent inhibitor of T-Type calcium channel. TTA-P2 penetrates well the CNS and blocks the native T-type currents in deep cerebellar nuclear neurons, the window current is completely abolished both for wild-type and mutant Cav3.1 channels. TTA-P2 has the potential for the research of neurology disease.
|
-
- HY-A0104J
-
|
HPMC (Type II,Viscosity:5mPa.s)
Hypromellose (type II,Viscosity:5mPa.s); (Hydroxypropyl)methyl cellulose (type II,Viscosity:5mPa.s); Celacol HPM 5000 (type II,Viscosity:5mPa.s)
|
Biochemical Assay Reagents
|
Others
|
|
HPMC (Hypromellose) (Type II,Viscosity:5mPa.s) is a hydrophilic, non-ionic cellulose ether used to form swellable-soluble matrices. HPMC (Type II,Viscosity:5mPa.s) is widely used in agent formulations due to its biocompatibility, uncharged nature, solubility in water and thermoplastic behavior.
|
-
- HY-W127324
-
-
- HY-A0104B
-
|
HPMC (Type I,Viscosity:100mPa.s)
Hypromellose (type I,Viscosity:100mPa.s); (Hydroxypropyl)methyl cellulose (type I,Viscosity:100mPa.s); Celacol HPM 5000 (type I,Viscosity:100mPa.s)
|
Biochemical Assay Reagents
|
Others
|
|
Hypromellose (Type I,Viscosity:100mPa.s) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
|
-
- HY-A0104H
-
|
HPMC (Type II,Viscosity:15000mPa.s)
Hypromellose (type II,Viscosity:15000mPa.s); (Hydroxypropyl)methyl cellulose (type II,Viscosity:15000mPa.s); Celacol HPM 5000 (type II,Viscosity:15000mPa.s)
|
Biochemical Assay Reagents
|
Others
|
|
Hypromellose (Type II,Viscosity:15000mPa.s) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
|
-
- HY-A0104E
-
|
HPMC (Type II,Viscosity:100mPa.s)
Hypromellose (type II,Viscosity:100mPa.s); (Hydroxypropyl)methyl cellulose (type II,Viscosity:100mPa.s); Celacol HPM 5000 (type II,Viscosity:100mPa.s)
|
Biochemical Assay Reagents
|
Others
|
|
Hypromellose (Type II,Viscosity:100mPa.s) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
|
-
- HY-A0104D
-
|
HPMC (Type I,Viscosity:4000mPa.s)
Hypromellose (type I,Viscosity:4000mPa.s); (Hydroxypropyl)methyl cellulose (type I,Viscosity:4000mPa.s); Celacol HPM 5000 (type I,Viscosity:4000mPa.s)
|
Biochemical Assay Reagents
|
Others
|
|
Hydroxypropylmethylcellulose (Type I,Viscosity:4000mPa.s) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
|
-
- HY-A0104C
-
|
HPMC (Type I,Viscosity:400mPa.s)
Hypromellose (type I,Viscosity:400mPa.s); (Hydroxypropyl)methyl cellulose (type I,Viscosity:400mPa.s); Celacol HPM 5000 (type I,Viscosity:400mPa.s)
|
Biochemical Assay Reagents
|
Others
|
|
Hydroxypropylmethylcellulose (Type I,Viscosity:400mPa.s) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
|
-
- HY-A0104G
-
|
HPMC (Type II,Viscosity:4000mPa.s)
Hypromellose (type II,Viscosity:4000mPa.s); (Hydroxypropyl)methyl cellulose (type II,Viscosity:4000mPa.s); Celacol HPM 5000 (type II,Viscosity:4000mPa.s)
|
Biochemical Assay Reagents
|
Others
|
|
Hypromellose (Type II,Viscosity:4000mPa.s) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
|
-
- HY-A0104I
-
|
HPMC (Type II,Viscosity:100000mPa.s)
Hypromellose (type II,Viscosity:100000mPa.s); (Hydroxypropyl)methyl cellulose (type II,Viscosity:100000mPa.s); Celacol HPM 5000 (type II,Viscosity:100000mPa.s)
|
Biochemical Assay Reagents
|
Others
|
|
Hydroxypropylmethylcellulose (Type II,Viscosity:100000mPa.s) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
|
-
- HY-A0104A
-
|
HPMC (Type I,Viscosity:30mPa.s)
Hypromellose (type I,Viscosity:30mPa.s); (Hydroxypropyl)methyl cellulose (type I,Viscosity:30mPa.s); Celacol HPM 5000 (type I,Viscosity:30mPa.s)
|
Biochemical Assay Reagents
|
Others
|
|
Hydroxypropylmethylcellulose (Type I,Viscosity:30mPa.s) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
|
-
- HY-A0104F
-
|
HPMC (Type II,Viscosity:400mPa.s)
Hypromellose (type II,Viscosity:400mPa.s); (Hydroxypropyl)methyl cellulose (type II,Viscosity:400mPa.s); Celacol HPM 5000 (type II,Viscosity:400mPa.s)
|
Biochemical Assay Reagents
|
Others
|
|
Hypromellose (Type II,Viscosity:400mPa.s) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
|
-
- HY-117178
-
-
- HY-P3674
-
|
LH-RH (7-10)
|
GnRH Receptor
|
Endocrinology
|
|
LH-RH (7-10) is a tetrapeptide, one of major degradation products of luteinising-hormone releasing hormone (LHRH) via pituitary and hypothalamus. LH-RH (7-10) produced in macrophages, type I-like and type II pneumocytes.
|
-
- HY-147708
-
|
T-Type calcium channel inhibitor 2
|
Calcium Channel
|
Cancer
|
|
T-Type calcium channel inhibitor 2 (compound 6g) is a potent T-type calcium channel inhibitor with IC50s of 31.0, 83.1, 69.3 µM for Cav3.1 (α1G), Cav3.2 (α1H), Cav3.3 (α1I) (α1H), respectively. T-Type calcium channel inhibitor 2 shows cytotoxicity for A549, HCT-116 cells with IC50s of 5.0, 6.4 µM, respectively.
|
-
- HY-P2972
-
-
- HY-P3495
-
-
- HY-124803
-
-
- HY-19904
-
|
Adomeglivant
LY2409021
|
GCGR
|
Metabolic Disease
|
|
Adomeglivant (LY2409021) is a potent, selective glucagon receptor (GluR) allosteric antagonist. Adomeglivant is widely used in the research for type 2 diabetes mellitus.
|
-
- HY-129131
-
-
- HY-P2466
-
-
- HY-P1160
-
|
Bay 55-9837
|
GCGR
|
Metabolic Disease
|
|
Bay 55-9837 is a potent and highly selective agonist of VPAC2, with a Kd of 0.65 nM. Bay 55-9837 may be a useful therapy for the research of type 2 diabetes.
|
-
- HY-122028
-
|
HSD-016
|
11β-HSD
|
Metabolic Disease
|
|
HSD-016 is a potent, selective and orally active 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor with IC50 values of 11, 1 and 8 nM against human, mouse and rat 11β-HSD1, respectively. HSD-016 can be used for type 2 diabetes research.
|
-
- HY-P1160A
-
|
Bay 55-9837 TFA
|
GCGR
|
Metabolic Disease
|
|
Bay 55-9837 TFA is a potent and highly selective agonist of VPAC2, with a Kd of 0.65 nM. Bay 55-9837 TFA may be a useful therapy for the research of type 2 diabetes.
|
-
- HY-P9910
-
|
Obinutuzumab
GA101; Anti-Human CD20 type II, Humanized Antibody
|
CD20
|
Cancer
|
|
Obinutuzumab (GA101) a novel glycoengineered Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin lymphoma.
|
-
- HY-13218
-
|
Acitazanolast
WP-871
|
Others
|
Inflammation/Immunology
|
|
Acitazanolast is an orally active antiallergic agent, can inhibit histamine release. Acitazanolast can be used in study of type I anaphylaxis (immediate) caused by IgE antibodies.
|
-
- HY-P99211
-
|
Otelixizumab
ChAglyCD3; TRX 4
|
CD3
|
Metabolic Disease
|
|
Otelixizumab (ChAglyCD3) is an anti-human CD3 monoclonal antibody and can be used for the research of type 1 diabetes.
|
-
- HY-N8136
-
|
Volvalerenic acid A
|
Others
|
Others
|
|
Volvalerenic acid A is a germacrane-type sesquiterpenoid that can be found in the roots of Valeriana officinalis var. latifolia.
|
-
- HY-P99383
-
|
Volagidemab
REMD-477; AMG-477
|
GCGR
|
Metabolic Disease
|
|
Volagidemab is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D).
|
-
- HY-13635A
-
|
Finasteride acetate
MK-906 acetate
|
5 alpha Reductase
|
Cancer
|
|
Finasteride (MK-906) acetate is a potent and competitive 5α-reductase inhibitor, with an IC50 of 4.2 nM for type II 5α-reductase. Finasteride acetate has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride acetate can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia.
|
-
- HY-13635
-
|
Finasteride
MK-906
|
5 alpha Reductase
|
Cancer
|
|
Finasteride (MK-906) is a potent and competitive 5α-reductase inhibitor, with an IC50 of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia.
|
-
- HY-109030
-
-
- HY-W010452
-
-
- HY-113378
-
-
- HY-108743
-
|
Insulin degludec
|
Insulin Receptor
|
Endocrinology
|
|
Insulin degludec is an ultra-long-acting form of insulin used for the research of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC50 value of 19.59 nM for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes.
|
-
- HY-144717
-
|
PTP1B-IN-18
|
Phosphatase
|
Metabolic Disease
|
|
PTP1B-IN-18 is an orally active complete mixed type protein tyrosine phosphatase 1B (PTP1B) inhibitor with a Ki of 35.2 μM. PTP1B-IN-18 can be used for type 2 diabetes research.
|
-
- HY-17020A
-
-
- HY-17020
-
-
- HY-145985
-
|
CBR-3465
|
Bacterial
|
Infection
|
|
CBR-3465 is a mycobacterium tuberculosis (Mtb) type II NADH dehydrogenase inhibitor, with the MIC of 0.16 μM against Mtb.
|
-
- HY-145986
-
|
CBR-6672
|
Bacterial
|
Infection
|
|
CBR-6672 is a mycobacterium tuberculosis (Mtb) type II NADH dehydrogenase inhibitor, with the MIC of 0.14 μM against Mtb.
|
-
- HY-P5161A
-
-
- HY-147423
-
-
- HY-144377
-
-
- HY-N10606
-
|
Uvagrandol
|
Glucosidase
|
Metabolic Disease
|
|
Uvagrandol potently inhibits α-glucosidase and porcine lipase (IC50: 15.2 μM, 11.2 μM respectively). Uvagrandol can be used in the research of Type 2 diabetes and obesity.
|
-
- HY-147318
-
|
PBENZ-DBRMD
|
Apoptosis
|
Cancer
|
|
PBENZ-DBRMD is a potent iodothyronine deiodinase type 3 (DIO3) inhibitor. PBENZ-DBRMD has anti-proliferative activity and induces apoaptosis. PBENZ-DBRMD can be used for cancer research.
|
-
- HY-N6580
-
|
Ginsenoside Rg4
|
Bacterial
|
Infection
Metabolic Disease
Inflammation/Immunology
|
|
Ginsenoside Rg4 is a major protopanaxatriol type ginsenoside isolated from the leaves of Panax ginseng C. A. Meyer. The protopanaxatriol type ginsenosides (such as Ginsenoside Rg4) exhibits various biological activities including anti-septic, anti-diabetic, wound healing, immune-stimulatory, and anti-antioxidant activity.
|
-
- HY-10449
-
|
Luseogliflozin
TS 071
|
SGLT
|
Metabolic Disease
|
|
Luseogliflozin (TS 071) is a potent, selective, orally active sodium-dependent glucose cotransporter (SGLT) 2 inhibitor, with an IC50 of 2.26 nM, about 1765-fold selectivity over SGLT1 (IC50, 3990 nM). Luseogliflozin has the protential for researching type 2 diabetes.
|
-
- HY-108196
-
|
PTP1B-IN-15
|
Phosphatase
|
Endocrinology
|
|
PTP1B-IN-15 is a potent and selective inhibitor of protein tyrosine phosphatase 1B (PTP1B). PTP1B-IN-15 has the potential for the research of type II diabetes and obesity.
|
-
- HY-13418A
-
|
Dorsomorphin
Compound C; BML-275
|
AMPK
TGF-β Receptor
Autophagy
|
Cancer
|
|
Dorsomorphin (Compound C) is a selective and ATP-competitive AMPK inhibitor (Ki=109 nM in the absence of AMP). Dorsomorphin (BML-275) selectively inhibits BMP type I receptors ALK2, ALK3, and ALK6. Dorsomorphin induces autophagy.
|
-
- HY-148247
-
|
BI-2081
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
BI-2081 is a GPR40 (FFAR1) partial agonist (EC50: 4 nM). BI-2081 induces glucose depending insulin secretion and reduces the plasma glucose concentration. BI-2081 can be used in the research of metabolic diseases, in particular diabetes type 2.
|
-
- HY-108524
-
-
- HY-12066
-
-
- HY-13418
-
|
Dorsomorphin dihydrochloride
Compound C dihydrochloride; BML-275 dihydrochloride
|
AMPK
TGF-β Receptor
Autophagy
|
Cancer
|
|
Dorsomorphin (Compound C) dihydrochloride is a potent, selective and ATP-competitive AMPK inhibitor, with a Ki of 109 nM. Dorsomorphin dihydrochloride inhibits BMP pathway by targeting the type I receptors ALK2, ALK3, and ALK6. Dorsomorphin dihydrochloride induces autophagy.
|
-
- HY-146262
-
|
LDC0496
|
EGFR
|
Cancer
|
|
LDC0496 is a potent and selective EGFR inhibitor. LDC0496 possesses intense inhibitory potency toward EGFR and Her2 exon20 insertion mutations, as well as selectivity over wild type EGFR and within the kinome.
|
-
- HY-148157
-
|
Amylocaine
|
Others
|
Others
|
|
Amylocaine is a local anaesthetic of the ester type. Amylocaine can cause reversible insensitization near the area where it is administered. Amylocaine is used mostly in spinal anesthesia.
|
-
- HY-134315
-
|
8-Nitroguanosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
8-Nitroguanosine is a guanosine analogue. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
|
-
- HY-W010452S1
-
-
- HY-W010452S2
-
-
- HY-154332
-
|
8-(Phenylmethoxy)guanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-(Phenylmethoxy)guanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
|
-
- HY-137406
-
|
1,2'-O-Dimethylguanosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
1,2'-O-Dimethylguanosine is a guanosine analogue. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
|
-
- HY-154506
-
|
N2-Phenoxyacetylguanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N2-Phenoxyacetylguanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
|
-
- HY-154361
-
|
TLR7 agonist 13
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
TLR7 agonist 13 is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
|
-
- HY-152430
-
|
8-Hydroxymethyl guanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Hydroxymethyl guanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
|
-
- HY-152610
-
|
3′-C-Methylguanosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3′-C-Methylguanosine is a guanosine analogue. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
|
-
- HY-152517
-
|
8-(Methylthio)guanosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
8-(Methylthio)guanosine is a guanosine analogue. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
|
-
- HY-152652
-
|
5’(R)-C-Methylguanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’(R)-C-Methylguanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
|
-
- HY-152478
-
|
3’-β-C-Ethynylguanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-β-C-Ethynylguanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
|
-
- HY-147987
-
-
- HY-144287
-
-
- HY-154111
-
|
8-(N-Boc-aminomethyl)guanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-(N-Boc-aminomethyl)guanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
|
-
- HY-152673
-
|
9-(β-D-Xylofuranosyl)guanine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
9-(β-D-Xylofuranosyl)guanine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
|
-
- HY-152742
-
|
8-(N,N-Dimethylaminomethyl)guanosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
8-(N,N-Dimethylaminomethyl)guanosine is a guanosine analogue. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
|
-
- HY-N2168
-
|
Pinoresinol 4-O-β-D-glucopyranoside
(+)-Pinoresinol 4-O-β-D-glucopyranoside
|
Others
|
Cardiovascular Disease
|
|
Pinoresinol 4-O-β-D-glucopyranoside ((+)-Pinoresinol 4-O-β-D-glucopyranoside) is the major active furofuran type lignans in Fructus Forsythiae. Pinoresinol 4-O-β-D-glucopyranoside shows antioxidant, blood pressure reducing, and cyclic adenosine monophosphate (cAMP) phosphodiesterase inhibitory effects.
|
-
- HY-113653
-
|
GSK2041706A
GSK706
|
GPR119
|
Metabolic Disease
|
|
GSK2041706A (GSK706) is a potent G protein-coupled receptor 119 (GPR119) agonist. GSK2041706A can be used for the research of type 2 diabetes.
|
-
- HY-141623
-
|
SRI-37330 hydrochloride
|
Others
|
Metabolic Disease
|
|
SRI-37330 hydrochloride is an orally bioavailable thioredoxin-interacting protein (TXNIP) inhibitor. SRI-37330 hydrochloride inhibits glucagon secretion and function, reduces hepatic glucose production and reverses hepatic steatosis. SRI-37330 hydrochloride can be used for type 2 diabetes research.
|
-
- HY-152993
-
|
2′-Deoxy-N-(2-furanylmethyl)guanosine
|
Others
|
Others
|
|
2′-Deoxy-N-(2-furanylmethyl)guanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
|
-
- HY-128139
-
|
2'-C-Methylguanosine
2'-C-beta-Methylguanosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2'-C-Methylguanosine (2'-C-beta-Methylguanosine) is a guanosine analogue. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
|
-
- HY-152991
-
|
6-Deoxo-8-oxo-3’-deoxy-guanosine
|
Others
|
Others
|
|
2′-Deoxy-N-(2-furanylmethyl)guanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
|
-
- HY-152493
-
|
3’-O-(2-Methoxyethyl)guanosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-O-(2-Methoxyethyl)guanosine is a guanosine analogue. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
|
-
- HY-108904
-
|
Urokinase (peptidolytic)
Urokinase-type plasminogen activator; Uronase; Win 22005; Win-Kinase
|
Ser/Thr Protease
|
Cancer
Cardiovascular Disease
|
|
Urokinase peptidolytic (Urokinase-type plasminogen activator) is a serine protease, an inactive form (zymogen) of the serine protease plasminogen. Activation of plasmin triggers a proteolytic cascade reaction, which in turn participates in thrombolysis or extracellular matrix degradation, implicated in vascular disease and cancer-related research.
|
-
- HY-P1124
-
-
- HY-154482
-
|
N2-iso-Butyroyl-3’-O-methylguanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N2-iso-Butyroyl-3’-O-methylguanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
|
-
- HY-154448
-
|
3,5-Bis-O-(2,4-dichlorobenzyl)guanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3,5-Bis-O-(2,4-dichlorobenzyl)guanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
|
-
- HY-154336
-
|
N-[2-[4-(1-Methylethyl)phenoxy]acetyl]guanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N-[2-[4-(1-Methylethyl)phenoxy]acetyl]guanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
|
-
- HY-154349
-
|
N2-iso-Butyroyl-2’-O-propargylguanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N2-iso-Butyroyl-2’-O-propargylguanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
|
-
- HY-154549
-
|
3’-O-MOE-G(iBu)-2’-phosphoramidite
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-MOE-G(iBu)-2’-phosphoramidite is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
|
-
- HY-152797
-
|
N4-Desmethyl-N5-Methyl wyosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N4-Desmethyl-N5-Methyl wyosine is a guanosine analogue. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
|
-
- HY-154484
-
|
3’-O-Me-G(iBu)-2’-phosphoramidite
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-Me-G(iBu)-2’-phosphoramidite is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
|
-
- HY-112603A
-
|
AP5 sodium
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
AP5 sodium is a potent, orall active, and selective GPR40 receptor agonist with a positive allosteric modulation of endogenous ligand (AgoPAM). AP5 sodium demonstrates rat and human inositol monophosphate (IP1) EC50 values of 0.49 nM and 0.8 nM against the GPR40 receptor, respectively. AP5 sodium has the potential for type II diabetes research.
|
-
- HY-152684
-
|
2′-O-2-Propyn-1-ylguanosine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2′-O-2-Propyn-1-ylguanosine is a guanosine analogue. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
|
-
- HY-112603
-
|
AP5
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
AP5 is a potent, orlly active, and selective GPR40 receptor agonist with a positive allosteric modulation of endogenous ligand (AgoPAM). AP5 demonstrates rat and human inositol monophosphate (IP1) EC50 values of 0.49 nM and 0.8 nM against the GPR40 receptor, respectively. AP5 has the potential for type II diabetes research.
|
-
- HY-N4143
-
|
Cyanidin 3-arabinoside
|
Phosphatase
|
Metabolic Disease
|
|
Cyanidin 3-arabinoside is a selective and reversible protein tyrosine phosphatase 1B (PTP1B) inhibitor, with an IC50 of 8.91 μM. Cyanidin 3-arabinoside is potential for the research of type 2 diabetes.
|
-
- HY-P0120
-
|
Dulaglutide
LY2189265
|
GCGR
|
Metabolic Disease
|
|
Dulaglutide (LY2189265) is a glucagon-like peptide-1 (GLP-1) receptor agonist. Dulaglutide can be uesd for the research of type 2 diabetes (T2D) .
|
-
- HY-152988
-
|
N2-iso-Butyroyl-7'-O-DMT-morpholinoguanine
|
Others
|
Others
|
|
N2-iso-Butyroyl-7'-O-DMT-morpholinoguanine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
|
-
- HY-152992
-
|
7-Cyano-7-deaza-2'-deoxy guanosine
|
Others
|
Others
|
|
7-Cyano-7-deaza-2'-deoxy guanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
|
-
- HY-154547
-
|
N2-iso-Butyroyl-3’-O-(methoxyethyl)guanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N2-iso-Butyroyl-3’-O-(methoxyethyl)guanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
|
-
- HY-147254
-
|
Cadisegliatin
TTP-399
|
Glucokinase
|
Metabolic Disease
|
|
Cadisegliatin (TTP-399) is a potential, orally active liver-selective glucokinase (GK) activator. Cadisegliatin has antihyperglycaemic activity. Cadisegliatin can be used for the research of type 2 diabetes.
|
-
- HY-N8669
-
|
Curcolonol
|
LIM Kinase (LIMK)
|
Cancer
|
|
Curcolonol is a furan type sesquiterpene. Curcolonol can be isolated from several medical herbs. Curcolonol has inhibitory activity for LIM kinase 1. Curcolonol can be used for the research of breast cancer.
|
-
- HY-102026
-
-
- HY-B0682
-
|
Mitiglinide
KAD-1229 free acid anhydrous; S21403 free acid anhydrous
|
Potassium Channel
|
Metabolic Disease
|
|
Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K + (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes.
|
-
- HY-152545
-
|
N1,N2-Dimethyl-2’-O-methylguanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1,N2-Dimethyl-2’-O-methylguanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
|
-
- HY-154350
-
|
5'-O-DMT-N2-isobutyryl-2'-O-propargylguanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5'-O-DMT-N2-isobutyryl-2'-O-propargylguanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
|
-
- HY-154606
-
|
2'-F-2'-ara-N2-ibu-dG Phosphoramidite
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2'-F-2'-ara-N2-ibu-dG Phosphoramidite is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
|
-
- HY-W073825
-
|
N2-iso-Butyryl-2'-O-(2-methoxyethyl)guanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N2-iso-Butyryl-2'-O-(2-methoxyethyl)guanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
|
-
- HY-116894
-
|
Rotundifuran
|
Apoptosis
|
Cancer
|
|
Rotundifuran, a labdane type diterpene, is isolated from Vitex rotundifolia. Rotundifuran can inhibit the cell cycle progression and induce apoptosis in human myeloid leukaemia cells.
|
-
- HY-N7581
-
|
23-Acetylshengmanol 3-O-β-D-xylopyranoside
Acetylshengmanol xyloside
|
Others
|
Others
|
|
23-Acetylshengmanol 3-O-β-D-xylopyranoside (Acetylshengmanol xyloside) is a 9,19-cyclolanostane type triterpenoid. 23-Acetylshengmanol 3-O-β-D-xylopyranoside can be isolated from the roots of Actaea pachypoda.
|
-
- HY-154548
-
-
- HY-154507
-
-
- HY-B0254
-
|
Glipizide
CP 28720; K 4024
|
Potassium Channel
|
Metabolic Disease
|
|
Glipizide (CP 2872; K 4024) a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2 diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium (KATP) channels among β cells of pancreatic islets of Langerhans.
|
-
- HY-103195
-
|
NKY80
|
Adenylate Cyclase
|
Metabolic Disease
|
|
NKY80 is a potent, selective and non-competitive adenylyl cyclase (AC) type V isoform inhibitor with IC50s of 8.3 µM, 132 µM and 1.7 mM for type V, III and II, respectively. NKY80 is a non-nucleoside quinazolinone and regulates the AC catalytic activity in heart and lung tissues.
|
-
- HY-B0682A
-
|
Mitiglinide calcium hydrate
KAD-1229; S-21403
|
Potassium Channel
|
Metabolic Disease
|
|
Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K + (KATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes.
|
-
- HY-152547
-
-
- HY-154464
-
-
- HY-P2501
-
|
Amylin (8-37), human
|
Amylin Receptor
|
Metabolic Disease
|
|
Amylin (8-37), human is a fragment of human Amylin. Amylin (8-37), human has direct vasodilator effects in the isolated mesenteric resistance artery of the rat. Human Amylin is a small hormone secreted by pancreatic β-cells that forms aggregates under insulin deficiency metabolic conditions, and it constitutes a pathological hallmark of type II diabetes mellitus.
|
-
- HY-17398
-
|
Mitiglinide calcium
KAD-1229 anhydrous; S21403 anhydrous
|
Potassium Channel
|
Metabolic Disease
|
|
Mitiglinide Calcium (KAD-1229 anhydrous), an insulinotropic agent, is an ATP-sensitive K + (KATP) channel antagonist. Mitiglinide Calcium is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium can be used for the research of type 2 diabetes.
|
-
- HY-P1131
-
|
M617
|
Neuropeptide Y Receptor
|
Cardiovascular Disease
|
|
M617 is a selective galanin receptor 1 (GAL1) agonist, with Kis of 0.23 and 5.71 nM for GAL1 and GAL2, respectively. M617, acting through its central GAL1, can promote GLUT4 expression and enhance GLUT4 content in the cardiac muscle of type 2 diabetic rats.
|
-
- HY-154351
-
-
- HY-154483
-
-
- HY-P1131A
-
|
M617 TFA
|
Neuropeptide Y Receptor
|
Cardiovascular Disease
|
|
M617 TFA is a selective galanin receptor 1 (GAL1) agonist, with Kis of 0.23 and 5.71 nM for GAL1 and GAL2, respectively. M617 TFA, acting through its central GAL1, can promote GLUT4 expression and enhance GLUT4 content in the cardiac muscle of type 2 diabetic rats.
|
-
- HY-N10648
-
|
PTP1B-IN-20
|
Phosphatase
|
Metabolic Disease
|
|
PTP1B-IN-20 is a selective inhibitor of protein tyrosine phosphatase 1B (PTP1B; IC50=1.05 μM) over the highly homologous T-cell protein tyrosine phosphatase (TCPTP; IC50=78.0 μM), which is a key target for type 2 diabetes inhibition.
|
-
- HY-147503
-
|
Vin-F03
|
Apoptosis
|
Cardiovascular Disease
|
|
Vin-F03 is a potent pancreatic β-cells protective agent with an EC50 of 0.27 µM. Vin-F03 effectively promotes β-cell survival and protects β-cells from STZ-induced apoptosis. Vin-F03 can be used for type 2 diabetes mellitus research.
|
-
- HY-147502
-
|
Vin-C01
|
Apoptosis
|
Cardiovascular Disease
|
|
Vin-C01 is a potent pancreatic β-cells protective agent with an EC50 of 0.22 µM. Vin-C01 effectively promotes β-cell survival and protects β-cells from STZ-induced apoptosis. Vin-C01 can be used for type 2 diabetes mellitus research.
|
-
- HY-N10649
-
|
PTP1B-IN-21
|
Phosphatase
|
Metabolic Disease
|
|
PTP1B-IN-21 is a selective inhibitor of protein tyrosine phosphatase 1B (PTP1B; IC50=1.56 μM) over the highly homologous T-cell protein tyrosine phosphatase (TCPTP; IC50>100 μM), which is a key target for type 2 diabetes inhibition.
|
-
- HY-124771
-
|
RH01386
|
Apoptosis
|
Metabolic Disease
|
|
RH01386 is a small molecule that can prevent endoplasmic reticulum stress (ERS)-induced β cell dysfunction and death, and inhibits proapoptotic gene expression. RH01386 restores ERS-impaired glucose-stimulated insulin secretion responses. RH01386 has the potential for type 2 diabetes treatment.
|
-
- HY-138688
-
-
- HY-135882
-
-
- HY-148072
-
|
MM3122
|
SARS-CoV
|
Infection
|
|
MM3122 is a selective type II transmembrane serine protease (TMPRSS2) inhibitor with an IC50 value of 0.34 nM. MM3122 effectively blocks TMPRSS2, thereby inhibiting the entry of SARS-CoV-2 and MERS-CoV into human cells.
|
-
- HY-147964
-
-
- HY-147965
-
-
- HY-114191B
-
-
- HY-109500
-
|
Masoprocol
meso-Nordihydroguaiaretic acid; meso-NDGA
|
Lipoxygenase
|
Metabolic Disease
|
|
Masoprocol (meso-Nordihydroguaiaretic acid) is a potent and orally active lipoxygenase inhibitor. Masoprocol shows antihyperglycemic activity. Masoprocol decreases the glucose concentration and hepatic triglyceride in vivo. Masoprocol has the potential for the research of type II diabetes.
|
-
- HY-B1245
-
|
Salsalate
Salicylsalicylic acid; Disalicylic acid
|
Reactive Oxygen Species
|
Inflammation/Immunology
|
|
Salsalate, a non-acetylated salicylate, is an effective antirheumatic agent that bypasses gastric absorption and also avoids cyclooxygenase inhibition. Salsalate has anti-inflammatory activity and reduces glucose levels, insulin resistance, and cytokine expression. Salsalate can be used in the research of type 2 diabetes.
|
-
- HY-135881
-
|
OMDM-5
|
TRP Channel
Endogenous Metabolite
|
Neurological Disease
|
|
OMDM-5 is a selective inhibitor of anandamide cellular uptake (ACU), with a Ki of 4.8 μM. OMDM-5 is also a potent vanilloid receptor type 1 (VR1, TRPV1) agonist, with an EC50 of 75 nM, and shows weakly active as cannabinoid receptor type 1 (CB1) ligand (Ki=4.9 μM).
|
-
- HY-10595
-
-
- HY-147645
-
|
FBPase-IN-2
|
FBPase
|
Metabolic Disease
|
|
FBPase-IN-2 (HS36) is a potent Fructose-1,6-bisphosphatase (FBPase) covalent inhibitor with an IC50 of 0.15 μM. FBPase-IN-2 reduces glucose production in hepatocytes. FBPase-IN-2 can be used for type 2 diabetes mellitus research.
|
-
- HY-106668
-
|
Isepamicin
Sch 21420
|
Antibiotic
Bacterial
|
Infection
|
|
Isepamicin (Sch 21420) is an aminoglycoside antibacterial. Isepamicin has better activity against strains producing type I 6'-acetyltransferase. Isepamicin’s antibacterial spectrum includes Enterobacteriaceae and staphylococci. Anaerobes, Neisseriaceae and streptococci are resistant. Isepamicin exhibits a strong concentration-dependent bactericidal effect, a long post-antibiotic effect (several hours) and induces adaptive resistance.
|
-
- HY-114191
-
-
- HY-114191A
-
-
- HY-116528
-
|
GCA-186
|
HIV
|
Infection
|
|
GCA-186 is a potent anti-HIV-1 agent. GCA-186 is highly active against both wild type and mutated HIV-1 strains with EC50s of 1, 180, 1, and 40 nM for IIIB, IIIB-R(Y181C), NL4-3 and NL4-3K103N of HIV-1 strains, respectively.
|
-
- HY-17471A
-
-
- HY-114566
-
-
- HY-152094
-
|
SRD5A1-IN-1
|
Others
|
Endocrinology
|
|
SRD5A1-IN-1 (Compound 4) is a competitive and covalent steroid 5α-reductase type 1 (SRD5A1) inhibitor with an IC50 of 1.44 µM. SRD5A1-IN-1 modulates SRD5A1 function, leading to a lower level of dihydrotestosterone (DHT) production and SRD5A1 protein suppression.
|
-
- HY-126042
-
|
(±)-Lisofylline
(±)-Lisophylline
|
Others
|
Metabolic Disease
Inflammation/Immunology
|
|
(±)-Lisofylline ((±)-Lisophylline) is the racemate of Lisofylline. Lisofylline inhibits the generation of phosphatidic acid and free fatty acids. Lisofylline also blocks the release of pro-inflammatory cytokines in oxidative tissue injury, in response to cancer chemotherapy and in experimental sepsis. Lisofylline can be used for Type 1 diabetes research.
|
-
- HY-122124
-
|
CAY10583
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
CAY10583 is a potent and selective full Leukotriene B4 receptor type 2 (BLT2) agonist. CAY10583 directly promotes keratinocyte migration in vitro and accelerates wound closure in vivo. CAY10583 is a promising pharmaceutical agent for diabetic wounds.
|
-
- HY-B0627
-
-
- HY-148418
-
|
TUG-499
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
TUG-499 is a selective free fatty acid receptor 1 (FFAR1 or GPR40) (Free Fatty Acid Receptor) agonist with a pEC50 of 7.39. TUG-499 exhibits >100-fold selectivity over the related receptors FFA2, FFA3, and the nuclear receptor PPARγ and other diverse receptors, ion channels, and transporters. TUG-499 can be used for the research of type 2 diabetes.
|
-
- HY-131902
-
|
MLT-231
|
MALT1
|
Cancer
|
|
MLT-231 is a potent, highly selective allosteric MALT1 Inhibitor with an IC50 of 9 nM. MLT-231 specifically prevents endogenous BCL10 cleavage with IC50 of 160 nM. MLT-231 shows antitumor activity in an ABC-DLBCL type xenograft model in mouse.
|
-
- HY-120160A
-
|
Darglitazone Sodium
CP 86325 Sodium
|
PPAR
|
Metabolic Disease
Neurological Disease
|
|
Darglitazone Sodium, a thiazolidinedione, is an orally active, potent, and selective PPAR-γ (peroxisome proliferator-activated receptor) agonist. Darglitazone Sodium is effective in controlling blood glucose and lipid metabolism, and can be used for type II diabetes research.
|
-
- HY-B1451
-
|
Imidapril hydrochloride
TA-6366
|
Angiotensin-converting Enzyme (ACE)
MMP
|
Metabolic Disease
Cardiovascular Disease
|
|
Imidapril hydrochloride (TA-6366) is an orally active angiotensin-converting enzyme (ACE) and MMP-9 inhibitor. Imidapril hydrochloride suppresses the conversion of angiotensin I to angiotensin II and thereby reduces total peripheral resistance and systemic blood pressure. Imidapril hydrochloride can be used for hypertension, type 1 diabetic, nephropathy and chronic heart failure research.
|
-
- HY-12928
-
|
ML336
|
Virus Protease
|
Infection
|
|
ML336 is quinazolinone-based inhibitor against venezuelan equine encephalitis virus (VEEV), with IC50s of 32, 20, and 42 nM for VEEV TC-83 CPE , VEEV V3526 CPE, VEEV Wild Type CPE, respectively. ML336 potently inhibits a VEEV-induced cytopathic effect in three strains of the virus (TC-83, V3526, and wild type Trinidad donkey) in the low nanomolar range.
|
-
- HY-125351
-
|
SPT-IN-1
|
Others
|
Metabolic Disease
|
|
SPT-IN-1 (compound 1) is an orally active and potent SPT (serine palmitoyl transferase) inhibitor, with an IC50 of 5.19 nM for hSPT1. SPT-IN-1 can be used for type 2 diabetes and dyslipidemia research.
|
-
- HY-147257
-
|
Cofrogliptin
HSK7653
|
Dipeptidyl Peptidase
|
Metabolic Disease
|
|
Cofrogliptin (HSK7653) (compound 2), a tetrahydropyran derivative, is a potent oral dipeptidyl aminopeptidase 4 (DPP-4) inhibitor with Long-acting antidiabetic efficacy. Cofrogliptin (compound 2) has a great potential for type 2 diabetes mellitus (T2DM) .
|
-
- HY-B1451A
-
|
Imidapril
TA-6366 free base
|
Angiotensin-converting Enzyme (ACE)
MMP
|
Metabolic Disease
Cardiovascular Disease
|
|
Imidapril (TA-6366 free base) is an orally active angiotensin-converting enzyme (ACE) and MMP-9 inhibitor. Imidapril suppresses the conversion of angiotensin I to angiotensin II and thereby reduces total peripheral resistance and systemic blood pressure. Imidapril can be used for hypertension, type 1 diabetic, nephropathy and chronic heart failure research.
|
-
- HY-147037
-
|
AMPK activator 7
|
AMPK
|
Metabolic Disease
Cardiovascular Disease
|
|
AMPK activator 7 (compound I-3-24) is a an AMPK activator with the EC50 of 8.8 nM. AMPK activator 7 can be used for the research of diseases involving AMPK, particularly diseases such as type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia and/or hypertension.
|
-
- HY-151193
-
|
NNMT-IN-3
|
Others
|
Cancer
Metabolic Disease
|
|
NNMT-IN-3 (compound 14) is a potent and selective nicotinamide N-methyltransferase NNMT inhibitor with IC50 values of 1.1 nM and 0.4 μM in cell-free and cell-based assays, respectively. NNMT-IN-3 can be used to research obesity, type 2 diabetes, alcohol-related liver disease, cancer, sarcopenia and so on.
|
-
- HY-P99530
-
|
Valanafusp alfa
AGT-181; HIRMAb-IDUA
|
Insulin Receptor
|
Metabolic Disease
|
|
Valanafusp alfa (AGT-181) is a brain penetrating recombinant fusion protein of a chimeric monoclonal antibody against the human insulin receptor (HIR) and human iduronidase (IDUA). Valanafusp alfa can be used for the research of Mucopolysaccharidosis type I (MPS I) .
|
-
- HY-147038
-
|
AMPK activator 8
|
AMPK
|
Metabolic Disease
|
|
AMPK activator 8 (compound 2) is an AMP-activated protein kinase (AMPK) activator with EC50s of 11, 27, 4, 2, and 4 nM for rAMPK α1β1γ1, rAMPK α2β1γ1, rAMPK α1β2γ1, rAMPK α2β2γ1, rAMPK α2β2γ3, respectively. AMPK activator 8 can be used for the research of type 2 diabetes.
|
-
- HY-N9410
-
|
Lysophosphatidylcholine 18:2
1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Lysophosphatidylcholine 18:2 (1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC), a lysophospholipid, is a potential biomarker identified from insulin resistance (IR) polycystic ovary syndrome (PCOS). Low plasma Lysophosphatidylcholine 18:2 also has been shown to predict impaired glucose tolerance, insulin resistance, type 2 diabetes, coronary artery disease, and memory impairment.
|
-
- HY-107535
-
|
AS1269574
|
GPR119
TRP Channel
|
Metabolic Disease
|
|
AS1269574 is a potent, orally available GPR119 agonist, with an EC50 of 2.5 μM in HEK293 cells expressing human GPR119. AS1269574 activates TRPA1 cation channels to stimulate glucagon-like peptide-1 (GLP-1) secretion. AS1269574 specifically induces glucose-dependent insulin secretion from pancreatic β-cells only under high-glucose conditions. AS1269574 has the potential for the research of type 2 diabetes.
|
-
- HY-151595
-
|
Menin-MLL inhibitor-22
|
Others
|
Cancer
|
|
Menin-MLL inhibitor-22 (compound C20) is an orally active inhibitor of the interaction between menin and mixed lineage leukemia (MLL) (IC50=7 nM). Menin-MLL inhibitor-22 binds menin protein and inhibits cancer cell growth (MV4 cells, IC50=0.3 μM). Menin is a putative tumor suppressor associated with multiple endocrine neoplasia type 1 (MEN-1 syndrome).
|
-
- HY-18555
-
|
TMPA
|
AMPK
|
Cancer
Metabolic Disease
Inflammation/Immunology
|
|
TMPA is a high-affinity Nur77 antagonist that binds to Nur77 leading to the release and shuttling of LKB1 in the cytoplasm to activate AMPKα. TMPA effectively lowers blood glucose and attenuates insulin resistance in type II db/db, high-fat diet and streptozotocin-induced diabetic mice. TMPA reduces RICD (restimulation-induced cell death) in human T cells, can also be used in studies of cancer and T-cell apoptosis dysregulation.
|
-
- HY-144713
-
|
PTP1B-IN-16
|
Phosphatase
|
Metabolic Disease
|
|
PTP1B-IN-16 (Compound 46), a potential selective benzimidazole derivative, acts as a protein tyrosine phosphatase 1B (PTP1B) inhibitor with a Ki of 12.6 μM. PTP1B-IN-16 can be used for the research of type 2 diabetes.
|
-
- HY-144718
-
|
PTP1B-IN-17
|
Phosphatase
|
Metabolic Disease
|
|
PTP1B-IN-17 (Compound 45), a potential selective benzimidazole derivative, acts as a protein tyrosine phosphatase 1B (PTP1B) inhibitor with a Ki of 30.2 μM. PTP1B-IN-17 can be used for the research of type 2 diabetes.
|
-
- HY-144716
-
|
PTP1B-IN-19
|
Phosphatase
|
Metabolic Disease
|
|
PTP1B-IN-19 (Compound 43), a potential selective benzimidazole derivative, acts as a protein tyrosine phosphatase 1B (PTP1B) inhibitor with a Ki of 23.3 μM. PTP1B-IN-19 can be used for the research of type 2 diabetes.
|
-
- HY-128348
-
|
PK68
|
RIP kinase
|
Cancer
Inflammation/Immunology
|
|
PK68 is a potent orally active and specifical type II inhibitor of receptor-interacting kinase 1 (RIPK1) with an IC50 of ~90 nM, displays inhibition of RIPK1-dependent necroptosis. PK68 powerfully ameliorates TNF-induced systemic inflammatory response syndrome, and can be used for the research of inflammatory disorders and cancer metastasis.
|
-
- HY-150723
-
|
PBI-6DNJ
|
Glucosidase
|
Metabolic Disease
|
|
PBI-6DNJ is an orally active and potent multivalent glycosidase inhibitor. PBI-6DNJ exhibits good inhibition activity against α-glucosidase from mice, with a Ki of 0.14 μM. PBI-6DNJ exhibits good hypoglycemic activity. PBI-6DNJ can be used for type 2 diabetes research.
|
-
- HY-108020
-
|
LY2881835
|
Free Fatty Acid Receptor
|
Endocrinology
|
|
LY2881835 is a potent and selective agonist of G protein-coupled receptor 40 (GPR40). LY2881835 has efficacious and durable dose-dependent reductions in glucose levels along with significant increases in insulin and GLP-1 secretion. LY2881835 has the potential for the research of type 2 diabetes mellitus.
|
-
- HY-136742
-
-
- HY-117985
-
|
Evogliptin
DA-1229
|
Dipeptidyl Peptidase
Autophagy
|
Metabolic Disease
Inflammation/Immunology
|
|
Evogliptin (DA-1229) is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation.
|
-
- HY-N9539
-
|
Phanginin A
|
Salt-inducible Kinase (SIK)
|
Metabolic Disease
|
|
Phanginin A is a potent and orally active SIK1 (salt-induced kinase 1) activator. Phanginin A inhibited gluconeogenesis. Phanginin A increases the expression of p-SIK1 and decreases the expression of p-CREB. Phanginin A reduces blood glucose levels and improves glucose tolerance and dyslipidemia. Phanginin A has the potential for the research of type 2 diabetes.
|
-
- HY-P3507
-
|
Dalazatide
ShK-186
|
Potassium Channel
|
Metabolic Disease
Inflammation/Immunology
|
|
Dalazatide (ShK-186) is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease.
|
-
- HY-111151
-
|
AR-9281
APAU
|
Epoxide Hydrolase
|
Infection
Metabolic Disease
|
|
AR9281 (APAU) is a potent, selective and orally active soluble epoxide hydrolase (s-EH) inhibitor. AR-9281 can inhibits human sEH (HsEH) and murine sEH (MsEH) with IC50 values of 13.8 nM and 1.7 nM, respectively. AR9281 can be used for the research of inflammation, hypertension and type 2 diabetes.
|
-
- HY-131728
-
-
- HY-117985B
-
|
Evogliptin tartrate
DA-1229 tartrate
|
Dipeptidyl Peptidase
Autophagy
|
Metabolic Disease
Inflammation/Immunology
|
|
Evogliptin (DA-1229) tartrate is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin tartrate also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin tartrate can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation.
|
-
- HY-P3507A
-
|
Dalazatide TFA
ShK-186 TFA
|
Potassium Channel
|
Metabolic Disease
Inflammation/Immunology
|
|
Dalazatide (ShK-186) TFA is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide TFA can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease.
|
-
- HY-119222
-
|
GSK256073
|
GPR109A
|
Metabolic Disease
|
|
GSK256073 is a potent, selective and orally active GPR109A agonist and a long-lasting and non-flushing HCA2 full agonist with a pEC50 of 7.5 (human HCA2). GSK256073 acutely improves glucose homeostasis via inhibition of lipolysis and has the potential for the study of type 2 diabetes mellitus (T2DM)and dyslipidemia. GPR109A: G-protein coupled receptor 109A; HCA2: hydroxy-carboxylic acid receptor 2
|
-
- HY-N3628
-
-
- HY-117724
-
|
AZ3976
|
PAI-1
|
Cardiovascular Disease
|
|
AZ3976 is a potent plasminogen activator inhibitor type 1 (PAI-1) inhibitor with an IC50 value of 26 μM in an enzymatic chromogenic assay. AZ3976 is active with an IC50 of 16 μM in a plasma clot lysis assay. AZ3976 does not bind to active PAI-1 but bound reversibly to latent PAI-1. AZ3976 inhibits PAI-1 by enhancing the latency transition of active PAI-1. AZ3976 displays profibrinolytic activities in a human plasma clot lysis assay.
|
-
- HY-111372
-
|
Finerenone
BAY 94-8862
|
Mineralocorticoid Receptor
|
Cardiovascular Disease
|
|
Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease.
|
-
- HY-143201
-
|
DS20362725
|
Estrogen Receptor/ERR
|
Metabolic Disease
|
|
DS20362725 is an estrogen-related receptor α (ERRα) agonist. DS20362725 inhibits the binding between receptor-interacting protein 140 (RIP140) corepressor peptide (10 nM) and GST-ERRα ligand-binding domain (LBD; 1.2 μM) with an IC50 value of 0.6 μM. DS20362725 can be used for the research of metabolic disorders, including type 2 diabetes mellitus (T2DM).
|
-
- HY-153335
-
|
Enpp-1-IN-16
|
Phosphodiesterase (PDE)
|
Cancer
Infection
Metabolic Disease
Inflammation/Immunology
Cardiovascular Disease
|
|
Enpp-1-IN-16 (compound 54) is an ENPP1 inhibitor. Enpp-1-IN-16 has the potential to study cancer, especially in cases of high ENPP1 expression or elevated cytoplasmic DNA levels. Enpp-1-IN-16 can also be used in other diseases mediated by ENPP1, such as bacterial or viral infections, insulin resistance and type II diabetes, chondrocalcinosis and osteoarthritis, calcium pyrophosphate deposition disorder (CPPD), low Phosphatase disease and soft tissue calcification disorders.
|
-
- HY-111615
-
|
J-2156
|
Somatostatin Receptor
|
Neurological Disease
|
|
J-2156 is a high potent, selective somatostatin receptor type 4 (SST4 receptor) agonist with IC50s of 0.05 nM and 0.07 nM for human and rat SST4 receptors, respectively. J-2156 is used for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws in rats.
|
-
- HY-P3542
-
|
Des His1, Glu8 Exendin-4
|
GCGR
|
Metabolic Disease
|
|
Des His1, Glu8 Exendin-4 is a potent glucagon-like peptide-1 receptor (GLP-1-R) antagonist. Des His1, Glu8 Exendin-4 improves glucose homeostasis by regulating both insulin secretion and glucose production. Des His1, Glu8 Exendin-4 can be used for the research of type 2 diabetic and gastrointestinal.
|
-
- HY-N1724
-
-
- HY-149254
-
|
PTP1B/AKR1B1-IN-1
|
Phosphatase
Aldose Reductase
|
Metabolic Disease
|
|
PTP1B/AKR1B1-IN-1 is a dual inhibitor of protein tyrosine phosphatase 1B (PTP1B) and aldose reductase (AKR1B1), with IC50s of 0.06 μM and 4.3 μM, respectively. PTP1B/AKR1B1-IN-1 also inhibits TC-PTP with an IC50 value of 9 μM. PTP1B/AKR1B1-IN-1 serves as an insulin-mimetic agent in murine myoblasts, and reduces AKR1B1-dependent sorbitol accumulation. PTP1B/AKR1B1-IN-1 inhibits development of type 2 diabetes mellitus (T2DM) to control blood glucose levels.
|
-
- HY-111615A
-
|
J-2156 TFA
|
Somatostatin Receptor
|
Inflammation/Immunology
Neurological Disease
|
|
J-2156 TFA is a high potent, selective somatostatin receptor type 4 (SST4 receptor) agonist with IC50s of 0.05 nM and 0.07 nM for human and rat SST4 receptors, respectively. J-2156 TFA has anti-inflammatory activity and it is used for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws in rats.
|
-
- HY-116815
-
|
Lalistat 1
|
Bacterial
|
Infection
Neurological Disease
|
|
Lalistat 1 is a potent, selective, and competitive inhibitor of lysosomal acid lipase (LAL) and against purified human LAL (phLAL) with an IC50 of 68 nM. Lalistat 1 is a inhibitor of immunoglobulin A1 protease (IgA1P) proteases for H. influenzae, has less effects on other serine hydrolases (trypsin or β-lactamase, etc.). Lalistat 1 can be used for the research of niemann-pick type C (NPC) disease.
|
-
- HY-W001601
-
|
Budipine
|
iGluR
|
Neurological Disease
|
|
Budipine is an anti-parkinson agent. Budipine also is a substrate of P-glycoprotein (P-gp), is mediated the uptake into the brain by P-gp. Budipine also is N-methyl-d-aspartate (NMDA) antagonist, and has indirect dopaminergic effects through an improved dopamine release, the inhibition of monoamine oxidase type B (MAO-B). Budipine can be used for the research of CNS disorders include Parkinson disease.
|
-
- HY-147626
-
-
- HY-109556
-
|
Insulin Detemir
|
Akt
ERK
|
Metabolic Disease
|
|
Insulin Detemir is an artificial insulin, shows effect on controlling blood sugar levels. Insulin Detemir stimulates GLP-1 secretion as a consequence of enhanced Gcg expression by a mechanism involving activation of Akt- and/or extracellular signal-regulated kinase (ERK)-dependent-cat and CREB signaling pathways. Insulin Detemir can be used for type 2 diabetes research.
|
-
- HY-19887
-
-
- HY-D0485
-
-
- HY-15209
-
-
- HY-151257
-
|
IHMT-MST1-58
|
Hippo (MST)
|
Metabolic Disease
|
|
IHMT-MST1-58 is a potent, selective mammalian and orally active STE20-like protein 1 kinase (MST1) inhibitor with IC50 value of 23 nM. IHMT-MST1-58 can be used for the research of Type 1/2 diabetes.
|
-
- HY-108795
-
|
Albiglutide
|
GLP Receptor
|
Metabolic Disease
|
|
Albiglutide, a glucagon-like peptide-1 (GLP-1) mimetic, is a long-acting GLP-1 receptor agonist. Albiglutide significantly reduces glycosylated hemoglobin (A1C). Albiglutide can be used for type 2 diabetes (T2D) research. Albiglutide is generated by the genetic fusion of a DPP-4-resistant GLP-1 dimer to human albumin.
|
-
- HY-108795A
-
|
Albiglutide TFA
|
GLP Receptor
|
Metabolic Disease
|
|
Albiglutide TFA, a glucagon-like peptide (GLP)-1 mimetic, is a long acting GLP-1 receptor agonist. Albiglutide TFA significantly reduces glycosylated hemoglobin (A1C). Albiglutide TFA can be used for type 2 diabetes (T2D) research. Albiglutide TFA is generated by the genetic fusion of a DPP-4-resistant GLP-1 dimer to human albumin.
|
-
- HY-12502B
-
-
- HY-12502
-
-
- HY-116399
-
|
MMP-2/MMP-9-IN-1
|
MMP
|
Cancer
|
|
MMP-2/MMP-9-IN-1 is a highly selective, orally active and potent type IV collagenase (MMP-9 and MMP-2) inhibitor with IC50s of 0.24 and 0.31 μM for MMP-9 and MMP-2, respectively. MMP-2/MMP-9-IN-1 is orally active in animal models of tumor growth and metastasis. MMP-2/MMP-9-IN-1 can be used for the research of cancer.
|
-
- HY-10326
-
|
GW788388
|
TGF-β Receptor
|
Cancer
|
|
GW788388 is a potent and selective inhibitor of ALK5 with IC50 of 18 nM, and also inhibits TGF-β type II receptor and activin type II receptor activities, without inhibiting BMP type II receptor.
|
-
- HY-109530
-
|
Insulin lispro
|
Others
|
Metabolic Disease
|
|
Insulin lispro is a recombinant human insulin analogue and is one of three rapid-acting insulin analogues available. Insulin lispro can be used for the research of hyperglycaemia in diabetes mellitus.
|
-
- HY-136466
-
|
A2ti-2
|
Virus Protease
HPV
|
Infection
|
|
A2ti-2 is a selective and low-affinity annexin A2/S100A10 heterotetramer (A2t) inhibitor with an IC50 of 230 μM. A2ti-2 specifically disrupts the protein-protein interaction (PPI) between A2 and S100A10. A2ti-2 prevents human papillomavirus type 16 (HPV16) infection.
|
-
- HY-136465
-
|
A2ti-1
|
Virus Protease
HPV
|
Infection
|
|
A2ti-1 is a selective and high-affinity annexin A2/S100A10 heterotetramer (A2t) inhibitor with an IC50 of 24 μM. A2ti-1 specifically disrupts the protein-protein interaction (PPI) between A2 and S100A10. A2ti-1 prevents human papillomavirus type 16 (HPV16) infection.
|
-
- HY-B0726
-
-
- HY-12502A
-
-
- HY-B0726A
-
-
- HY-13012
-
|
RepSox
E-616452; SJN 2511
|
TGF-β Receptor
|
Metabolic Disease
|
|
RepSox (E-616452) is a potent and selective transforming growth factor-beta receptor I/activin like kinase 5 (TGF-β-RI/ALK5) inhibitor. RepSox inhibits ALK5 autophosphorylation with an IC50 value of 4 nM. RepSox can be used for the research of obesity and associated metabolic diseases such as type 2 diabetes.
|
-
- HY-111069
-
-
- HY-B1006
-
-
- HY-105349
-
|
T-0156
|
Phosphodiesterase (PDE)
|
Neurological Disease
|
|
T-0156 is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor. T-0156 specifically inhibits the hydrolysis of cyclic guanosine monophosphate (cGMP) by PDE5 in a competitive manner (IC50=0.23 nM). T-0156 inhibits PDE6 (IC50=56 nM) and has low potencies against PDE1, PDE2, PDE3, and PDE4 (IC50>10 μM). T-0156 enhances the nitric oxide (NO)/cGMP pathway.
|
-
- HY-15553A
-
-
- HY-P3522
-
|
REDV
|
Integrin
|
Cancer
|
|
REDV is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV can mediate adhesion to the IIICS region of plasma fibronectin by binding the integrin alpha 4 beta 1(α4β1). REDV can be used for the research of cell adhesion.
|
-
- HY-15553
-
|
Mibefradil
Ro 40-5967
|
Calcium Channel
|
Cardiovascular Disease
|
|
Mibefradil (Ro 40-5967) is a calcium channel blocker with moderate selectivity for T-type Ca 2+ channels displaying IC50s of 2.7 μM and 18.6 μM for T-type and L-type currents, respectively.
|
-
- HY-153530
-
|
LI-2242
|
Others
|
Metabolic Disease
Neurological Disease
|
LI-2242 is an inositol hexakisphosphate kinase (IP6K) inhibitor. LI-2242 has inhibition effect for IP6K1, IP6K2, IP6K3 and IPMK with IC50 values of 31 nM, 42 nM, 8.7 nM and 1944 nM, respectively. LI-2242 can be used for thew research of type II diabetes, obesity, metabolic complications, venous thrombosis, and psychiatric disorders.
|
-
- HY-B0202
-
|
Irbesartan
SR-47436; BMS-186295
|
Angiotensin Receptor
Apoptosis
|
Cardiovascular Disease
Endocrinology
|
|
Irbesartan (SR-47436) is an orally active Ang II type 1 (AT1) receptor blocker (ARB). Irbesartan can relax the blood vessels, low blood pressure and increase the supply of blood and oxygen to the heart. Irbesartan can be used for the research of high blood pressure, heart failure, and diabetic kidney disease.
|
-
- HY-B0202A
-
|
Irbesartan hydrochloride
SR-47436 hydrochloride; BMS-186295 hydrochloride
|
Angiotensin Receptor
Apoptosis
|
Metabolic Disease
Neurological Disease
|
|
Irbesartan (SR-47436) hydrochloride is an orally active Ang II type 1 (AT1) receptor blocker (ARB). Irbesartan hydrochloride can relax the blood vessels, low blood pressure and increase the supply of blood and oxygen to the heart. Irbesartan hydrochloride can be used for the research of high blood pressure, heart failure, and diabetic kidney disease.
|
-
- HY-15209S
-
-
- HY-147678
-
|
GPR40 agonist 5
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
GPR40 agonist 5 (compound I-14) is an orally active and potent GPR40 (G protein coupled receptor 40) agonist, with an EC50 of 47 nM. GPR40 agonist 5 decreases the levels of blood glucose and improves the glucose tolerance. GPR40 agonist 5 has sufficient effectiveness for the control of hyperglycemia state in type 2 diabetic mice.
|
-
- HY-109555
-
|
Insulin glulisine
HMR 1964
|
Insulin Receptor
|
Metabolic Disease
|
|
Insulin glulisine (HMR 1964) is a rapid-acting insulin analogue, it mimics the pharmacokinetic and pharmacodynamic profiles of physiological human insulin. Insulin glulisine can be used for the research of diabetes.
|
-
- HY-152251
-
|
CB2R/FAAH modulator-1
|
Cannabinoid Receptor
FAAH
|
Inflammation/Immunology
|
|
CB2R/FAAH modulator-1 is a cannabinoid type 2 receptor (CB2R) full agonist with Kis of 14.8 nM and 241.3 nM for CB2R and CB1R, respectively. CB2R/FAAH modulator-1 is a fatty acid amide hydrolase (FAAH) inhibitor with an IC50 of 4 μM. CB2R/FAAH modulator-1 decreases pro-inflammatory and increases anti-inflammatory cytokines production.
|
-
- HY-P1080
-
|
ω-Agatoxin IVA
|
Calcium Channel
|
Neurological Disease
|
|
ω-Agatoxin IVA is a potent, selective P/Q type Ca 2+ (Cav2.1) channel blocker with IC50s of 2 nM and 90 nM for P-type and Q-type Ca 2+ channels, respectively. ω-Agatoxin IVA (IC50, 30-225 nM) inhibits glutamate exocytosis and calcium influx elicited by high potassium. ω-Agatoxin IVA also blocks the high potassium-induced release of serotonin and norepinephrine. ω-Agatoxin IVA has no effect on L-type or N-type calcium channels.
|
-
- HY-B0410A
-
|
Pramipexole dihydrochloride hydrate
|
Dopamine Receptor
|
Neurological Disease
|
|
Pramipexole dihydrochloride hydrate is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride hydrate can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS).
|
-
- HY-B0410
-
|
Pramipexole
|
Dopamine Receptor
|
Neurological Disease
|
|
Pramipexole is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS).
|
-
- HY-17355
-
|
Pramipexole dihydrochloride
|
Dopamine Receptor
|
Neurological Disease
|
|
Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS).
|
-
- HY-N7938
-
-
- HY-139070
-
-
- HY-P1079
-
|
ω-Agatoxin TK
|
Calcium Channel
|
Neurological Disease
|
|
ω-Agatoxin TK, a peptidyl toxin of the venom of Agelenopsis aperta, is a potent and selective P/Q type Ca 2+ channel blocker. ω-Agatoxin TK inhibits the high K + depolarisation-induced rise in internal Ca 2+ in cerebral isolated nerve endings with an IC50 of of 60 nM. ω-Agatoxin TK has no effect on L-type, N-type, or T-type calcium channels.
|
-
- HY-N6071
-
-
- HY-W002008
-
-
- HY-P1080A
-
|
ω-Agatoxin IVA TFA
|
Calcium Channel
|
Neurological Disease
|
|
ω-Agatoxin IVA TFA is a potent, selective P/Q type Ca 2+ (Cav2.1) channel blocker with IC50s of 2 nM and 90 nM for P-type and Q-type Ca 2+ channels, respectively. ω-Agatoxin IVA TFA (IC50, 30-225 nM) inhibits glutamate exocytosis and calcium influx elicited by high potassium. ω-Agatoxin IVA TFA also blocks the high potassium-induced release of serotonin and norepinephrine. ω-Agatoxin IVA TFA has no effect on L-type or N-type calcium channels.
|
-
- HY-150701
-
-
- HY-15286
-
|
Sodium 4-pentynoate
|
Others
|
Others
|
|
Sodium 4-pentynoate is a alkynylacetate analogue, can be metabolically incorporated onto cellular proteins through biosynthetic mechanisms for profiling of acetylated proteins in diverse cell types.
|
-
- HY-B0726S
-
-
- HY-N6867
-
-
- HY-N10178
-
-
- HY-18936
-
-
- HY-14907
-
|
Verubulin
MPC 6827
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Verubulin (MPC-6827) is a microtubule-disrupting agent with potent and broad-spectrum in vitro and in vivo cytotoxic activities, and acts as a promising candidate for the treatment of multiple cancer types.
|
-
- HY-17355S1
-
|
Pramipexole-d5 dihydrochloride
|
Dopamine Receptor
|
Neurological Disease
|
|
Pramipexole-d5 (dihydrochloride) is deuterium labeled Pramipexole (dihydrochloride). Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS)[1][2][3].
|
-
- HY-17355S
-
|
Pramipexole-d7 dihydrochloride
|
Dopamine Receptor
|
Neurological Disease
|
|
Pramipexole-d7 (dihydrochloride) is the deuterium labeled Pramipexole dihydrochloride. Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS)[1][2][3].
|
-
- HY-B0410S1
-
|
Pramipexole-d5
|
Dopamine Receptor
|
Neurological Disease
|
|
Pramipexole-d5 is the deuterium labeled Pramipexole[1]. Pramipexole is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS)[2][3][4].
|
-
- HY-N2326
-
|
(±)-Anatoxin A fumarate
|
nAChR
|
Neurological Disease
|
|
(±)-Anatoxin A fumarate is a natural alkaloid isolated from freshwater cyanobacterium.(±)-Anatoxin A fumarate is a potent nicotinic receptor agonist and exhibits Ki values of 1.25 nM and 1.84 μM for binding to putative α4β2-type nAChR and α7-type nAChR in rat brain membranes, respectively. (±)-Anatoxin A fumarate stimulates [ 3H]-dopamine release from rat striatal synaptosomes (EC50=134 nM).
|
-
- HY-10432
-
|
A 83-01
|
TGF-β Receptor
|
Cancer
|
|
A 83-01 is a potent inhibitor of TGF-β type I receptor ALK5 kinase, type I nodal receptor ALK4 and type I nodal receptor ALK7, with IC50s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively.
|
-
- HY-P1985A
-
|
Notch 1 TFA
|
Notch
|
Cancer
Cardiovascular Disease
|
|
Notch 1 TFA (Notch homolog 1, translocation-associated) can encode a member of the NOTCH family of proteins. Members of this Type I transmembrane protein family share structural characteristics including an extracellular domain consisting of multiple epidermal growth factor-like (EGF) repeats, and an intracellular domain consisting of multiple different domain types.
|
-
- HY-P99693
-
|
Lenvervimab
GC1102
|
HBV
|
Infection
|
|
Lenvervimab (GC1102) is a IgG1-type recombinant human hepatitis B Immunoglobulin. Lenvervimab can be used for research of hepatitis B virus infection.
|
-
- HY-14462
-
-
- HY-N1995
-
|
Methylswertianin
|
Others
|
Metabolic Disease
|
|
Methylswertianin is an active constituent in Swertia punicea Hemsl, with anti-diabetic effect. Methylswertianin can abates type-2 diabetes, likely via the improvement of insulin resistance (IR).
|
-
- HY-P9913
-
-
- HY-N7653
-
|
Azaleatin
|
Dipeptidyl Peptidase
|
Metabolic Disease
|
|
Azaleatin is an O-methylated flavonol isolated from Rhododendron species. Azaleatin is a dipeptidyl peptidase-IV inhibitor. Azaleatin can be used for the research of type-2 diabetes and obesity.
|
-
- HY-P1752
-
-
- HY-131942
-
-
- HY-17355S2
-
|
Pramipexole-d7-1 dihydrochloride
|
Dopamine Receptor
|
Neurological Disease
|
|
Pramipexole-d7-1 (dihydrochloride) is the deuterium labeled Pramipexole dihydrochloride[1]. Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS)[2][3][4].
|
-
- HY-P1752A
-
-
- HY-100639
-
-
- HY-B0768A
-
-
- HY-U00245
-
-
- HY-15449
-
-
- HY-111807
-
-
- HY-13209
-
-
- HY-107123
-
|
TMC310911
|
HIV Protease
|
Infection
|
|
TMC310911 is a potent and orally active HIV type-1 (HIV-1) protease inhibitor with EC50 values ranged from 2.2 nM to 14.2 nM for wild-type HIV-1. TMC310911 has potent activity against a wide spectrum of recombinant HIV-1 isolates. TMC310911 has strong antiviral activity.
|
-
- HY-142645
-
|
RSV-IN-2
|
RSV
|
Infection
|
|
RSV-IN-2 is a potent dual inhibitor of wild-type and mutant respiratory syncytial virus fusion proteins (wild-type, EC50 = 0.27 nM; D486N-mutant, EC50 = 0.70 nM).
|
-
- HY-134036
-
-
- HY-100587
-
-
- HY-126583
-
|
Nemadipine-A
|
Calcium Channel
|
Cancer
|
|
Nemadipine-A is a specific inhibitor of the EGL-19 L-type Ca 2+ channel. Nemadipine-A, a cell-permeable L-type calcium channel inhibitor, sensitizes TRAIL-resistant cancer cells to this ligand.
|
-
- HY-12085
-
-
- HY-112707
-
-
- HY-105182
-
|
Xanomeline
LY-246708
|
mAChR
|
Neurological Disease
|
|
Xanomeline, as an effective and selective muscarinic type 1 and type 4 (M1/M4) receptor agonist, increases neuronal excitability. Xanomeline can be used for the research of neurological disorders, such as schizophrenia.
|
-
- HY-P3294
-
-
- HY-P5127
-
-
- HY-B0458
-
-
- HY-B0458A
-
-
- HY-N11101
-
-
- HY-N11091
-
-
- HY-N10193
-
-
- HY-U00236
-
-
- HY-N7687
-
|
Caulophyllogenin
|
PPAR
|
Metabolic Disease
Inflammation/Immunology
|
|
Caulophyllogenin is a triterpene saponin extracted from M. polimorpha. Caulophyllogenin is a partial PPARγ agonist, with an EC50 of 12.6 μM. Caulophyllogenin can be used for the research of type-2 diabetes, obesity, metabolic syndrome and inflammation.
|
-
- HY-131004
-
|
CB2R PAM
|
Cannabinoid Receptor
|
Neurological Disease
|
|
CB2R PAM is an orally active cannabinoid type-2 receptors (CB2Rs) positive allosteric modulator. CB2R PAM displays antinociceptive activity in vivo in an experimental mouse model of neuropathic pain.
|
-
- HY-P1078
-
|
Huwentoxin XVI
|
Calcium Channel
|
Neurological Disease
|
|
Huwentoxin XVI, an analgesic, is a highly reversible and selective mammalian N-type calcium channel (IC50 of ~60 nM) antagonist from Chinese tarantula Ornithoctonus huwena. Huwentoxin XVI has no effect on voltagegated T-type calcium channels, potassium channels or sodium channels.
|
-
- HY-U00432
-
-
- HY-B0898
-
-
- HY-16742
-
-
- HY-B2075
-
-
- HY-101214
-
-
- HY-147628
-
-
- HY-147623
-
-
- HY-144289
-
|
BMS-820132
|
Glucokinase
|
Metabolic Disease
|
|
BMS-820132 is an orally active and partial glucokinase (GK) activator with a AC50 of 29 nM. BMS-820132 decreases the glucose levels in glucose tolerance test (OGTT) model in normal rats, but not Zucker diabetic fatty (ZDF) rats. BMS-820132 exhibits pharmacological toxicity secondary to strong GK activation.
|
-
- HY-147629
-
-
- HY-115661
-
|
Bisdionin C
|
Bacterial
|
Infection
|
|
Bisdionin C is a potent GH18 chitinases inhibitor, with an IC50 of 0.2 μM for A. fumigatus ChiB1 (AfChiB1). Bisdionin C inhibits HCHT (human macrophage chitotriosidase) and acidic mammalian chitinase (AMCase) with IC50s of 8.3 and 3.4 μM, respectively.
|
-
- HY-13635S
-
|
Finasteride-d9
MK-906-d9
|
5 alpha Reductase
|
Cancer
|
|
Finasteride-d9 is deuterium labeled Finasteride. Finasteride (MK-906) is a potent and competitive 5α-reductase inhibitor, with an IC50 of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia[1][2][3].
|
-
- HY-50722
-
-
- HY-108974
-
|
Drotaverine hydrochloride
|
Phosphodiesterase (PDE)
Calcium Channel
|
|
|
Drotaverine (hydrochloride) is a type 4 cyclic nucleotide phosphodiesterase (PDE4) inhibitor and an L-type voltage-dependent calcium channel (L-VDCC) blocker, blocks the degradation of 3',5'-cyclic adenosine monophosphate. Drotaverine (hydrochloride) exhibits in vivo antispasmodic efficacy without anticholinergic effects.
|
-
- HY-112779
-
|
Pertussis Toxin
|
Others
|
Infection
|
|
Pertussis Toxin is a protein-based AB5-type exotoxin produced by the bacterium Bordetella pertussis, which causes whooping cough. Pertussis Toxin inhibits G protein-coupled receptor (GPR) signaling through Gi proteins.
|
-
- HY-14127
-
|
R121919
NBI30775
|
CRFR
|
Neurological Disease
Endocrinology
|
|
R121919 (NBI30775) is a potent small-molecule CRF1 receptor antagonist with a Ki of 2 to 5 nM for the CRF1 receptor and over 1000-fold weaker activity at the CRF2 receptor, CRF-binding protein, or 70 other receptor types.
|
-
- HY-12085S
-
-
- HY-P1078A
-
|
Huwentoxin XVI TFA
|
Calcium Channel
|
Neurological Disease
|
|
Huwentoxin XVI TFA, an analgesic, is a highly reversible and selective mammalian N-type calcium channel (IC50 of ~60 nM) antagonist from Chinese tarantula Ornithoctonus huwena. Huwentoxin XVI TFA has no effect on voltagegated T-type calcium channels, potassium channels or sodium channels.
|
-
- HY-B0900
-
|
Anethole
Anise camphor; p-Propenylanisole; Isoestragole
|
Others
|
Cancer
|
|
Anethole is a type of aromatic compound that occurs widely in nature, widely used as a flavoring substance.
|
-
- HY-141415
-
-
- HY-13930
-
|
Miquelianin
Quercetin 3-O-glucuronide; Quercetin 3-glucuronide
|
Endogenous Metabolite
|
Cancer
|
|
Miquelianin (Quercetin 3-O-glucuronide) is a metabolite of quercetin and a type of natural flavonoid.
|
-
- HY-102093
-
-
- HY-N7620
-
-
- HY-106181
-
-
- HY-110304
-
-
- HY-B0920
-
-
- HY-N6079
-
-
- HY-N0600
-
-
- HY-117103
-
|
AMG131
INT131
|
PPAR
|
Metabolic Disease
|
|
AMG131 (INT131), a potent and highly selective PPARγ partial agonist, binds to PPARγ and displaces Rosiglitazone with a Ki of ~10 nM. AMG131 can be used for research of type-2 diabetes mellitus (T2DM).
|
-
- HY-P35433
-
|
Tifuvirtide
T-1249
|
HIV
|
Inflammation/Immunology
|
|
Tifuvirtide (T-1249) is a peptide human immunodeficiency virus type-1 (HIV-1) fusion inhibitor. Tifuvirtide is a synthetically designed hybrid retroviral envelope polypeptide. Tifuvirtide has antiretroviral activity. Tifuvirtide can be used for the research of HIV infection.
|
-
- HY-D1301
-
|
BODIPY 581/591 C11
|
Fluorescent Dye
Ferroptosis
|
Cancer
Metabolic Disease
Inflammation/Immunology
|
|
BODIPY 581/591 C11 is a BODIPY borofluoroprene derivative with good light stability and low fluorescence artifacts. BODIPY 581/591 C11 can be used for study lipid peroxidation and antioxidant properties in living cells, or detect ferroptosis by reaction with hydroxyl radicals. BODIPY 581/591 C11 is emitted at 591 nm (reduced prototype), or redshifted to 510 nm (oxidized type). The excitation wavelengths were 581 nm (reduced prototype) and 500 nm (oxidized type). Storage: protect from light.
|
-
- HY-107260
-
-
- HY-B1023
-
-
- HY-P0189
-
-
- HY-N3003
-
-
- HY-N7625
-
-
- HY-B1048
-
|
Pasiniazid
Paraniazide; Pasiniazide; Isonicotinic acid hydrazide p-aminosalicylate
|
Bacterial
|
Inflammation/Immunology
|
|
Pasiniazid is an anti-TB and anti-leprosy drug, used to treat various types of TB and leprosy.
|
-
- HY-B0636
-
-
- HY-108917
-
|
Morphothiadin
GLS4
|
HBV
|
Infection
|
|
Morphothiadin is a potent inhibitor on the replication of both wild-type and adefovir-resistant HBV with an IC50 of 12 nM.
|
-
- HY-15025A
-
-
- HY-N7954
-
-
- HY-121038
-
-
- HY-14367
-
-
- HY-136435
-
-
- HY-13971
-
-
- HY-13433
-
-
- HY-N10223
-
|
Phostriecin
|
Antibiotic
Phosphatase
|
Cancer
Infection
Inflammation/Immunology
|
|
Phostriecin is an antitumor antibiotic produced by Streptomyces pulveraceus. Phostriecin is a strong inhibitor of type 2A (PP2A) and a weak inhibitor of type 1 (PP1) serine/threonine protein phosphatases with IC50s of 3.2 nM and 131 μM, respectively. Phostriecin has the potential for the research of cancer.
|
-
- HY-P3503
-
|
Vosoritide
BMN 111
|
FGFR
|
Others
|
|
Vosoritide (BMN 111) is a modified recombinant CNP (C-type natriuretic peptide) analogue, binds to NPR-B (natriuretic peptide receptor type B) and reduces the activity of FGFR3 (fibroblast growth factor receptor 3). Vosoritide can be used in achondroplasia and dwarfism research.
|
-
- HY-100600
-
|
BGG463
K03859
|
CDK
|
Others
|
|
BGG463 (K03859) is an orally active type II CDK2 inhibitor.
|
-
- HY-16503
-
-
- HY-N2234
-
-
- HY-B1190
-
-
- HY-148800
-
-
- HY-B0023
-
-
- HY-12639
-
|
Bephenium
|
Parasite
|
Infection
|
|
Bephenium is an anthelmintic agent formerly used in the treatment of hookworm infections and ascariasis; B-type AChR activator.
|
-
- HY-16465
-
-
- HY-N10746
-
-
- HY-101096
-
-
- HY-19721
-
-
- HY-W015346
-
-
- HY-N10747
-
-
- HY-B0023S
-
-
- HY-P0189A
-
-
- HY-101616
-
-
- HY-N0371
-
|
Pachymic acid
3-O-Acetyltumulosic acid
|
Akt
ERK
|
Cancer
|
|
Pachymic acid is a lanostrane-type triterpenoid from P. cocos. Pachymic acid inhibits Akt and ERK signaling pathways.
|
-
- HY-144690
-
-
- HY-150057
-
|
CB1R Allosteric modulator 4
|
Cannabinoid Receptor
|
Others
|
|
CB1R Allosteric modulator 4 is a positive allosteric modulator of cannabinoid type-1 (CB1R) with good biological activity. CB1R Allosteric modulator 4 inhibits cAMP production and shows robust activity in β-arrestin-2 recruitment.
|
-
- HY-128888
-
|
(R,R)-GSK321
|
Isocitrate Dehydrogenase (IDH)
|
Cancer
|
|
(R,R)-GSK321 is a wild-type isocitrate dehydrogenase 1 (WT IDH1) inhibitor with an IC50 value of 120 nM. (R,R)-GSK321 as a mutant R132H IDH1 inhibitor, is an isomer of GSK321 with some wild-type cross reactivity.
|
-
- HY-136909
-
|
SR33805
|
Calcium Channel
|
Cardiovascular Disease
|
|
SR33805 is a potent Ca 2+ channel antagonist, with EC50s of 4.1 nM and 33 nM in depolarized and polarized conditions, respectively. SR33805 blocks L-type but not T-type Ca 2+ channels. SR33805 can be used for the research of acute or chronic failing hearts.
|
-
- HY-P1705
-
|
Linopristin
|
Antibiotic
Bacterial
|
Infection
|
|
Linopristin is a kind of type B streptogramin antibiotics. Linopristin, together with type A, Flopristin, to form the streptogramin combination NXL 103. Linopristin exhibit synergistic antimicrobial activity against certain pathogenic bacteria with Flopristin. The preference ratio of Linopristin/Flopristin is 30:70 (w/w) or 70 μM Linopristin +120 μM Flopristin.
|
-
- HY-P1105
-
|
GaTx2
|
Chloride Channel
|
Neurological Disease
|
|
GaTx2 is a seletive and a high affinity inhibitor of ClC-2 channels with a voltage-dependent apparent KD of ∼20 pM. GaTx2 is a peptide toxin inhibitor from Leiurus quinquestriatus hebraeus venom. GaTx2 is useful in determining the role and the membrane localization of ClC-2 in specific cell types.
|
-
- HY-147638
-
-
- HY-136181A
-
-
- HY-136181
-
-
- HY-P3959
-
|
(Tyr0)-Urocortin, rat
|
CRFR
|
Endocrinology
|
|
(Tyr0)-Urocortin, rat is a high-affinity agonist of corticotropin-releasing factor receptor type 1 (CRF-R1) and type 2 (CRF-R2). (Tyr0)-Urocortin, rat shows inhibitory binding constants (Ki) of 1-2 nM.
|
-
- HY-N11025
-
|
Kansenone
|
Others
|
Others
|
|
Kansenone, a euphane-type triterpene, can be isolated from a 60% EtOH extract of Euphorbia kansui.
|
-
- HY-15025
-
-
- HY-N11458
-
-
- HY-12639A
-
-
- HY-B0353
-
-
- HY-123210
-
-
- HY-N8958
-
|
Deacetylorientalide
|
Others
|
Others
|
|
Deacetylorientalide (compound 19) is a germacrane-type sesquiterpenoid compound that can be found in from Sigesbeckia orientalis.
|
-
- HY-N8715
-
|
Cimilactone A
|
Others
|
Others
|
|
Cimilactone A is a cycloartane-type triterpene glycoside. Cimilactone A can be isolated from the rhizomes of Cimicifuga foetida.
|
-
- HY-105074
-
|
Farglitazar
GI262570; GI262570X
|
PPAR
|
Metabolic Disease
|
|
Farglitazar is a PPARγ agonist that has significant therapeutic benefits such as glycemic control in type 2 diabetic patients.
|
-
- HY-N11068
-
|
Huzhangoside C
|
Others
|
Others
|
|
Huzhangoside C is a oleanane-type triterpenoid saponin that can be isolated from the roots of Clematis argentilucida.
|
-
- HY-102016
-
-
- HY-N0601
-
-
- HY-N3630
-
|
Coronarin D
|
Others
|
Others
|
|
Coronarin D is a cytotoxic labdan-type diterpenes compound isolated from the rhizomes of H. coronarium.
|
-
- HY-133225
-
|
Caesalpine A
|
Others
|
Others
|
|
Caesalpine A, a cassane-type diterpene, is a natural product that could be isolated from the seeds of Caesalpinia minax.
|
-
- HY-N7511
-
-
- HY-15566
-
|
APD597
JNJ-38431055
|
GPR119
|
Metabolic Disease
|
|
APD597 is a GPR119 agonist intended for the treatment of type 2 diabetes, with EC50 of 46 nM for hGPR119.
|
-
- HY-B1288A
-
-
- HY-N7785
-
-
- HY-13209C
-
-
- HY-N11100
-
|
Geranin A
|
Parasite
|
Infection
|
Geranin A is an A-type proanthocyanidin. Geranin A can be isolated from the antiprotozoal extract of Geranium niveum.
|
-
- HY-10955
-
|
TTA-P1
|
Calcium Channel
|
Neurological Disease
|
|
TTA-P1 is a potent state-independent compound inhibiting human T-type calcium channel. T-type calcium channels play a role in diverse physiological responses including neuronal burst firing, hormone secretion, and cell growth. TTA-P1 has the potential for the research of absence epilepsy.
|
-
- HY-118091
-
|
LY191704
|
5 alpha Reductase
|
Endocrinology
|
|
LY191704, as a benzoquinolinone, is a potent, nonsteroidal, noncompetitive and selective human type I 5α-reductase inhibitor. LY191704 is a racemic mixture of the compounds LY300502 and LY300503. LY191704 may be useful in the research of human endocrine disorders associated with overproduction of dihydrotestosterone (DHT) by 5α-reductase type 1.
|
-
- HY-151383
-
-
- HY-151384
-
-
- HY-B0881
-
-
- HY-15465A
-
-
- HY-112154
-
-
- HY-B1902
-
|
Diaveridine
EGIS-5645
|
Antifolate
Bacterial
|
Infection
|
|
Diaveridine (EGIS-5645) is a dihydrofolate reductase (DHFR) inhibitor with a Ki of 11.5 nM for the wild type DHFR and also an antibacterial agent.
|
-
- HY-B0382
-
-
- HY-15465
-
|
KN-93
|
CaMK
Autophagy
|
Cancer
|
|
KN-93 is a cell-permeable, reversible and competitive inhibitor calmodulin-dependent kinase type II (CaMKII) with a Ki of 370 nM.
|
-
- HY-B1216
-
-
- HY-111951
-
|
D-Panose
|
Others
|
Others
|
|
D-Panose is a PAN-type oligosaccharide. D-Panose is a food ingredient based on isomaltooligosaccharides (IMOs).
|
-
- HY-121118
-
-
- HY-N2047
-
|
Jujuboside B1
|
Others
|
Others
|
|
Jujuboside B1, a dammarane-type triterpene oligoglycoside, is isolated from Ziziphi Spinosae Semen.
|
-
- HY-101267
-
|
CHMFL-BMX-078
CHMFL-BMX 078
|
BMX Kinase
|
Cancer
|
|
CHMFL-BMX-078 is a highly potent and selective type II irreversible BMX kinase inhibitor with an IC50 of 11 nM.
|
-
- HY-11013
-
-
- HY-B1114
-
|
Gliquidone
AR-DF 26
|
Others
|
Metabolic Disease
|
|
Gliquidone (AR-DF 26) is an anti-diabetic agent in the sulfonylurea class, used in the treatment of diabetes mellitus type 2.
|
-
- HY-N3769
-
-
- HY-N7830
-
-
- HY-76938
-
|
Actarit
4-Acetylaminophenylacetic acid; MS-932
|
Others
|
Inflammation/Immunology
|
|
Actarit, an orally active antirheumatic compound, has the potential to treat type II collagen-induced arthritis.
|
-
- HY-12777
-
-
- HY-18620
-
|
DZ2002
|
Others
|
Inflammation/Immunology
|
|
DZ2002 is an orally active, reversible and low-cytotoxic type III SAHH inhibitor (Ki=17.9 nM), with good immunosuppressive activity. DZ2002 prevents the development of experimental dermal fibrosis by reversing the profibrotic phenotype of various cell types. DZ2002 can be used in studies of autoimmune diseases such as lupus syndrome and systemic sclerosis.
|
-
- HY-10555
-
|
AMG-221
|
11β-HSD
|
Metabolic Disease
|
|
AMG-221 is an inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) with a Ki of 12.8 nM in vitro biochemical scintillation proximity assay (SPA) and an IC50 of 10.1 nM in cell-based assays. AMG-221 can be used for the research of type 2 diabetes.
|
-
- HY-122906
-
|
JTE-952
|
c-Fms
|
Inflammation/Immunology
|
|
JTE-952 is a potent, oral active and selective Type II inhibitor of colony stimulating factor-1 receptor (CSF-1R or cFMS, type III receptor tyrosine kinase), with IC50 values of 13 nM and 261 nM for CSF1R and TrkA , respectively. Effective against a mouse collagen-induced model of arthritis.
|
-
- HY-P1194A
-
|
Spantide I TFA
|
Neurokinin Receptor
|
Inflammation/Immunology
|
|
Spantide I TFA, a substance P analog, is a selective NK1 receptor antagonist, with Ki values of 230 nM and 8150 nM for NK1 and NK2 receptor, respectively. Spantide I provides an approach to reduce type 1 and enhance the type 2 cytokine IL-10 in the infected cornea, leading to a significant reduction in corneal perforation.
|
-
- HY-108974S
-
|
Drotaverine-d10 hydrochloride
|
Phosphodiesterase (PDE)
Calcium Channel
|
|
|
Drotaverine-d10 (hydrochloride) is the deuterium labeled Drotaverine hydrochloride. Drotaverine hydrochloride is a type 4 cyclic nucleotide phosphodiesterase (PDE4) inhibitor and an L-type voltage-dependent calcium channel (L-VDCC) blocker, blocks the degradation of 3',5'-cyclic adenosine monophosphate. Drotaverine hydrochloride exhibits in vivo antispasmodic efficacy without anticholinergic effects[1][2].
|
-
- HY-P1194
-
|
Spantide I
|
Neurokinin Receptor
|
Inflammation/Immunology
|
|
Spantide I, a substance P analog, is a selective NK1 receptor antagonist, with Ki values of 230 nM and 8150 nM for NK1 and NK2 receptor, respectively. Spantide I provides an approach to reduce type 1 and enhance the type 2 cytokine IL-10 in the infected cornea, leading to a significant reduction in corneal perforation.
|
-
- HY-108355
-
|
R59949
|
PKC
|
Cancer
|
|
R59949 is a pan diacylglycerol kinase (DGK) inhibitor with an IC50 of 300 nM. R59949 strongly inhibits the activity of type I DGK α and γ and moderately attenuates the activity of type II DGK θ and κ. R59949 activates protein kinase C (PKC) by enhancing the levels of the endogenous ligand diacyl glycerol.
|
-
- HY-150769
-
|
ZLM-66
|
HIV
|
Inflammation/Immunology
|
|
ZLM-66 is a potent non-nucleoside reverse transcriptase inhibitor (NNRTIs) with an IC50 of 41 nM for wild-type (WT) HIV-1 reverse transcriptase and an EC50 value of 13 nM for wild-type HIV-1. ZLM-66 is a Doravirine (HY-16767) analogs. ZLM-66 can be used for the research of AIDS.
|
-
- HY-108460
-
|
A-784168
|
TRP Channel
|
Neurological Disease
|
|
A-784168 is a potent and orally active inhibitor of vanilloid receptor type 1 (TRPV1). Vanilloid receptor type 1 (TRPV1) is a ligand-gated nonselective cation channel that is considered to be an important integrator of various pain stimuli such as endogenous lipids, capsaicin, heat, and low pH. A-784168 has good CNS penetration.
|
-
- HY-126666
-
|
PNU-159682 carboxylic acid
|
ADC Cytotoxin
|
Cancer
Inflammation/Immunology
|
|
PNU-159682 carboxylic acid (compound 53) is a potent ADCs cytotoxin and encodes a member of the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily. PNU-159682 carboxylic acid has protein fold and diverse functions, such as cell adhesion, cell-cell signalling, glycoprotein turnover, and roles in inflammation and immune response.
|
-
- HY-111202
-
-
- HY-150539
-
-
- HY-118091B
-
|
LY300503
|
Others
|
Others
|
|
LY300503 is an enantiomer of LY191704. LY191704 is a human type I 5α-reductase inhibitor.
|
-
- HY-U00433
-
-
- HY-N11498
-
|
β-Obscurine
|
Others
|
Others
|
|
β-Obscurine is a lycopodine-type alkaloid, which can be isolated from the club moss Lycopodium casuarinoides.
|
-
- HY-120546
-
-
- HY-12075
-
-
- HY-N4263
-
-
- HY-121161A
-
|
Brassinazole
|
Others
|
Others
|
|
Brassinazole is a selective triazole-type brassinosteroid (BR) biosynthesis inhibitor. Brassinazole is used for regulating plant growth and development.
|
-
- HY-132893
-
-
- HY-10397
-
-
- HY-P99509
-
-
- HY-13226
-
|
Galunisertib
LY2157299
|
TGF-β Receptor
|
Cancer
|
|
Galunisertib (LY2157299) is an oral and selective TGF-β receptor type I (TGF-βRI) kinase inhibitor with an IC50 of 56 nM.
|
-
- HY-N2046
-
|
Jujuboside D
Jujuboside A1
|
Others
|
Others
|
|
Jujuboside D (Jujuboside A1) is a dammarane-type saponin that can be isolated from the seeds of Ziziphus jujube.
|
-
- HY-16465A
-
-
- HY-78139
-
|
L-Xylose
L-(-)-Xylose
|
Others
|
Others
|
|
L-Xylose (L-(-)-Xylose) is the levo-isomer of Xylose. Xylose is classified as a monosaccharide of the aldopentose type.
|
-
- HY-125588
-
-
- HY-N6799
-
|
Neosolaniol
|
Others
|
Infection
|
|
Neosolaniol is a type A trichothecene mycotoxin from Fusarium sp. Neosolaniol evokes robust anorectic response.
|
-
- HY-111056
-
|
UK122
|
Ser/Thr Protease
|
Cancer
|
|
UK122 is a potent and selective urokinase-type plasminogen activator (uPA) inhibitor with an IC50 of 0.2 μM. UK122 shows no or little inhibition of tissue-type PA (tPA), plasmin, thrombin, and trypsin (all IC50>100 μM). UK122, 4-oxazolidinone analogue, is an anticancer agent and inhibits cancer cell migration and invasion.
|
-
- HY-112540
-
|
Acetoacetic acid
|
Endogenous Metabolite
|
Neurological Disease
Metabolic Disease
|
|
Acetoacetic acid is an endogenous metabolite present in Cerebrospinal_Fluid and Blood that can be used for the research of Meningitis, Pregnancy, 3 Hydroxy 3 Methylglutaryl CoA Lyase Deficiency, Preeclampsia/Eclampsia, Diabetes Mellitus Type 2, Glucose Transporter Type 1 Deficiency Syndrome and Succinyl CoA:3 Oxoacid CoA Transferase Deficiency.
|
-
- HY-N7683
-
|
Prunetin 5-O-β-D-glucopyranoside
|
Glucosidase
|
Metabolic Disease
|
|
Prunetin 5-O-β-D-glucopyranoside is an isoflavone isolated from extracts of Potentilla astracanica. Prunetin 5-O-β-D-glucopyranoside is a potent and uncompetitive inhibitor of α-glucosidase, with an IC50 of 56.05 μg/mL. Prunetin 5-O-β-D-glucopyranoside can be used for the research of type-2 diabetes.
|
-
- HY-U00137
-
-
- HY-142952
-
-
- HY-111070
-
|
Karavilagenin D
|
Others
|
Cancer
|
|
Karavilagenin D, a cucurbitane-type triterpene isolated from Japanese bitter melon leaves, is a potential tumor-promoting inhibitor.
|
-
- HY-N1945
-
|
Bonvalotidine A
|
Others
|
Others
|
|
Bonvalotidine A is a lycoctonine-type C19-diterpenoid alkaloid isolated from the roots of Delphinium bonvalotii Franch.
|
-
- HY-N6928
-
-
- HY-17603
-
-
- HY-N0891
-
|
Tubeimoside II
Tubeimoside-B
|
Others
|
Cancer
|
|
Tubeimoside II(Tubeimoside-B) is a natural analogue of oleanane type of triterpenoid saponin; show anti-inflammatory, antitumor, and antitumor-promoting effects.
|
-
- HY-N10971
-
|
Noraucuparin
|
Others
|
Infection
|
|
Noraucuparin is a biphenyl-type phytoalexin. Noraucuparin has antifungal effect. Noraucuparin can be isolated from the leaves of Sorbus pohuashanensis.
|
-
- HY-137452
-
-
- HY-N8410
-
|
Momordicoside P
|
Others
|
Others
|
|
Momordicoside P is a cucurbitane-type triterpenoid saponin. Momordicoside P can be isolated from the fresh fruits of Momordica charantia.
|
-
- HY-100856
-
-
- HY-113005
-
-
- HY-N7179
-
-
- HY-14831
-
|
Arhalofenate
MBX 102; JNJ 39659100
|
PPAR
|
Metabolic Disease
|
|
Arhalofenate (MBX 102) is a selective partial agonist of peroxisome proliferator-activated receptor (PPAR)-γ, used for the treatment of type 2 diabetes.
|
-
- HY-115496
-
-
- HY-103318
-
-
- HY-137440
-
-
- HY-12083
-
|
PPY-A
|
Bcr-Abl
|
Cancer
|
|
PPY-A is a potent T315I mutant and wild-type Abl kinases inhibitor with IC50s of 9 and 20 nM, respectively. PPY-A inhibits Ba⁄F3 cells transformed with wild-type Abl and Abl T315I mutantl with IC50s of 390 and 180 nM, respectively. PPY-A can be used for the research of chronic myeloid leukemia (CML).
|
-
- HY-123671
-
|
CYM2503
|
Neuropeptide Y Receptor
|
Neurological Disease
|
|
CYM2503 is a putative GalR2-positive allosteric modulator. CYM2503 increases the latency to first electrographic seizure and decreases the total time in seizure. CYM2503 also attenuates electroshock-induced seizures in mice. Galanin receptors type 1 (GalR1) and/or type 2 (GalR2) represent unique pharmacological targets for the research of seizures and epilepsy.
|
-
- HY-12071
-
|
LDN193189
DM-3189
|
TGF-β Receptor
|
Cancer
|
|
LDN193189 is a potent selective BMP type I receptor (BMP I) inhibitor. LDN-193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively. LDN-193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva.
|
-
- HY-B0254S
-
|
Glipizide-d11
|
Potassium Channel
|
Metabolic Disease
|
|
Glipizide-d11 is the deuterium labeled Glipizide. Glipizide (CP 2872; K 4024) a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2 diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium (KATP) channels among β cells of pancreatic islets of Langerhans[1][2].
|
-
- HY-12098
-
|
Verubulin hydrochloride
MPC-6827 hydrochloride
|
Microtubule/Tubulin
|
Cancer
|
|
Verubulin hydrochloride (MPC-6827 hydrochloride) is a blood brain barrier permeable microtubule-disrupting agent, with potent and broad-spectrum in vitro and in vivo cytotoxic activities. Verubulin hydrochloride (MPC-6827 hydrochloride) exhibits potent anticancer activity in human MX-1 breast and other mouse xenograft cancer models. Verubulin hydrochloride (MPC 6827 hydrochloride) is a promising candidate for the treatment of multiple cancer types.
|
-
- HY-N8621
-
|
(11S)-(-)-Hydroxyjasmonic acid
|
Others
|
Others
|
|
(11S)-(-)-Hydroxyjasmonic acid is a hydroxylated cyclopentane fatty acid of the jasmonic acid type that can be found in the culture filtrate of the fungus Botryodiplodia theobromae<.
|
-
- HY-13783
-
|
BIBF0775
|
TGF-β Receptor
|
Cancer
|
|
BIBF0775 is a potent and selective transforming growth factor β (TGFβ) type I receptor (Alk5) inhibitor with an IC50 of 34 nM.
|
-
- HY-U00437
-
-
- HY-117605
-
-
- HY-122615B
-
-
- HY-N8609
-
|
Uralsaponin C
|
Others
|
Others
|
|
Uralsaponin C is an analogue of oleanane-type triterpenoid saponin. Uralsaponin C can be isolated from the roots of Glycyrrhiza uralensis Fisch.
|
-
- HY-19400
-
-
- HY-50081
-
-
- HY-16664
-
-
- HY-19900
-
-
- HY-N2084
-
-
- HY-147880
-
-
- HY-133813A
-
-
- HY-101746
-
|
GSK376501A
|
PPAR
|
Metabolic Disease
|
|
GSK376501A is a selective peroxisome proliferator-activated receptor gamma (PPARγ) modulator for the treatment of type 2 diabetes mellitus.
|
-
- HY-103307
-
-
- HY-P0014
-
-
- HY-122615A
-
-
- HY-124584
-
|
Minnelide
|
Apoptosis
|
Cancer
|
|
Minnelide is a prodrug of triptolide that shows potent antitumor activity in a number of tumor types, particularly in pancreatic cancer. Minnelide promotes apoptosis.
|
-
- HY-117273
-
|
AZ304
|
Raf
Autophagy
|
Cancer
|
|
AZ304 is an ATP-competitive dual BRAF kinase inhibitor, potently inhibits wild type BRAF, V600E mutant BRAF and wild type CRAF, with IC50s of 79 nM, 38 nM and 68 nM, respectively. AZ304 also has significant effect on other kinases, such as p38 (IC50, 6 nM), CSF1R (IC50, 35 nM). Anti-tumor activity.
|
-
- HY-101292
-
|
FK614
|
PPAR
|
Metabolic Disease
|
|
FK614 is an orally active, non-thiazolidinedione (TZD) type, and selective PPARγ modulator (SPPARM). FK614 functions as a PPARγ agonist with potent anti-diabetic activity in vivo. FK614 has different effects on the activation of PPARγ at each stage of adipocyte differentiation. FK614 can be used for the research of hyperglycemia, hypertriglyceridemia, glucose intolerance and type 2 diabetes.
|
-
- HY-147526
-
|
RM-581
|
Others
|
Cancer
|
|
RM-581, an aminosteroid derivative, has potent anticancer activity in different types of cancer, including high fatality pancreatic cancer.
|
-
- HY-111634
-
|
Epsilon-momfluorothrin
|
Others
|
Cancer
|
|
Epsilon-momfluorothrin is a type I synthetic pyrethroid insecticide, activates constitutive androstane receptor (CAR), and induces hepatocellular tumors in rats.
|
-
- HY-131413
-
-
- HY-153577
-
-
- HY-N11443
-
-
- HY-B0076S
-
-
- HY-14914S
-
-
- HY-108848
-
|
Reteplase
BM 06.022
|
Others
|
Metabolic Disease
|
|
Reteplase (BM 06.022) is a recombinant plasminogen activator, consists of the kringle 2 and protease domains of human tissue-type plasminogen activator.
|
-
- HY-114772
-
|
Methyl reserpate
NSC 81464; Me reserpate
|
Others
|
Others
|
|
Methyl reserpate (NSC 81464) is a Yohimbine (HY-12715) type alkaloid, that can be isolated from Rauwolfia vomitoria roots and leaves.
|
-
- HY-N2077
-
-
- HY-10388
-
-
- HY-W115740
-
-
- HY-N9328
-
|
Tarasaponin IV
|
Others
|
Cancer
|
|
Tarasaponin IV, as an oleanane-type triterpene saponin, is isolated from the bark of Aralia elata. Tarasaponin IV can be used for the research of cancer.
|
-
- HY-N8156
-
|
Soyasapogenol C
|
HSV
|
Infection
|
|
Soyasapogenol C is an oleanane-type triterpenoid. Soyasapogenol C exhibits anti-HSV-1 activity, with an IC50 of 18.9 μM.
|
-
- HY-N3303
-
|
Meliasenin B
|
Others
|
Others
|
|
Meliasenin B (compound 2) is an apotirucallane-type triterpenoid. Meliasenin B is a nature product that could be isolated from the fruits of Melia azedarach.
|
-
- HY-B2010
-
|
Fomesafen
|
Others
|
Others
|
|
Fomesafen is a type of efficient and selective protoporphyrinogen IX oxidase (PPO) inhibitor. Fomesafen is a herbicide and has the advantages of low toxicity and high selectivity.
|
-
- HY-B0202S
-
-
- HY-N1492
-
-
- HY-147351
-
-
- HY-123046
-
-
- HY-120598
-
-
- HY-145196
-
|
RTICBM-189
|
Cannabinoid Receptor
|
Neurological Disease
|
|
RTICBM-189 is a potent, brain-penetrant allosteric modulator of the cannabinoid type-1 (CB1) receptor with a pIC50 of 7.54 in Ca 2+ mobilization assay. RTICBM-189 has pIC50s of 5.29 and 6.25 for hCB1 and mCB1, respectively. RTICBM-189 significantly and selectively attenuates the reinstatement of the addictive agent-seeking behavior in rats.
|
-
- HY-N10661
-
|
Ipomoeassin F
Ipom-F
|
SARS-CoV
|
Cancer
Infection
|
|
Ipomoeassin F is a potent and selective endoplasmic reticulum (ER) protein-translocation inhibitor by targeting the pore-forming subunit of the Sec61 complex (Sec61α) at the ER membrane. Ipomoeassin F selectively inhibits the ER membrane translocation of SARS-CoV-2 proteins. Ipomoeassin F block the ER translocation of secretory proteins and type I transmembrane proteins (TMPs), but not type III TMPs.
|
-
- HY-112861A
-
-
- HY-17402
-
-
- HY-135328
-
-
- HY-N11011
-
|
Withaphysalin A
|
Others
|
Inflammation/Immunology
|
|
Withaphysalin A is a withanolide-type compound. Withaphysalin A can be obtained from the anti-inflammatory fraction of P. minima. Withaphysalin A can be used for the research of inflammation.
|
-
- HY-U00124
-
|
Tromantadine
|
HSV
|
Infection
|
|
Tromantadine hydrochloride, an Amantadine derivative with antiherpetic activity, inhibits herpes simplex virus type 1 (HSV-1) and HSV-2 replication.
|
-
- HY-139785
-
|
Cavrotolimod
|
Toll-like Receptor (TLR)
|
Others
|
|
Cavrotolimod is an immunostimulatory spherical nucleic acid (SNA) modified with type B CpG oligonucleotides designed to agonize TLR9 and elicit immune responses useful in oncology applications.
|
-
- HY-D0949
-
|
Pyronine B
|
Fluorescent Dye
|
Others
|
|
Pyronine B is an organic cationic dye. Pyronin B as a solution-processable and heating-free n-type dopant can be used for soft electronics.
|
-
- HY-12957
-
-
- HY-18055
-
-
- HY-14955
-
-
- HY-W011151
-
-
- HY-12525
-
|
LGD-6972
|
GCGR
|
Metabolic Disease
|
|
LGD-6972 is a selective and orally active glucagon receptor antagonist. LGD-6972 has the potential for type 2 diabetes research.
|
-
- HY-N4305
-
-
- HY-B1378
-
-
- HY-100750
-
-
- HY-111110
-
-
- HY-136435S1
-
-
- HY-B1190S
-
|
Cefadroxil-d4 hydrate
BL-S 578-d4 (hydrate)
|
Bacterial
Antibiotic
|
Infection
|
|
Cefadroxil-d4 (hydrate) is the deuterium labeled Cefadroxil. Cefadroxil is a broad-spectrum antibiotic of the cephalosporin type, effective in Gram-positive and Gram-negative bacterial infections.
|
-
- HY-17512A
-
-
- HY-17435
-
|
4'-Demethylepipodophyllotoxin
4'-O-demethylepipodophyllotoxin; 4'-DMEP
|
Microtubule/Tubulin
|
Cancer
|
|
4'-Demethylepipodophyllotoxin(4'-DMEP) is a key intermediate compound for the preparation of podophyllotoxin-type anti-cancer drugs; a potent inhibitor of microtubule assembly.
|
-
- HY-18053
-
-
- HY-144231
-
|
SIK1 activator 1
|
Others
|
Metabolic Disease
|
|
SIK1 activator 1 exhibited remarkable inhibitory activity on hepatic gluconeogenesis by enhancing the SIK1 phosphorylation and ameliorated the hyperglyceamia of type 2 diabetic mice.
|
-
- HY-18960
-
|
CHZ868
|
JAK
|
Cancer
|
|
CHZ868 is a type II JAK2 inhibitor with an IC50 of 0.17 μM in EPOR JAK2 WT Ba/F3 cell.
|
-
- HY-113005A
-
-
- HY-N10588A
-
-
- HY-N6724
-
|
Altertoxin I
Dihydroalterperylenol
|
Others
|
Metabolic Disease
|
|
Altertoxin I (Dihydroalterperylenol) is a quinone-type mycotoxin produced by Alternaria alternata fungi, which is mutagenic and cytotoxic, and can weakly disrupts metabolic communication.
|
-
- HY-N8103
-
-
- HY-13780
-
|
Vinblastine sulfate
Vincaleukoblastine sulfate salt
|
Microtubule/Tubulin
Autophagy
|
Cancer
|
|
Vinblastine sulfate is a cytotoxic alkaloid used against various cancer types. Vinblastine sulfate inhibits the formation of microtubule and suppresses nAChR with an IC50 of 8.9 μM.
|
-
- HY-N2530
-
-
- HY-U00124B
-
-
- HY-17458
-
-
- HY-101832
-
-
- HY-146108
-
|
RSV-IN-5
|
RSV
|
Infection
|
|
RSV-IN-5 (Compound 4) is a potent dual inhibitor of wild-type and mutant respiratory syncytial virus (RSV) fusion proteins. RSV-IN-5 exhibits potent anti-RSV activities against not only wild-type A2 F protein (EC50=2.0 nM), but also D486N-mutant F protein (EC50=8.1 nM).
|
-
- HY-E70053
-
-
- HY-121392
-
-
- HY-P1110
-
|
AF12198
|
Interleukin Related
|
Inflammation/Immunology
|
|
AF12198 is a potent, selective and specific peptide antagonist for human type I interleukin-1 receptor (IL1-R1) (IC50=8 nM) but not the human type II receptor (IC50=6.7 µM) or the murine type I receptor (IC50>200 µM). AF12198 inhibits IL-1-induced IL-8 production (IC50=25 nM) and IL-1-induced intercellular adhesion molecule-1 (ICAM-1) expression (IC50=9 nM) in vitro. AF12198 has anti-inflammatory activities and blocks responses to IL-1 in vivo.
|
-
- HY-P0165
-
|
Taspoglutide
ITM077; R1583; BIM51077
|
GCGR
|
Metabolic Disease
|
|
Taspoglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist developed for treatment of type 2 diabetes, with an EC50 value of 0.06 nM.
|
-
- HY-142953
-
-
- HY-N3269
-
-
- HY-150541
-
-
- HY-P0119A
-
-
- HY-B0636S
-
-
- HY-N6583
-
|
Licoflavonol
|
Bacterial
|
Infection
|
|
Licoflavonol, a minor flavone from the roots of Glycyrrhiza uralensis, is an inhibitor of the Salmonella type III secretion system (T3SS).
|
-
- HY-14736
-
-
- HY-121161
-
-
- HY-P0119
-
|
Lixisenatide
|
GCGR
|
Metabolic Disease
|
|
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes mellitus (T2DM).
|
-
- HY-12505
-
|
CX546
|
iGluR
Autophagy
|
Neurological Disease
|
|
CX546 is a first-generation and selective benzamide-type positive AMPAR modulator. CX546 is a prototypical ampakine agent and has antipsychotic effects.
|
-
- HY-N10589
-
-
- HY-P99478
-
-
- HY-N10588
-
|
Nardoguaianone K
10-epi-Nardoguaianone J
|
Others
|
Cancer
|
|
Nardoguaianone K, a guaiane-type compound, can be isolated from Nardostachys chinensis roots. Nardoguaianone K cam be used in the research of pancreatic cancer.
|
-
- HY-101323
-
|
Olvanil
NE-19550; N-Vanillyloleamide
|
TRP Channel
|
Neurological Disease
|
|
Olvanil (NE-19550) is an analgesic and an agonist of transient receptor potential vanilloid type 1 (TRPV1) channels with an EC50 of 0.7 nM.
|
-
- HY-136649
-
-
- HY-P9913A
-
-
- HY-109188
-
|
Relzomostat
|
Others
|
Metabolic Disease
|
|
Relzomostat is a methionine aminopeptidase 2 (MetAP2) inhibitor.Relzomostat may be useful for the research of obesity, type 2 diabetes, and other obesity-associated conditions.
|
-
- HY-14844
-
|
Lagociclovir
MIV-210
|
HBV
|
Infection
|
|
Lagociclovir (FLG) is a nucleoside analogue that inhibits wild-type hepatitis B virus (HBV) replication in a human hepatoma cell line permanently expressing HBV.
|
-
- HY-100325
-
-
- HY-N10483
-
|
Telekin
|
Apoptosis
|
Cancer
|
|
Telekin is an eucalyptus-type sesquiterpene lactone compound found in Carpesium divaricatum. Telekin can activate mitochondria-mediated cell apoptosis and has anticancer activity.
|
-
- HY-W012788
-
|
Maltol
|
Endogenous Metabolite
|
Others
|
|
Maltol, a type of aromatic compound, exists in high concentrations in red ginseng. Maltol is a potent antioxidative agent and typically is used to enhance flavor and preserve food.
|
-
- HY-111050
-
|
JNJ-38877618
|
c-Met/HGFR
|
Cancer
|
|
JNJ-38877618 is a potent, highly selective, orally bioavailable Met kinase inhibitor with IC50s of 2 and 3 nM for wild type and mutant Met, respectively.
|
-
- HY-10286A
-
-
- HY-P3884
-
-
- HY-N10934
-
-
- HY-N1018
-
|
11-Hydroxygelsenicine
|
Others
|
Others
|
|
11-Hydroxygelsenicine is a 11-hydroxy-substituted gelsedine-type indole alkaloid compound isolated from the EtOH extract of the stems of Gelsemium elegans.
|
-
- HY-B1655
-
|
Fluspirilene
R 6218; Redeptin
|
Calcium Channel
|
Neurological Disease
|
|
Fluspirilene is a non-competitive antagonist of L-type calcium channels with an IC50 of 0.03 μM. Fluspirileneis a long-acting injectable depot antipsychotic agent used for schizophrenia.
|
-
- HY-N10672
-
-
- HY-120597
-
|
SAK3
|
Calcium Channel
|
Neurological Disease
|
|
SAK3 is a potent T-type voltage-gated Ca 2+ channels (T-VGCCs) enhancer. SAK3 enhances Cav3.1 and Cav3.3 T-type Ca 2+ channel currents. Acute SAK3 administration improves memory deficits in olfactory-bulbectomized mice. SAK3 inhibits amyloid β plaque formation in APP-KI mice by activating the proteasome activity.
|
-
- HY-15371
-
|
Forskolin
Coleonol; Colforsin; HL 362
|
Adenylate Cyclase
FXR
Autophagy
|
Cancer
Endocrinology
Metabolic Disease
Inflammation/Immunology
|
|
Forskolin (Coleonol) is a potent adenylate cyclase activator with an IC50 of 41 nM and an EC50 of 0.5 μM for type I adenylyl cyclase. Forskolin is also an inducer of intracellular cAMP formation. Forskolin induces differentiation of various cell types and activates pregnane X receptor (PXR) and FXR. Forskolin exerts a inotropic effect on the heart, and has platelet antiaggregatory and antihypertensive actions. Forskolin also induces autophagy.
|
-
- HY-118250
-
|
GSK2245035
|
Toll-like Receptor (TLR)
IFNAR
TNF Receptor
|
Inflammation/Immunology
|
|
GSK2245035 is a highly potent and selective intranasal Toll-Like receptor 7 (TLR7) agonist with preferential Type-1 interferon (IFN)-stimulating properties. GSK2245035 has pEC50s of 9.3 and 6.5 for IFNα and TFNα. GSK2245035 effectively suppresses allergen-induced Th2 cytokine production in human peripheral blood cell cultures. GSK2245035 is used for asthma.
|
-
- HY-125857
-
-
- HY-146056
-
|
Anabolic agent-1
|
Others
|
Others
|
|
Compounds, as a new type of bone morphogenetic protein-2 up regulator, can not only correct the bone loss in patients, but also have a wide range of clinical applicability.
|
-
- HY-18623
-
|
VI 16832
|
Others
|
Cancer
|
|
VI 16832 is a broad spectrum Type I kinase inhibitor which can be used as an enrichment tool for the comparative expression analysis of protein kinases in different cancer cell lines.
|
-
- HY-12195
-
-
- HY-13660
-
-
- HY-119373
-
-
- HY-142963
-
-
- HY-136457
-
|
2-NP-AHD
|
Drug Metabolite
|
Others
|
|
2-NP-AHD is a 2-nitrophenyl derivative of AHD (a metabolite of nitrofurans type of antibiotics), can be used as indicator of the illegal usage of nitrofuran agents.
|
-
- HY-115363
-
|
Curcumenone
|
Others
|
Cardiovascular Disease
Metabolic Disease
|
|
Curcumenone is a major constituent of the plants of medicinally important genus of Curcuma. Curcumenone, a caraborane type sesquiterpene has been reported to be a vasorelaxant, hepatoprotective and an effective inhibitor of intoxication.
|
-
- HY-10388A
-
-
- HY-U00433A
-
-
- HY-153239
-
-
- HY-103227
-
-
- HY-111645
-
-
- HY-15675
-
|
AZD1656
|
Glucokinase
|
Metabolic Disease
|
|
AZD1656 is a potent, selective and orally active glucokinase activator with an EC50 of 60 nM. AZD1656 has the potential for type 2 diabetes research.
|
-
- HY-B0202S1
-
-
- HY-113081
-
|
1-Methyladenosine
|
Endogenous Metabolite
|
Others
|
|
1-Methyladenosine is an RNA modification originating essentially from two different reaction types, one catalyzed by enzymes and the other the result of the reaction of RNA with certain alkylating agents.
|
-
- HY-136548
-
-
- HY-B1114S
-
-
- HY-10286
-
-
- HY-128574
-
-
- HY-110363
-
-
- HY-N0252
-
-
- HY-112089
-
|
LXH254
|
Raf
p38 MAPK
Bcr-Abl
|
Cancer
|
|
LXH254 is a potent, selective, orally active, type II BRAF and CRAF inhibitor, with IC50 values of 0.072 and 0.21 nM against CRAF and BRAF, respectively.
|
-
- HY-N0252A
-
-
- HY-17041
-
|
Darunavir Ethanolate
TMC114 Ethanolate
|
HIV
HIV Protease
|
Infection
|
|
Darunavir ethanolate (TMC114 Ethanolate) is a potent HIV protease inhibitor used to treat and prevent HIV/AIDS. Darunavir has a Ki of 1 nM for wild type HIV-1 protease.
|
-
- HY-P4391
-
-
- HY-122615
-
|
SPOP-IN-6b
|
Others
|
Cancer
|
|
SPOP-IN-6b is a speckle-type POZ protein (SPOP) inhibitor with an IC50 of 3.58 μM (patent CN 107141287, SPOP-B-88).
|
-
- HY-15025AS
-
-
- HY-N3241
-
|
Mucrolidin
|
Bacterial
|
Infection
|
|
Mucrolidin is an eudesmane-type sesquiterpenoid isolated from aerial parts of homalomena occulta. Mucrolidin exhibits weak antibacterial activities when it compares to Rifampicin (HY-B0272).
|
-
- HY-15386
-
-
- HY-128366
-
|
Waltonitone
|
Apoptosis
|
Cancer
|
|
Waltonitone is a ursane-type pentacyclic triterpene isolated from Gentian waltonii Burkill. Waltonitone significantly inhibits hepatocellular carcinoma cells growth and induces apoptosis in vitro and in vivo.
|
-
- HY-141807
-
|
MS21
|
PROTACs
|
Cancer
|
|
MS21, a novel degrader of AKT, selectively inhibits the growth of PI3K/PTEN pathway-mutant cancers with wild-type KRAS and BRAF.
|
-
- HY-N1041
-
-
- HY-144215
-
|
TLR8 agonist 4
|
HBV
|
Inflammation/Immunology
|
|
TLR8 agonist 4 showed effective inhibition on wild-type and drug-resistant (lamivudine and entecavir) HBV strains. The IC50 values are 0.15 and 0.10 respectively μM.
|
-
- HY-15004
-
|
AUZ 454
K03861
|
CDK
|
Cancer
|
|
AUZ 454 (K03861) is a type II CDK2 inhibitor with Kd of 8.2 nM. AUZ 454 (K03861) inhibits CDK2 activity by competing with binding of activating cyclins.
|
-
- HY-N2247
-
|
Guaiacin
|
Phosphatase
|
Metabolic Disease
|
|
Guaiacin is a arylnaphthalene type lignin isolated from the barks of Machilus thunbergii SIEB. et ZUCC (Lauraceae). Guaiacin significantly increases alkaline phosphatase activity and osteoblast differentiation.
|
-
- HY-108045
-
-
- HY-16421
-
|
Ragaglitazar
(-)-DRF 2725; NNC 61-0029
|
PPAR
|
Metabolic Disease
|
|
Ragaglitazar is a PPARα and PPARγ agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic.
|
-
- HY-B1052
-
-
- HY-16942
-
|
Damulin B
|
Apoptosis
|
Cancer
|
|
Damulin B is a dammarane-type saponin found in Gynostemma pentaphyllum.Damulin B can induce cell apoptosis and has anti-cancer activities in vitro.
|
-
- HY-P3835
-
-
- HY-B0199A
-
-
- HY-B1052A
-
-
- HY-78349
-
|
A 77-01
|
TGF-β Receptor
|
Cancer
|
|
A 77-01 is a potent inhibitor of transforming growth factor (TGF)-β type I receptor superfamily activin-like kinase ALK5 with an IC50 of 25 nM.
|
-
- HY-N0134
-
-
- HY-128661
-
-
- HY-115831
-
|
SAR247799
S1P1 agonist 3
|
LPL Receptor
|
Cardiovascular Disease
|
|
SAR247799 (S1P1 agonist 3) is an oral activity, selective G-protein-biased sphingosine-1 phosphate receptor-1 (S1P1 ) agonist, with EC50s rang from 12.6 to 493 nM in S1P1-overexpressing cells and HUVECs. SAR247799 can be used for the research of endothelial protection, including type-2 diabetes, metabolic syndrome.
|
-
- HY-13001
-
|
Quizartinib
AC220
|
FLT3
Ligands for Target Protein for PROTAC
Apoptosis
Autophagy
|
Cancer
|
|
Quizartinib (AC220) is an orally active, highly selective and potent second-generation type II FLT3 tyrosine kinase inhibitor, with a Kd of 1.6 nM. Quizartinib inhibits wild-type FLT3 and FLT3-ITD autophosphorylation in MV4-11 cells with IC50s of 4.2 and 1.1 nM, respectively. Quizartinib can be linked to the VHL ligand via an optimized linker to form a PROTAC FLT3 degrader. Quizartinib induces apoptosis.
|
-
- HY-P99171
-
|
Gevokizumab
|
Interleukin Related
|
Inflammation/Immunology
|
|
Gevokizumab is a potent anti-IL-1β antibody, negatively modulates IL-1β signaling through an allosteric mechanism. Gevokizumab selectively decreases the binding affinity of IL-1β for the IL-1 receptor type I (IL-1RI) signaling receptor instead of IL-1 counter-regulatory decoy receptor (IL-1 receptor type II).
|
-
- HY-144827
-
|
AM8936
|
Cannabinoid Receptor
|
Neurological Disease
Metabolic Disease
|
|
AM8936 acts as a balanced and potent cannabinoid receptor type-1 (CB1) agonist in functional assays (EC50s of 8.6 and 1.4 nM for rCB1 and hCB1, respectively). AM8936 exhibits high affinity for rat CB1 (rCB1) with Ki of 0.55 nM. AM8936 is a potent and efficacious CB1 agonist in vivo. AM8936 can be used for the research of CNS and metabolic disorders, pain, glaucoma, etc.
|
-
- HY-151500
-
|
JBSNF-000028 free base
|
Others
|
Metabolic Disease
|
|
JBSNF-000028 is an orally active nicotinamide N-methyltransferase (NNMT) inhibitor with IC50s of 0.033 µM, 0.19 µM and 0.21 µM against human NNMT (hNNMT), monkey NNMT (mkNNMT), and mouse NNMT (mNNMT), respectively. JBSNF-000028 can be used for the research of metabolic disorders.
|
-
- HY-139059
-
|
ERD03
|
Others
|
Neurological Disease
|
|
ERD03 is a potent disruptor of the EXOSC3-RNA interaction, with a Kd of 17±7 μM . ERD03 induces PCH1B-like phenotype in zebrafish embryo and can be used for neurological disorder disease research.
|
-
- HY-151173
-
-
- HY-151500B
-
|
JBSNF-000028 hydrochloride
|
Others
|
Metabolic Disease
|
|
JBSNF-000028 hydrochloride is an orally active nicotinamide N-methyltransferase (NNMT) inhibitor with IC50s of 0.033 μM, 0.19 μM and 0.21 μM against human NNMT (hNNMT), monkey NNMT (mkNNMT), and mouse NNMT (mNNMT), respectively. JBSNF-000028 hydrochloride can be used for the research of metabolic disorders.
|
-
- HY-151500A
-
|
JBSNF-000028 TFA
|
Others
|
Metabolic Disease
|
|
JBSNF-000028 TFA is an orally active nicotinamide N-methyltransferase (NNMT) inhibitor with IC50s of 0.033 μM, 0.19 μM and 0.21 μM against human NNMT (hNNMT), monkey NNMT (mkNNMT), and mouse NNMT (mNNMT), respectively. JBSNF-000028 TFA can be used for the research of metabolic disorders.
|
-
- HY-128593
-
-
- HY-128878
-
-
- HY-P2767
-
|
Urease
|
Bacterial
|
Others
|
|
Urease is produced by many types of bacteria and is an effective virulence factor for some pathogenic bacteria. Urease is also central to the metabolism and virulence of Helicobacter pylori, helping it colonize the stomach lining.
|
-
- HY-P99576
-
|
Tarcocimab
OG1953
|
VEGFR
|
Others
|
|
Tarcocimab (OG1953) is a humanized anti-VEGFA monoclonal antibody (IgG1 type). Tarcocimab is available for research in retinal vein occlusion (RVO) and wet age-related macular degeneration (AMD).
|
-
- HY-121604
-
|
(Rac)-MEM 1003
|
Calcium Channel
|
Others
|
|
(Rac)-MEM 1003 is the racemate of MEM 1003. MEM 1003, a dihydropyridine compound, is a potent L-type Ca 2+ channel antagonist and has the potential for Alzheimer’s disease research.
|
-
- HY-135152
-
|
CYPMPO
|
Reactive Oxygen Species
|
Cancer
|
|
CYPMPO is a spin-trapping reagent. CYPMPO, a cyclic DEPMPO-type nitrone, is evaluated for spin-trapping capabilities toward hydroxyl and superoxide radicals. anti-oxidant and anti-tumor activity.
|
-
- HY-113424A
-
-
- HY-N2096
-
|
Kavain
|
GABA Receptor
|
Neurological Disease
|
|
Kavain is a class of kavalactone isolated from Piper methysticum, which has anxiolytic properties in animals and humans. Kavain positively modulated γ-Aminobutyric acid type A (GABAA) receptor.
|
-
- HY-N2911
-
-
- HY-136564A
-
|
DAD
|
Potassium Channel
|
Neurological Disease
|
|
DAD is a type of ion channel blocker that blocks voltage-gated potassium channels. DAD is a third-generation photoswitch that responds to visible light. DAD has the potential for restoring visual function.
|
-
- HY-120149
-
|
Inotodiol
|
Others
|
Cancer
|
|
Inotodiol (compound 3) is a lanostane-type triterpenoid compound isolated from the sclerotia of Inonotus obliquus. Inotodiol exhibits the potent anti-tumor promoting activity in the in vivo carcinogenesis test.
|
-
- HY-114118
-
|
Semaglutide
|
GCGR
|
Metabolic Disease
|
|
Semaglutide, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide has the potential for type 2 diabetes treatment.
|
-
- HY-P0062
-
-
- HY-110238
-
|
MK6-83
|
TRP Channel
|
Metabolic Disease
|
|
MK6-83 is a new candidate agonist of TRPML1 with an improved efficacy and potency. MK6-83 has the potential for Mucolipidosis type IV study.
|
-
- HY-133592
-
|
Neoabietic acid
|
Bacterial
|
Infection
|
|
Neoabietic acid, an abietic-type acid, is a nature product that could be isolated from the oleoresin and rosin of Pinus palustris. Neoabietic acid is highly susceptible to mineral acid. Neoabietic acid has antibacterial activity.
|
-
- HY-139631
-
|
HIV-1 inhibitor-9
|
HIV
|
Infection
|
|
HIV-1 inhibitor-9 is found to be potent inhibitor against the wild-type (WT) HIV-1 strain or multiple NNRTI-resistant strains at low nanomolar levels.
|
-
- HY-N1443
-
-
- HY-113005S
-
-
- HY-P2641
-
|
Peptide 74
|
MMP
|
Cancer
|
|
Peptide 74 is a synthetic peptide containing the prodomain sequence of matrix metalloproteinase (MMP). Peptide 74 inhibits the activated form of the 72-kDa type IV collagenase in vitro.
|
-
- HY-12599
-
-
- HY-16305
-
|
Maribavir
1263W94; BW1263W94; GW257406X
|
CMV
|
Infection
|
|
Maribavir is a potent inhibitor of histone phosphorylation catalyzed by wild-type pUL97 in vitro, with an IC50 of 3 nM. Maribavir has potent antiviral activity against HCMV and Epstein-Barr virus (EBV).
|
-
- HY-139646
-
-
- HY-100650
-
|
Carbodenafil
|
Phosphodiesterase (PDE)
|
Others
|
|
Carbodenafil is a Sildenafil (UK-92480) related compound found in health foods. Sildenafil is a potent phosphodiesterase type 5 (PDE5) inhibitor with an IC50 of 5.22 nM.
|
-
- HY-112723
-
|
Apinocaltamide
ACT-709478
|
Calcium Channel
|
Neurological Disease
|
|
Apinocaltamide (ACT-709478) is a potent, selective, orally active, and brain penetrating T-type calcium channel blocker. ACT-709478 is used in the research of generalized epilepsies.
|
-
- HY-15025S
-
-
- HY-136548A
-
-
- HY-18343A
-
-
- HY-19771
-
|
amyloid P-IN-1
|
Amyloid-β
|
Cancer
|
|
amyloid P-IN-1 is used in the research of diseases or disorders wherein depletion of serum amyloid P component (SAP), including amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.
|
-
- HY-B1289
-
|
Cetylpyridinium chloride monohydrate
Hexadecylpyridinium chloride monohydrate
|
Bacterial
|
Infection
|
|
Cetylpyridinium chloride monohydrate is a cationic quaternary ammonium compound, used in some types of mouthwashes, toothpastes, throat and nasal sprays, is an antiseptic that kills bacteria and other microorganisms, effective in preventing dental plaque and reducing gingivitis.
|
-
- HY-P0062B
-
-
- HY-N2894
-
|
Piperolactam A
|
Parasite
|
Infection
|
|
Piperolactam A is a natural product that can be isolated from root of Piper betle. Piperolactam A exhibits promising leishmanicidal action against wild type and drug resistant strains of Leishmania donovani.
|
-
- HY-N4191
-
|
Isorosmanol
|
Cholinesterase (ChE)
|
Neurological Disease
|
|
Isorosmanol is an abietane-type diterpene isolated from Rosmarinus officinalis L. aerial parts, with antioxidant, neuroprotective and neurotrophic effects. Isorosmanol inhibits AChE activity and melanin synthesis.
|
-
- HY-118144
-
|
PD166326
|
BCRP
Src
|
Cancer
|
|
PD166326 is a pyridopyrimidine-type inhibitor of receptor tyrosine kinases, with IC50s of 6 nM and 8 nM for Src and Abl, respectively. PD166326 exhibits antileukemic activity.
|
-
- HY-12293
-
|
LY2857785
|
CDK
Apoptosis
|
Cancer
|
|
LY2857785 is a type I reversible and competitive ATP kinase inhibitor against CDK9 (IC50 11 nM) and other transcription kinases CDK8 (IC50 16 nM), and CDK7 (IC50 246 nM).
|
-
- HY-13237
-
-
- HY-116808
-
-
- HY-15124
-
-
- HY-D0140
-
|
Chromoionophore I
ETH 5294
|
Fluorescent Dye
|
Others
|
|
Chromoionophore I (ETH 5294) is a hydrophobic pH indicator. Chromoionophore I is used as a transmissive or fluorescent probe molecule in many types of hydrophobic sensor membranes. Chromoionophore I is oil-soluble.
|
-
- HY-W008820
-
|
Glutaric acid
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Glutaric acid, C5 dicarboxylic acid, is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I.
|
-
- HY-135715
-
|
(E)-UK122 TFA
|
Others
|
Others
|
|
(E)-UK122 TFA is the isomer of UK122 TFA. UK122 is a potent and selective urokinase-type plasminogen activator (uPA) inhibitor with an IC50 of 0.2 μM.
|
-
- HY-13810
-
|
PF-04880594
|
Raf
|
Cancer
|
|
PF-04880594 is a potent and selective RAF inhibitor. PF-04880594 inhibits both wild-type and mutant BRAF and CRAF. PF-04880594 shows antitumor activity.
|
-
- HY-N1621
-
|
1-Deacetylnimbolinin B
|
Fungal
Parasite
|
Infection
|
|
1-Deacetylnimbolinin B is a nimbolinin-type limonoid isolated from the fruits of Melia toosendan. Limonoids are a class of highly oxygenated nortriterpenoids that exhibit insecticidal, antifungal, nematicidal and cytotoxic properties.
|
-
- HY-13955
-
-
- HY-N4157
-
-
- HY-B0517
-
|
Mepivacaine
|
Sodium Channel
|
Neurological Disease
|
|
Mepivacaine is an amide-type local anesthetic agent. Mepivacaine binds to specific voltage-gated sodium ion channels in neuronal cell membranes, which inhibits both sodium influx and membrane depolarization.
|
-
- HY-N11639
-
|
Ganoderic acid Df
|
Aldose Reductase
|
Metabolic Disease
|
|
Ganoderic acid Df is a lanostane-type triterpenoid, that can be isolated from the fruiting body of Ganoderma lucidum. Ganoderic acid Df potently inhibits aldose reductase, with an IC50 of 22.8 ± 0.6 μM.
|
-
- HY-N6650
-
-
- HY-N2998
-
|
Ganoderenic acid A
|
Others
|
Metabolic Disease
|
|
Ganoderenic acid A is a lanostane-type triterpene. Ganoderenic acid A is a potent inhibitor of β-glucuronidase. Ganoderenic acid A has a potent hepatoprotective effect against CCl4-induced liver injury.
|
-
- HY-17404
-
-
- HY-148874
-
|
FXR antagonist 2
|
FXR
|
Metabolic Disease
|
|
FXR antagonist 2 (compound A-26) is a diarylamide derivative, as well as a moderate FXR antagonist. FXR antagonist 2 can be used in the study of hyperlipidemia and type 2 diabetes.
|
-
- HY-147580
-
|
BTK-IN-10
|
Btk
|
Cancer
|
|
BTK-IN-10 is a potent BTK inhibitor with IC50s of <5 nM for wild-type BTK or mutated BTK (C481S), respectively (WO2022012509A1; example 111).
|
-
- HY-141566
-
-
- HY-U00224
-
|
BRL44385
|
HSV
|
Infection
|
|
BRL44385 is a potent and selective inhibitor of the replication of herpes simplex virus types 1 and 2 (HSV-1 and HSV2), varicella zoster virus (VZV) and Epstein-Barr virus (EBV).
|
-
- HY-120478
-
|
ASP6432
|
LPL Receptor
|
Infection
|
|
ASP6432 is a potent and selective type 1 lysophosphatidic acid receptor (LPA1) antagonist with IC50s of 11 nM and 30 nM for human LPA1 and rat LPA1, respectively.
|
-
- HY-111507
-
|
PDGFRα kinase inhibitor 1
|
PDGFR
|
Cancer
|
|
PDGFRα kinase inhibitor 1 is a highly selective type II PDGFRα kinase inhibitor with IC50s of 132 nM and 6115 nM for PDGFRα and PDGFRβ, respectively.
|
-
- HY-116457
-
|
Propanidid
Sombrevin; Fabantol
|
GABA Receptor
|
Neurological Disease
|
|
Propanidid (Sombrevin; Fabantol) is a γ-aminobutyric acid type A (GABAA) receptor agonist and a short-acting non-barbiturate general anesthetic agent. Propanidid can decrease the arterial pressure.
|
-
- HY-W004284
-
-
- HY-W001959
-
|
D-Allothreonine
|
Endogenous Metabolite
|
Metabolic Disease
|
|
D-Allothreonine is the D type stereoisomer of Allothreonine. D-Allothreonine is a peptido-lipid derived from bacteria. D-Allothreonine, amide-linked to the D-galacturonic acid, is also a constituent in the polysaccharide.
|
-
- HY-15025S1
-
-
- HY-19980A
-
-
- HY-N7542
-
|
Praeroside II
|
Others
|
Others
|
|
Praeroside II is an angular-type pyranocoumarm glycoside. Praeroside II can be isolated from the n-butanol-extracts of P. praeruptorum Dunn. Praeroside II can be used for pharmacological study.
|
-
- HY-145872
-
|
HBV-IN-20
|
HBV
|
Infection
|
|
HBV-IN-20 is a potent and oral active HBV inhibitor with an EC50 of 0.46 µM. HBV-IN-20 is a typical type II CpAM (core protein assembly modulators).
|
-
- HY-12149
-
|
A-867744
|
nAChR
|
Neurological Disease
|
|
A-867744 is a highly potent and selective type II positive allosteric modulator (PAM) of the alpha7 nicotinic acetylcholine receptors (nAChR) with an EC50 of 1.0 μM.
|
-
- HY-P0188
-
-
- HY-P2847
-
|
Urocortin II, mouse
|
CRFR
|
Endocrinology
Metabolic Disease
|
|
Urocortin II, mouse is a potent and selective endogenous peptide agonist of type-2 corticotropin-releasing factor (CRF2) receptor with Ki values of 0.66 nM and ﹥100 nM for CRFR2 and CRFR1, respectively. Urocortin II, mouse activates CRF2 receptors in a cAMP/PKA- and Ca 2+/CaMKII-dependent manner.Urocortin II, mouse is expressed in discrete areas of the central nervous system, and activates central neurons involved in the processing of visceral sensory information, and in modulating autonomic outflow.
|
-
- HY-119706
-
|
Barbadin
|
Apoptosis
Arrestin
|
Others
|
|
Barbadin is a novel and selective β-arrestin/β2-adaptin interaction inhibitor, has IC50 values of 19.1 μM for β-arrestin1 and 15.6 μM for β-arrestin2. Barbadin blocks agonist-promoted endocytosis of the prototypical β2-adrenergic, V2-vasopressin and angiotensin-II type-1 receptors. Barbadin can induce apoptosis.
|
-
- HY-151801
-
|
DIBA-Cy5
|
mAChR
|
Others
|
|
DIBA-Cy5 is a fluorescent DIBA antagonist made up be DIBA-alkyne binding Cyanine5 fluorophores (Cy5) and polyethylene glycol (PEG) biomolecules. DIBA-Cy5 can serve as a fluorescent ligand, suitable for probe attachment through click chemistry. DIBA-Cy5 exerts a high binding affinity to type-2 mAChR (M2R) with the Kd value of 1.80 nM, can directly stain M2R receptors in the sinoatrial node of a mouse heart.
|
-
- HY-125134
-
|
Alloaromadendrene
|
Parasite
|
Inflammation/Immunology
|
|
Alloaromadendrene, an antioxidant, can be isolated from the leaves of mixed-type C. osmophloeum. Alloaromadendrene protects C. elegans against oxidative stress induced by walnut quinone and prolongs the life of C. elegans.
|
-
- HY-18253
-
|
Udenafil
DA8159
|
Phosphodiesterase (PDE)
|
Endocrinology
Others
|
|
Udenafil (DA8159) is a potent, selective and orally active phosphodiesterase type 5 (PDE5) inhibitor. Udenafil also inhibits cGMP hydrolysis and can be used for erectile dysfunction research.
|
-
- HY-118893
-
-
- HY-118982
-
|
CT-2584
|
Reactive Oxygen Species
|
Cancer
|
|
CT-2584 is a chemotherapeutic compound that reduces the expression of NKEF-B in several tumor cell types and kills tumor cells by inducing the production of ROS in mitochondria, commonly used in cancer research.
|
-
- HY-131503
-
|
13-Methyltetradecanoic acid
13-MTD; 13-Methylmyristic acid
|
Apoptosis
|
Cancer
|
|
13-Methyltetradecanoic acid (13-MTD), a saturated branched-chain fatty acid with potent anticancer effects. 13-Methyltetradecanoic acid induces apoptosis in many types of human cancer cells.
|
-
- HY-14596
-
|
Genistein
NPI 031L
|
EGFR
Autophagy
Apoptosis
Endogenous Metabolite
|
Cancer
|
|
Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis.
|
-
- HY-146305
-
-
- HY-100783A
-
|
(-)-Bicuculline methochloride
l-Bicuculline methochloride
|
GABA Receptor
|
Neurological Disease
|
|
(-)-Bicuculline methochloride (l-Bicuculline methochloride) is a potent GABAA receptor antagonist. (-)-Bicuculline methochloride blocks afterhyperpolarizations (AHPs) mediated by Ca 2+-activated K + channels in various types of neurons.
|
-
- HY-112256
-
-
- HY-141715
-
|
BRD-8000.3
|
Antibiotic
|
Infection
|
|
BRD-8000.3, as a specific EfpA inhibitor, is a narrow-spectrum, bactericidal antimycobacterial agent with good wild-type activity. BRD-8000.3 can be used for the research of tuberculosis.
|
-
- HY-141724
-
|
PCSK9 ligand 1
|
Ser/Thr Protease
|
Cancer
|
|
PCSK9 ligand 1 is a selective proprotein convertase substilisin-like/kexin type 9 (PCSK9) ligand. PCSK9 ligand 1 does not affect PCSK9 function.
|
-
- HY-P0188A
-
-
- HY-100875A
-
|
Bisantrene dihydrochloride
CL-216942 dihydrochloride
|
Topoisomerase
|
Cancer
|
|
Bisantrene dihydrochloride is a highly effective antitumor agent, it exerts its cytotoxicity by affecting DNA intercalation. Bisantrene dihydrochloride targets eukaryotic type II topoisomerases. Bisantrene dihydrochloride is a substrate of MDR1.
|
-
- HY-132885
-
-
- HY-100783
-
|
(-)-Bicuculline methobromide
l-Bicuculline methobromide
|
GABA Receptor
|
Neurological Disease
|
|
(-)-Bicuculline methobromide (l-Bicuculline methobromide) is a potent GABAA receptor antagonist. (-)-Bicuculline methobromide blocks afterhyperpolarizations (AHPs) mediated by Ca 2+-activated K + channels in various types of neurons.
|
-
- HY-100875
-
|
Bisantrene
CL216942
|
Topoisomerase
|
Cancer
|
|
Bisantrene is a highly effective antitumor agent, it exerts its cytotoxicity by affecting DNA intercalation. Bisantrene targets eukaryotic type II topoisomerases. Bisantrene is a substrate of MDR1.
|
-
- HY-N11034
-
-
- HY-114118A
-
|
Semaglutide TFA
|
GCGR
|
Metabolic Disease
|
|
Semaglutide TFA, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide TFA has the potential for type 2 diabetes treatment.
|
-
- HY-N11570
-
-
- HY-16271
-
|
Kevetrin hydrochloride
4-Isothioureidobutyronitrile hydrochloride; thioureidobutyronitrile hydrochloride; thioureido butyronitrile hydrochloride
|
MDM-2/p53
Apoptosis
|
Cancer
|
|
Kevetrin hydrochloride is a potent activator of p53, induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells. Kevetrin a preferential cytotoxic activity against blast cells.
|
-
- HY-135130
-
|
Bischloroanthrabenzoxocinone
(-)-BABX
|
Bacterial
|
Infection
|
|
Bischloroanthrabenzoxocinone is a potent Type II fatty acid synthesis (FASII) inhibitor. Bischloroanthrabenzoxocinone inhibits fatty acid synthesis. Bischloroanthrabenzoxocinone shows antibacterial activities and inhibits phospholipid, DNA, RNA, protein, and cell wall synthesis.
|
-
- HY-P0202
-
-
- HY-113446
-
-
- HY-N6054
-
|
Niranthin
|
Parasite
Topoisomerase
|
Infection
Inflammation/Immunology
|
|
Niranthin, a lignan with a wide spectrum of pharmacological activities.?Niranthin is a potent and non-competitive inhibitor of heterodimeric type IB topoisomerase of L. donovani. Niranthin can be used for the research of drug-resistant leishmaniasis research.
|
-
- HY-N9376
-
|
Kansuinine E
|
Others
|
Inflammation/Immunology
|
|
Kansuinine E is a plant-derived nitric oxide inhibitor (IC50=6.3 μM). Kansuinine E belongs to jatrophane-type diterpenoids and is isolated from the roots of E. kansui.
|
-
- HY-13948
-
|
Angiotensin II human
Angiotensin II; Ang II; DRVYIHPF
|
Angiotensin Receptor
Apoptosis
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Angiotensin II (Angiotensin II) is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. Angiotensin II human plays a central role in regulating human blood pressure, which is mainly mediated by interactions between Angiotensin II and the G-protein-coupled receptors (GPCRs) Angiotensin II type 1 receptor (AT1R) and Angiotensin II type 2 receptor (AT2R). Angiotensin II human stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. Angiotensin II human induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. Angiotensin II human also induces apoptosis. Angiotensin II induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway.
|
-
- HY-113736
-
|
Glycyllysine
|
Amino Acid Derivatives
|
Others
|
|
Glycyllysine is a polypeptide that can be used in the synthesis of antibodies and amino acid type gemini surfactants. Glycyllysine has potential applications in modifying plasmid/gemini/lipid (P/G/L) nanoparticles transport carriers.
|
-
- HY-P0202A
-
-
- HY-B0632
-
|
Diltiazem
|
Calcium Channel
|
Cardiovascular Disease
|
|
Diltiazem is an orally active L-type Ca 2+ channel blocker. Diltiazem shows antihypertensive and antiarrhythmic effects. Diltiazem can be used for the research of cardiac arrhythmia, hypertension, and angina pectoris.
|
-
- HY-P1731B
-
|
Tirzepatide hydrochloride
LY3298176 hydrochloride
|
GCGR
|
Metabolic Disease
|
|
Tirzepatide hydrochloride (LY3298176 hydrochloride) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes.
|
-
- HY-121368
-
|
Mahanine
|
Parasite
|
Cancer
Infection
Inflammation/Immunology
|
|
Mahanine is a carbazole alkaloid with various biological properties. Mahanine is a potent anticancer agent against different types of cancer cells. Mahanine exhibits antileishmanial activity and can be used for Leishmania?infection research research.
|
-
- HY-12402
-
-
- HY-N2004
-
|
Isoborneol
(±)-Isoborneol
|
HSV
|
Infection
Neurological Disease
|
|
Isoborneol ((±)-Isoborneol) is a monoterpenoid alcohol present in the essential oils of numerous medicinal plants and has antioxidant and antiviral properties. Isoborneol is a potent inhibitor of herpes simplex virus type 1 (HSV-1).
|
-
- HY-116100
-
-
- HY-N11079
-
|
Toonaciliatin M
|
Fungal
|
Infection
|
|
Toonaciliatin M (compound 6) is a pmaradiene-type diterpenoid that can be isolated from Toona ciliate. Toonaciliatin M show antifungal activity against Trichophyton rubrum with an MIC value of 12.5 µg/mL.
|
-
- HY-112951
-
|
ChX710
|
STING
|
Cancer
|
|
ChX710 could prime the type I interferon response to cytosolic DNA, which induces the ISRE promoter sequence, specific cellular Interferon-Stimulated Genes (ISGs), and the phosphorylation of Interferon Regulatory Factor (IRF) 3.
|
-
- HY-N7168
-
-
- HY-128710
-
|
2'-Fluorothymidine
2'-Deoxy-2'-fluoro-5-Methyluridine
|
Others
|
Cancer
|
|
2'-Fluorothymidine (2'-Fluoro-2'-deoxythymidine), a bioisostere of both thymidine (TdR) and methyluridine, is a putative highly selective substrate for thymidine kinase type 2 (TK2).
|
-
- HY-136564
-
|
DAD dichloride
|
Potassium Channel
|
Neurological Disease
|
|
DAD dichloride is a type of ion channel blocker that blocks voltage-gated potassium channels. DAD dichloride is a third-generation photoswitch that responds to visible light. DAD dichloride has the potential for restoring visual function.
|
-
- HY-P3136A
-
-
- HY-135328S
-
-
- HY-P1731
-
|
Tirzepatide
LY3298176
|
GCGR
|
Metabolic Disease
|
|
Tirzepatide (LY3298176) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes.
|
-
- HY-120160
-
|
Darglitazone
CP-86325
|
PPAR
|
Metabolic Disease
Neurological Disease
|
|
Darglitazone (CP-86325), a thiazolidinedione, is a potent, selective, and orally active PPAR-γ agonist. Darglitazone is effective in controlling blood glucose and lipid metabolism, and can be used for type II diabetes research.
|
-
- HY-135328AS
-
|
Norverapamil-d7 hydrochloride
(±)-Norverapamil-d7 (hydrochloride); D591-d7 (hydrochloride)
|
Calcium Channel
|
Cardiovascular Disease
|
|
Norverapamil-d7 (hydrochloride) is a deuterium labeled Norverapamil. Norverapamil ((±)-Norverapamil), an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor[1][2].
|
-
- HY-14655
-
-
- HY-P1281
-
|
Kaliotoxin
|
Potassium Channel
|
Neurological Disease
|
|
Kaliotoxin is a peptidyl inhibitor of neuronal BK-Type. Kaliotoxin can specific inhibit Kv channels and calcium-activated potassium channels. Kaliotoxin can be used for the research of the regulation of membrane potential and neuron excitability.
|
-
- HY-P3818
-
|
PKCδ Peptide Substrate
|
PKC
|
Others
|
|
PKCδ Peptide Substrate is an absolutely specific substrate for the δ-type of PKC, with a sequence corresponding to sequence 422-443 of murine eEF-1α and containing Thr-431.
|
-
- HY-147360
-
|
Tribendimidine
|
nAChR
|
Infection
|
|
Tribendimidine is an orally active, broad-spectrum anthelmintic agent, with particularly high activity against A. lumbricoides and N. americanus. Tribendimidine is also an L-type nicotinic acetylcholine receptor (nAChR) agonist.
|
-
- HY-N6955
-
|
Eupalinilide B
|
Others
|
Cancer
|
|
Eupalinilide B is a guaiane type sesquiterpene lactone that can be found in Eupatorium lindleyanum. Eupalinilide B shows potent cytotoxicity against P-388 and A-549 tumor cell lines.
|
-
- HY-B1068
-
|
Tyloxapol
Triton WR1339
|
Biochemical Assay Reagents
|
Metabolic Disease
|
|
Tyloxapol (Triton WR1339) is a nonionic liquid polymer of the alkyl aryl polyether alcohol type, used as a surface active stabilizer. Tyloxapol (Triton WR1339) is used to induce hyperlipidemia in animals.
|
-
- HY-P0062A
-
-
- HY-122782
-
|
Lucidal
Lucialdehyde C
|
Glucosidase
|
Cancer
Metabolic Disease
|
|
Lucidal (Lucialdehyde C) is a natural lanostante-type triterpene aldehyde that shows inhibitory effects against α-glucosidase (Glucosidase) with an IC50 of 0.635 mM. Lucidal has anticancer and antidiabetic effects.
|
-
- HY-138825
-
|
NCGC00188636
|
Pyk2
|
Metabolic Disease
|
|
NCGC00188636 is a novel covalent pyruvate kinase (PYK) inhibitor. NCGC00188636 blocks nucleotide binding to the active site of pyruvate kinase. NCGC00188636 can be used for the research of the metabolism of many organisms and cell types.
|
-
- HY-17402S
-
-
- HY-N1060
-
|
Yatein
|
HSV
Apoptosis
|
Cancer
Infection
|
|
Yatein is a lignan isolated from A. chilensis, with antiproliferative activity. Yatein suppresses herpes simplex virus type 1 (HSV-1 ) replication by interruption the immediate-early gene expression.
|
-
- HY-119248
-
|
KRP-297
MK-0767
|
PPAR
|
Metabolic Disease
|
|
KRP-297 is a PPARα and PPARγ agonist potentially for the research of type 2 diabetes and dyslipidemia. KRP-297 restores reduced lipid oxidation, and inhibits of enhanced lipogenesis and triglyceride accumulation in the liver.
|
-
- HY-139276
-
|
Pal-Glu(OSu)-OH
|
GLP Receptor
|
Others
|
|
Pal-Glu(OSu)-OH is a side chain of Liraglutide. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used for type 2 diabetes mellitus research.
|
-
- HY-111627
-
-
- HY-120049
-
|
TAK-603
|
Others
|
Inflammation/Immunology
|
|
TAK-603 is a potent and orally active antirheumatic agent. TAK-603 inhibits Thl-type cytokine production. TAK-603 has the potential for the research of adjuvant arthritis.
|
-
- HY-15714
-
|
NMS-859
|
p97
|
Cancer
|
|
NMS-859 is a potent, covalent VCP (p97) inhibitor, with IC50s of 0.37 and 0.36 μM for wild-type VCP in the presence of 60 μM and 1 mM ATP in cells, respectively.
|
-
- HY-P3136
-
-
- HY-N10277
-
|
Inubritannolide A
|
Others
|
Neurological Disease
|
|
Inubritannolide A displays slight strong neuroprotective potency against different types of neuronal cells mediated by various inducers including H2O2, 6-hydroxydopamine (6-OHDA), and lipopolysaccharide (LPS).
|
-
- HY-B1378S1
-
-
- HY-108704
-
|
CT-721
|
Bcr-Abl
|
Cancer
|
|
CT-721 is a potent and time-dependent Bcr-Abl kinase inhibitor with an IC50 of 21.3 nM for wild-type Bcr-Abl kinase, and possesses anti-chronic myeloid leukemia (CML) activities.
|
-
- HY-113599
-
|
Isoprocurcumenol
|
EGFR
ERK
Akt
|
Others
|
|
Isoprocurcumenol is a guaiane type sesquiterpene, that can be isolated from Curcuma comosa. Isoprocurcumenol can activate EGFR signaling. Isoprocurcumenol increases the phosphorylation of ERK and AKT. Isoprocurcumenol promotes the proliferation of keratinocytes.
|
-
- HY-112306
-
|
Ripretinib
DCC-2618
|
c-Kit
PDGFR
FLT3
VEGFR
Apoptosis
|
Cancer
|
|
Ripretinib (DCC-2618) is an orally bioavailable, selective KIT and PDGFRA switch-control inhibitor. Ripretinib (DCC-2618) targets and binds to both wild-type and mutant forms of KIT and PDGFRA specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. Ripretinib (DCC-2618) also inhibits multiple other kinase targets, such as FLT3 and KDR (or VEGFR-2). DCC-2618 exerts antineoplastic effect and induces apoptosis.
|
-
- HY-13637B
-
|
Ganciclovir hydrate
BW-759 hydrate; 2'-Nor-2'-deoxyguanosine hydrate
|
CMV
HSV
Antibiotic
Nucleoside Antimetabolite/Analog
|
Cancer
Infection
|
|
Ganciclovir (BW 759) hydrate, a nucleoside analogue, is an orally active antiviral agent with activity against CMV. Ganciclovir hydrate also has activity in vitro against members of the herpes group and some other DNA viruses. Ganciclovir hydrate inhibits the in vitro replication of human herpes viruses (HSV 1 and 2, CMV) and adenovirus serotypes 1, 2, 4, 6, 8, 10, 19, 22 and 28. Ganciclovir hydrate has an IC50 of 5.2 μM for feline herpesvirus type-1 (FHV-1) and can diffuse into the brain.
|
-
- HY-103309A
-
|
ML218 hydrochloride
|
Calcium Channel
|
Neurological Disease
|
|
ML218 hydrochloride is a potent, selective and orally active T-type Ca 2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC50s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 hydrochloride inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 hydrochloride has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 hydrochloride can penetrate the blood-brain barrier.
|
-
- HY-103309
-
|
ML218
|
Calcium Channel
|
Neurological Disease
|
|
ML218 is a potent, selective and orally active T-type Ca 2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC50s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier.
|
-
- HY-13637
-
|
Ganciclovir
BW 759; 2'-Nor-2'-deoxyguanosine
|
CMV
HSV
Antibiotic
Nucleoside Antimetabolite/Analog
|
Infection
Cancer
|
|
Ganciclovir (BW 759), a nucleoside analogue, is an orally active antiviral agent with activity against CMV. Ganciclovir also has activity in vitro against members of the herpes group and some other DNA viruses. Ganciclovir inhibits the in vitro replication of human herpes viruses (HSV 1 and 2, CMV) and adenovirus serotypes 1, 2, 4, 6, 8, 10, 19, 22 and 28. Ganciclovir has an IC50 of 5.2 μM for feline herpesvirus type-1 (FHV-1) and can diffuse into the brain.
|
-
- HY-15814
-
|
HG-7-85-01
|
Bcr-Abl
PDGFR
c-Kit
Src
JAK
Apoptosis
|
Cancer
|
|
HG-7-85-01 is a type II ATP competitive inhibitor of wild-type and gatekeeper mutations forms of Bcr-Abl, PDGFRα, Kit, and Src kinases. HG-7-85-01 inhibits T315I mutant Bcr-Abl kinase, KDR and RET with IC50s of 3 nM, 20 nM and 30 nM, and is only weak or no inhibition of other kinases (IC50>2 μM). HG-7-85-01 inhibits the cell proliferation, which is mediated by the induction of apoptosis, and inhibition of cell-cycle progression.
|
-
- HY-13637A
-
|
Ganciclovir sodium
BW 759 sodium; 2'-Nor-2'-deoxyguanosine sodium
|
CMV
HSV
Antibiotic
Nucleoside Antimetabolite/Analog
|
Infection
Cancer
|
|
Ganciclovir (BW 759) sodium, a nucleoside analogue, is an orally active antiviral agent with activity against CMV. Ganciclovir sodium also has activity in vitro against members of the herpes group and some other DNA viruses. Ganciclovir sodium inhibits the in vitro replication of human herpes viruses (HSV 1 and 2, CMV) and adenovirus serotypes 1, 2, 4, 6, 8, 10, 19, 22 and 28. Ganciclovir sodium has an IC50 of 5.2 μM for feline herpesvirus type-1 (FHV-1) and can diffuse into the brain.
|
-
- HY-13637S
-
|
Ganciclovir-d5
BW 759-d5; 2'-Nor-2'-deoxyguanosine-d5
|
Isotope-Labeled Compounds
CMV
HSV
Antibiotic
Nucleoside Antimetabolite/Analog
|
Infection
|
|
Ganciclovir-d5 is the deuterium labeled Ganciclovir. Ganciclovir (BW 759), a nucleoside analogue, is an orally active antiviral agent with activity against CMV. Ganciclovir also has activity in vitro against members of the herpes group and some other DNA viruses. Ganciclovir inhibits the in vitro replication of human herpes viruses (HSV 1 and 2, CMV) and adenovirus serotypes 1, 2, 4, 6, 8, 10, 19, 22 and 28. Ganciclovir has an IC50 of 5.2 μM for feline herpesvirus type-1 (FHV-1)[1][2][3].
|
-
- HY-100818
-
|
Futibatinib
TAS-120
|
FGFR
|
Cancer
|
|
Futibatinib (TAS-120) is an orally bioavailable, highly selective, and irreversible FGFR inhibitor, with IC50s of 3.9, 1.3, 1.6, and 8.3 nM for FGFR 1-4, respectively. Futibatinib inhibits mutant and wild-type FGFR2 with similar IC50s (wild-type FGFR2=0.9 nM; V5651=1-3 nM; N550H=3.6 nM; E566G=2.4 nM).
|
-
- HY-128344
-
|
BR102375
|
PARP
Apoptosis
|
Metabolic Disease
|
|
BR102375 is a non-TZD peroxisome proliferator-activated receptor γ (PPAR γ) full agonist for the treatment of type 2 diabetes, reveals EC50 value of 0.28 μM and Amax ratio of 98%.
|
-
- HY-N2119
-
|
Sciadopitysin
|
NF-κB
|
Inflammation/Immunology
|
|
Sciadopitysin is a type of biflavonoids in leaves from ginkgo biloba. Sciadopitysi inhibits RANKL-induced osteoclastogenesis and bone loss by inhibiting NF-κB activation and reducing the expression of c-Fos and NFATc1.
|
-
- HY-W020043
-
|
Pyribencarb
|
Fungal
|
Infection
|
|
Pyribencarb is a benzylcarbamate-type fungicide, which is active against a wide range of plant pathogenic fungi. Pyribencarb is a potent Qo inhibitor of cytochrome b. Pyribencarb is especially active against Botrytis cinerea and Sclerotinia sclerotirum.
|
-
- HY-W404002
-
|
BR102910
|
Prolyl Endopeptidase (PREP)
|
Metabolic Disease
|
|
BR102910 is a selective fibroblast activation protein (FAP) inhibitor with the IC50 of 2 nM. BR102910 also inhibits prolyl oligopeptidase (PREP) with the IC50 of 49.00 μM. BR102910 can be used for the researchof type 2
|
-
- HY-118861
-
|
Enclomiphene
(E)-Clomiphene; trans-Clomiphene; Enclomifene
|
Estrogen Receptor/ERR
|
Endocrinology
Metabolic Disease
|
|
Enclomiphene ((E)-Clomiphene) is a potent and orally active non-steroidal estrogen receptor antagonist, with antioestrogenic property. Enclomiphene can be used for the research of ovarian dysfunction, testosterone deficiency, male hypogonadism and type 2 diabetes.
|
-
- HY-78139S
-
|
L-Xylose-1-13C
L-(-)-Xylose-1-13C
|
Isotope-Labeled Compounds
|
Others
|
|
L-Xylose-1- 13C is the 13C labeled L-Xylose. L-Xylose (L-(-)-Xylose) is the levo-isomer of Xylose. Xylose is classified as a monosaccharide of the aldopentose type[1][2].
|
-
- HY-118861B
-
|
Enclomiphene hydrochloride
(E)-Clomiphene hydrochloride; trans-Clomiphene hydrochloride; Enclomifene hydrochloride
|
Estrogen Receptor/ERR
|
Endocrinology
Metabolic Disease
|
|
Enclomiphene ((E)-Clomiphene) hydrochloride is a potent and orally active non-steroidal estrogen receptor antagonist, with antioestrogenic property. Enclomiphene hydrochloride can be used for the research of ovarian dysfunction, testosterone deficiency, male hypogonadism and type 2 diabetes.
|
-
- HY-78139S2
-
|
L-Xylose-5-13C
L-(-)-Xylose-5-13C
|
Isotope-Labeled Compounds
|
Others
|
|
L-Xylose-5- 13C is the 13C labeled L-Xylose. L-Xylose (L-(-)-Xylose) is the levo-isomer of Xylose. Xylose is classified as a monosaccharide of the aldopentose type[1][2].
|
-
- HY-78139S1
-
|
L-Xylose-2-13C
L-(-)-Xylose-2-13C
|
Isotope-Labeled Compounds
|
Others
|
|
L-Xylose-2- 13C is the 13C labeled L-Xylose. L-Xylose (L-(-)-Xylose) is the levo-isomer of Xylose. Xylose is classified as a monosaccharide of the aldopentose type[1][2].
|
-
- HY-N3515
-
|
Multicaulisin
|
Bacterial
|
Infection
|
|
Multicaulisin, a new Diels-Alder type adduct from Morus multicaulis roots, potently effects against Staphylococcus aureus (MRSA) isolates. Multicaulisin is an antibacterial agent and has the potential for MRSA infections research.
|
-
- HY-P3675
-
|
LH-RH (4-10)
|
GnRH Receptor
|
Endocrinology
|
|
LH-RH (4-10) is a heptapeptide, one of major degradation products of luteinising-hormone releasing hormone (LHRH) via pituitary and hypothalamus. LH-RH (4-10) produced in macrophages and type II pneumocytes.
|
-
- HY-144188
-
|
PRMT5-IN-17
|
Histone Methyltransferase
|
Cancer
|
|
PRMT5-IN-17 (Compound 6) is a PRMT5 inhibitor with anti-tumor activity. PRMT5 is a type of protein arginine methyltransferase, and is a new anti-tumor target related to epigenetic modification.
|
-
- HY-P2319
-
-
- HY-112668
-
-
- HY-144187
-
|
PRMT5-IN-16
|
Histone Methyltransferase
|
Cancer
|
|
PRMT5-IN-16 (Compound 20) is a PRMT5 inhibitor with anti-tumor activity. PRMT5 is a type of protein arginine methyltransferase, and is a new anti-tumor target related to epigenetic modification.
|
-
- HY-135335
-
-
- HY-N4171
-
|
Dihydrocucurbitacin B
|
Apoptosis
|
Inflammation/Immunology
|
|
Dihydrocucurbitacin B, a triterpene isolated from Cayaponia tayuya roots, inhibits nuclear factor of activated T cells (NFAT), induces cell cycle arrested in the G0 phase, and inhibits delayed type hypersensitivity.
|
-
- HY-119942
-
|
c-Fms-IN-8
|
c-Fms
|
Cancer
|
|
c-Fms-IN-8 (compound 4a) is a colony stimulating factor-1 receptor (CSF-1R, c-FMS) Type II inhibitor, with an IC50 of 9.1 nM.
|
-
- HY-12462
-
|
WS3
|
Others
|
Inflammation/Immunology
|
|
WS3 is a novel proliferative molecule that promotes pancreatic β cell proliferation in rodent and human primary islets. WS3 can be used for the research of type 1 diabetes.
|
-
- HY-103245
-
|
Cl-4AS-1
|
Androgen Receptor
|
Cancer
|
|
Cl-4AS-1, a potent steroidal androgen receptor (AR) agonist (IC50 = 12 nM), is also an inhibitor of 5α-reductase types I and II (IC50 = 6 and 10 nM, respectively).
|
-
- HY-N0252B
-
|
Catharanthine Sulfate
(+)-3,4-Didehydrocoronaridine Sulfate
|
Calcium Channel
|
Cancer
Cardiovascular Disease
|
|
Catharanthine Sulfate ((+)-3,4-Didehydrocoronaridine Sulfate) is an alkaloid isolated from Madagascar periwinkle, inhibits voltage-operated L-type Ca 2+ channel, with anti-cancer and blood pressure-lowering activities.
|
-
- HY-13525
-
|
CP-91149
|
Others
|
Cancer
Metabolic Disease
|
|
CP-91149 is a GP (glycogen phosphorylase) inhibitor. CP-91149 promotes glycogen resynthesis, but not its overaccumulation. CP-91149 has the potential for Type II (insulin-dependent) diabetes study.
|
-
- HY-108508
-
|
SMANT hydrochloride
|
Smo
Hedgehog
|
Cancer
|
|
SMANT hydrochloride is a Smoothened (Smo) signaling inhibitor. SMANT hydrochloride is antagonist of Smo accumulation within the primary cilium (PC). SMANT hydrochloride has an equivalent activity in inhibiting SmoM2 (oncogenic form of Smo) and wild-type Smo.
|
-
- HY-135525
-
-
- HY-P3533
-
|
EILEVPST
|
Integrin
|
Cardiovascular Disease
|
|
EILEVPST is a recombinant human fibronectinderived low-molecular-weight peptide fragment. EILEVPST can promote cell type-specific α4 integrin-mediated adhesion. EILEVPST can be used for the research of thrombogenesis.
|
-
- HY-112668A
-
-
- HY-103568
-
|
YM-298198 hydrochloride
|
mGluR
|
Neurological Disease
|
|
YM-298198 hydrochloride is a high-affinity, selective, orally active, and non-competitive antagonist of metabotropic glutamate receptor type 1 (mGluR1). YM-298198 hydrochloride can be used for the research of neurological disorders.
|
-
- HY-17518
-
|
Valifenalate
IR5885; Valiphenal
|
Bacterial
|
Others
|
|
Valifenalate(IR5885; Valiphenal), which is approved for application on high-value crops such as grapes, tomatoes and other vegetables, is effective against various types of mildew and is currently marketed primarily under the Valis moniker; insecticide agent.
|
-
- HY-18634
-
|
NSC319726
ZMC1
|
MDM-2/p53
|
Cancer
|
|
NSC319726 (ZMC1) is a mutant p53R175 reactivator; inhibits growth of fibroblasts expressing the p53R175 mutation (IC50 = 8 nM); shows no inhibition for p53 wild-type cells.
|
-
- HY-147582
-
|
BTK-IN-12
|
Btk
|
Cancer
|
|
BTK-IN-12 is a potent BTK inhibitor with IC50s of 1.2 nM and 0.8 nM for wild-type BTK or mutated BTK (C481S), respectively (WO2022037649A1; compound 8).
|
-
- HY-13633
-
|
Exisulind
|
Aldose Reductase
|
Metabolic Disease
|
|
Exisulind is an inactive metabolite of the nonsteroidal, anti-inflammatory agent sulindac. Exisulind inhibits aldose reductase with an IC50 of 367 nM in vitro and may contribute to the beneficial pharmacological effects of sulindac on type 2 diabetic complications.
|
-
- HY-133127A
-
-
- HY-10999A
-
|
Trametinib (DMSO solvate)
GSK-1120212 (DMSO solvate); JTP-74057 (DMSO solvate)
|
MEK
Apoptosis
|
Cancer
|
|
Trametinib (DMSO solvate) (GSK-1120212 (DMSO solvate);JTP-74057 (DMSO solvate)) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib (DMSO solvate) activates autophagy and induces apoptosis.
|
-
- HY-10999
-
|
Trametinib
GSK1120212; JTP-74057
|
MEK
Autophagy
Apoptosis
|
Cancer
|
|
Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib activates autophagy and induces apoptosis.
|
-
- HY-133127
-
|
AR453588
|
Glucokinase
|
Metabolic Disease
|
|
AR453588 is a potent and orally bioavailable anti-diabetic glucokinase activator, with an EC50 of 42 nM. AR453588 shows anti-hyperglycemic activity.
|
-
- HY-12608
-
|
TA-1887
JNJ-39933673
|
SGLT
|
Metabolic Disease
|
|
TA-1887 (JNJ-39933673) is a highly potent, selective and orally active SGLT2 inhibitor (IC50: 1.4 nM) with antihyperglycemic effects. TA-1887 can be used in the research of diabetes.
|
-
- HY-130750
-
-
- HY-13948B
-
|
Angiotensin II human TFA
Angiotensin II TFA; Ang II TFA; DRVYIHPF TFA
|
Angiotensin Receptor
Apoptosis
|
Cancer
Endocrinology
Cardiovascular Disease
|
|
Angiotensin II human (Angiotensin II) TFA is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. Angiotensin II human TFA plays a central role in regulating human blood pressure, which is mainly mediated by interactions between Angiotensin II and the G-protein-coupled receptors (GPCRs) Angiotensin II type 1 receptor (AT1R) and Angiotensin II type 2 receptor (AT2R). Angiotensin II human TFA stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. Angiotensin II human TFA induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. Angiotensin II human TFA also induces apoptosis. Angiotensin II human TFA induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway.
|
-
- HY-13948A
-
|
Angiotensin II human acetate
Angiotensin II acetate; Ang II acetate; DRVYIHPF acetate
|
Angiotensin Receptor
Apoptosis
|
Cancer
Endocrinology
Cardiovascular Disease
|
|
Angiotensin II human (Angiotensin II) acetate is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. Angiotensin II human acetate plays a central role in regulating human blood pressure, which is mainly mediated by interactions between Angiotensin II and the G-protein-coupled receptors (GPCRs) Angiotensin II type 1 receptor (AT1R) and Angiotensin II type 2 receptor (AT2R). Angiotensin II human acetate stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. Angiotensin II human acetate induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. Angiotensin II human acetate also induces apoptosis. Angiotensin II human acetate induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway.
|
-
- HY-N2531
-
|
Notoginsenoside Fc
|
Autophagy
|
Cardiovascular Disease
|
|
Notoginsenoside Fc, a protopanaxadiol- (PPD-) type saponin isolated from the leaves of Panax notoginseng, effectively counteracts platelet aggregation. Notoginsenoside Fc can accelerate reendothelialization following vascular injury in diabetic rats by promoting autophagy.
|
-
- HY-B0614B
-
|
Mafenide hydrochloride
|
Bacterial
Antibiotic
|
Infection
|
|
Mafenide hydrochloride is an effective sulfonamide-type antimicrobial agent used for burn wounds. Mafenide hydrochloride shows activity against both Gram-positive and Gram-negative organisms, including Pseudomonas aeruginosa, via inhibition of nucleotide synthesis.
|
-
- HY-N3942
-
|
Glabranine
|
HIV
Influenza Virus
|
Infection
|
|
Glabranine, an flavonoid, is isolated from Tephrosia s.p, exerts a inhibitory effect in vitro on the dengue virus.
Glabranine forms interaction with the soluble ectodomain of DENV type 2 (DENV2) E protein.
|
-
- HY-10468
-
|
NM107
2'-C-Methylcytidine; NM-107
|
HCV
|
Infection
|
|
NM107 (2'-C-Methylcytidine) is an nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase, the EC50 of NM107 in the wild-type replicon cells is 1.85 μM.
|
-
- HY-123377
-
|
Fotagliptin
|
Dipeptidyl Peptidase
|
Metabolic Disease
|
|
Fotagliptin is a Dipeptidyl Peptidase IV (DPP-4) inhibitor (IC50=2.27 nM). Fotagliptin displays great security in rat and dog. Fotagliptin can be used for Type 2 diabetes mellitus research.
|
-
- HY-19437
-
|
Bimolane
AT-1727
|
Topoisomerase
|
Cancer
|
|
Bimolane (AT-1727), a human topoisomerase II inhibitor, can be used as an anti-neoplastic agent and for the research of psoriasis. Bimolane shows leukemogenic activity and induces multiple types of chromosomal aberrations in human lymphocytes.
|
-
- HY-14728
-
|
Aleglitazar
R1439; RO0728804
|
PPAR
|
Metabolic Disease
|
|
Aleglitazar (R1439) is a potent dual PPARα/γ agonist, with IC50s of 38 nM and 19 nM for human PPARa and PPARγ, respectively. Aleglitazar can be used for the research of type II diabetes.
|
-
- HY-100320
-
|
AVE5688
|
Others
|
Metabolic Disease
|
|
AVE5688 is an inhibitor of glycogen phosphorylase (GP), with IC50s of 430 nM and 915 nM and Kds of 170 nM and 530 nM for rabbit muscle glycogen phosphorylase (rmGPb and rmGPa, respectively); AVE5688 can be used for the research of type 2 diabetes.
|
-
- HY-B0614A
-
|
Mafenide Acetate
|
Bacterial
Antibiotic
|
Infection
|
|
Mafenide Acetate is an effective sulfonamide-type antimicrobial agent used for burn wounds. Mafenide Acetate shows activity against both Gram-positive and Gram-negative organisms, including Pseudomonas aeruginosa, via inhibition of nucleotide synthesis.
|
-
- HY-N10791
-
|
Neobritannilactone B
|
Others
|
Infection
|
|
Neobritannilactone B, a sesquiterpene, can be isolated from the chloroform fraction of the I. britannica. Neobritannilactone B is cytotoxic. Other extracts of I. britannica are also Dihydrofolate reductase (DHFR) inhibitors, which inhibit Shigella dysenteriae type 1.
|
-
- HY-B0614
-
|
Mafenide
|
Bacterial
Antibiotic
|
Infection
|
|
Mafenide is an effective sulfonamide-type antimicrobial agent used for burn wounds. Mafenide shows activity against both Gram-positive and Gram-negative organisms, including Pseudomonas aeruginosa, via inhibition of nucleotide synthesis.
|
-
- HY-132217
-
-
- HY-P2319A
-
-
- HY-B0523
-
|
Anagrelide
|
Phosphodiesterase (PDE)
|
Cancer
Cardiovascular Disease
|
|
Anagrelide, an inhibitor of phosphodiesterase type III (PDEIII) (IC50=36 nM), inhibits platelet production. Anagrelide, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide plays in the antithrombopoietic action. The platelet-lowering agent.
|
-
- HY-114192
-
|
TGFβRI-IN-1
|
TGF-β Receptor
|
Cancer
|
|
TGFβRI-IN-1 is an oral active and selective TGFβ receptor type I (TGFβRI) kinase inhibitor, with IC50 values of 2 nM and 7.6 μM for TGFβRI and TGFβRII, respectively .
|
-
- HY-116808B
-
|
TPN729MA
TPN729 maleate
|
Phosphodiesterase (PDE)
|
Neurological Disease
|
|
TPN729MA (TPN729 maleate) is a selective phosphodiesterase type 5 (PDE5) inhibitor with an IC50 value of 2.28 nM. TPN729MA affects erectile function and it can be used for the research of erectile dysfunction.
|
-
- HY-12025
-
|
Serdemetan
JNJ-26854165
|
MDM-2/p53
E1/E2/E3 Enzyme
Apoptosis
|
Cancer
|
|
Serdemetan(JNJ-26854165) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53.
|
-
- HY-146394
-
|
HBV-IN-22
|
HBV
DNA/RNA Synthesis
|
Infection
|
|
HBV-IN-22 (Compound LC5f) is an inhibitor of HBV DNA replication with IC50 values of 0.71 μM and 0.84 μM against wild-type and agent resistant HBV strains, respectively.
|
-
- HY-13223
-
|
Crenolanib
CP-868596
|
FLT3
PDGFR
Autophagy
|
Cancer
|
|
Crenolanib is a potent and selective inhibitor of wild-type and mutant isoforms of the class III receptor tyrosine kinases FLT3 and PDGFRα/β with Kds of 0.74 nM and 2.1 nM/3.2 nM, respectively.
|
-
- HY-P1540
-
-
- HY-P1731A
-
|
Tirzepatide TFA
LY3298176 TFA
|
GCGR
|
Metabolic Disease
|
|
Tirzepatide TFA (LY3298176 TFA) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes.
|
-
- HY-B1837
-
|
Cyfluthrin
|
Sodium Channel
|
Infection
|
|
Cyfluthrin is a type II pyrethroid and has effects on various insects. Cyfluthrin is a modulator of Nav1.8 sodium channels by repetitive stimulation. Cyfluthrin can be applied in agriculture,veterinary, insecticide,pyrethroid and stored product.
|
-
- HY-10572
-
-
- HY-N9327
-
|
3,11,15,23-Tetraoxo-27ξ-lanosta-8,16-dien-26-oic acid
|
Others
|
Inflammation/Immunology
|
|
3,11,15,23-Tetraoxo-27ξ-lanosta-8,16-dien-26-oic acid, a lanostane-type triterpenoid, is isolated from Antrodia camphorate.
|
-
- HY-N7205
-
|
Glaucocalyxin D
|
Others
|
Cancer
|
|
Glaucocalyxin D is a ent-kauranoid-type diterpenoid that can be isolated from Rabdosia japonica. Glaucocalyxin D shows cytotoxicity against various human tumor cell lines. Glaucocalyxin D can be used for cancer research.
|
-
- HY-N3307
-
-
- HY-129138
-
-
- HY-19947
-
|
PF-06291874
Glucagon receptor antagonists-4
|
GCGR
|
Metabolic Disease
|
|
PF-06291874 is a highly potent, non-peptide and orally active glucagon receptor antagonist. PF-06291874 is under the study for type 2 diabetes mellitus (T2DM).
|
-
- HY-145918
-
|
MRT-14
|
Smo
|
Cancer
|
|
MRT-14 is a potent antagonist of Smo. Smo is the major component involved in signal transduction of the Hedgehog (Hh) morphogens. MRT-14 has the potential for the research of several types of cancers linked to abnormal Hh signaling.
|
-
- HY-121381
-
|
Kuraridine
|
Phosphodiesterase (PDE)
|
Others
|
|
Kuraridine is a prenylated flavonol extract from the roots of Sophora flavescens. Kuraridine has an inhibitory effect on cGMP specific phosphodiesterase type 5 (PDE5) (IC50=0.64 μM).
|
-
- HY-101930
-
|
BMS-816336
|
11β-HSD
|
Metabolic Disease
|
|
BMS-816336 is a novel, potent and orally bioavailable inhibitor against human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme with an IC50 of 3.0 nM.
|
-
- HY-P99538
-
|
Ublituximab
LFB-R603; TG-1101; TGTX-1101
|
CD20
|
Cancer
|
|
Ublituximab (LFB-R603; TG-1101; TGTX-1101) is a next-generation, type 1 chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen. Ublituximab has anticancer effects.
|
-
- HY-151450
-
-
- HY-110228
-
-
- HY-B0358
-
-
- HY-119524
-
|
Clofibride
|
Others
|
Metabolic Disease
|
|
Clofibride is an orally active hypolipaemic agent of pchlorophenoxyisobutyric type. Clofibride has weak toxicity and marked hypocholesterolaemic and hypotriglyceridaemic activity. Clofibride is converted into 4-chlorophenoxyisobutyric acid (CPIB) and 4-hydroxy-N-dimethylbutyramide (HMB) in vivo.
|
-
- HY-108534
-
|
PMX464
AW 464
|
TrxR
|
Cancer
Inflammation/Immunology
|
|
PMX464 (AW 464), a thiol-reactive quinol, is the inhibitor of thioredoxin-thioredoxin reductase (Trx/TrxR) system. PMX464 can inhibit NF-κB-mediated proinflammatory activation of human type II alveolar epithelial cells.
|
-
- HY-N10490
-
|
Blestrin D
|
Cholinesterase (ChE)
|
Neurological Disease
|
|
Blestrin D is a potent butyrylcholinesterase (BChE) mixed-type inhibitor with an IC50 value of 8.1 μM. Blestrin D can be isolated from Bletilla striata. Blestrin D can be used for the research of Alzheimer's disease (AD).
|
-
- HY-W011474
-
|
Geranylgeraniol
|
NF-κB
|
Inflammation/Immunology
|
|
Geranylgeraniol is an orally acitve vitamin K2 sub-type, an intermediate of the mevalonate pathway. Geranylgeraniol targets NF-kB signaling pathway and could alleviate LPS-induced microglial inflammation in animal model.
|
-
- HY-N0618
-
|
Sanggenon D
|
Others
|
Inflammation/Immunology
|
|
Sanggenon D is a Diels-Alder-type adduct from Chinese crude agent root bark of mulberry ( Morus alba L.). Sanggenon D possesses antioxidant and inhibits Pancreatic lipase (PL) with the an IC50 of 0.77?μM.
|
-
- HY-114412A
-
-
- HY-125466
-
|
cRIPGBM
|
RIP kinase
Apoptosis
Caspase
|
Cancer
|
|
cRIPGBM, a proapoptotic derivative of RIPGBM, a cell type-selective inducer of apoptosis in GBM cancer stem cells (CSCs) by binding to receptor-interacting protein kinase 2 (RIPK2), with an EC50 of 68 nM in GBM-1 cells.
|
-
- HY-17424S
-
|
Penciclovir-d4
BRL 39123-d4; VSA 671-d4
|
HSV
|
Infection
|
|
Penciclovir-d4 is the deuterium labeled Penciclovir. Penciclovir is reported to be potent against HSV types 1 and 2 with IC50 of 0.04-1.8 μg/mL and 0.06-4.4 μg/mL, respectively[1][2].
|
-
- HY-B1378S
-
-
- HY-B2181
-
|
Bismuth subnitrate
Bismuth(III) oxynitrate
|
Others
|
Others
|
|
Bismuth subnitrate (Bismuth(III) oxynitrate) is a bismuth(III) compound that bears significant medical uses (e.g., as an antidiarrheic agent). Bismuth subnitrate is a simple, readily available and effective catalyst for the Markovnikov-type hydration of terminal acetylenes.
|
-
- HY-B0358A
-
-
- HY-W341625
-
|
Trihexosylceramide (d18:1/12:0)
|
Others
|
Inflammation/Immunology
|
|
Trihexosylceramide (d18:1/12:0) is a type of Trihexosylceramide. In the renal tissue of heterozygous Fabry's disease, the cytoplasm of glomerular epithelial cells appears foamy. Trihexosylceramide accumulated in glomerular epithelial cells as identified by immunostaining.
|
-
- HY-N1513
-
|
Ganoderic acid H
|
AP-1
NF-κB
|
Cancer
|
|
Ganoderic acid H is a lanostane-type triterpene isolated from Ganoderma lucidum. Ganoderic acid H suppresses growth and invasive behavior of breast cancer cells through the inhibition of transcription factors AP-1 and NF-kappaB signaling.
|
-
- HY-119370
-
|
CHMFL-ABL-121
|
Bcr-Abl
Apoptosis
|
Cancer
|
|
CHMFL-ABL-121 is a highly potent type II ABL kinase inhibitor with IC50s of 2 nM and 0.2 nM against purified inactive ABL wt and T315I kinase protein, respectively.
|
-
- HY-W008820S
-
|
Glutaric acid-d6
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Glutaric acid-d6 is the deuterium labeled Glutaric acid. Glutaric acid is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I[1][2][3].
|
-
- HY-B0255
-
-
- HY-N0301
-
|
Thiocolchicoside
|
GABA Receptor
|
Inflammation/Immunology
Neurological Disease
|
|
Thiocolchicoside is a competitive γ-aminobutyric acid type A (GABAA) receptor antagonist and glycine receptor agonist in the central nervous system. Thiocolchicoside is a semisynthetic sulfur derivative of colchicoside. Thiocolchicoside is a muscle relaxant and has anti-inflammatory, and analgesic properties.
|
-
- HY-B0632A
-
|
Diltiazem malate
MK 793
|
Calcium Channel
|
Cardiovascular Disease
|
|
Diltiazem malate is a potent and orally active L-type calcium channel inhibitor. Diltiazem malate shows antihypertensive and antiarrhythmic effects. Diltiazem malate can be used for the research of cardiac arrhythmia, hypertension, and angina pectoris.
|
-
- HY-120088A
-
-
- HY-N3361
-
-
- HY-118861A
-
|
Enclomiphene citrate
(E)-Clomiphene citrate; trans-Clomiphene citrate; Enclomifene citrate
|
Estrogen Receptor/ERR
|
Endocrinology
Metabolic Disease
|
|
Enclomiphene ((E)-Clomiphene) citrate is a potent and orally active non-steroidal estrogen receptor antagonist, with antioestrogenic property. Enclomiphene citrate can be used for the research of ovarian dysfunction, testosterone deficiency, male hypogonadism and type 2 diabetes.
|
-
- HY-124603
-
-
- HY-P1201
-
|
Cyclosomatostatin
|
Somatostatin Receptor
|
Cancer
|
|
Cyclosomatostatin is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells.
|
-
- HY-N1514
-
|
Ganoderenic acid B
|
P-glycoprotein
|
Cancer
|
|
Ganoderenic acid B is a lanostane-type triterpene isolated from Ganoderma lucidum. Ganoderenic acid B exhibits potent reversal effect on ABCB1-mediated multidrug resistance of HepG2/ADM cells to Doxorubicin.
|
-
- HY-N10913
-
-
- HY-132613
-
|
Lumasiran sodium
|
Small Interfering RNA (siRNA)
|
Metabolic Disease
|
|
Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) .
|
-
- HY-113767
-
|
Momordin II
|
Others
|
Metabolic Disease
|
|
Momordin II, an oleanane-type triterpene glycoside, is a ribosome inactivating protein. Momordin II inhibits cell-free protein synthesis, releases adenine from rat liver ribosomes and from DNA, and has no RNase activity.
|
-
- HY-10542A
-
|
(Z)-GW 5074
|
Raf
|
Neurological Disease
|
|
(Z)-GW 5074 is a compound which interacts with both mHTT (mutant huntingtin protein) and LC3, but not but not with the wild-type HTT protein. (Z)-GW 5074 inhibits c-Raf, shows no effect on autophagy, and is effective for neurodegenerative disorder.
|
-
- HY-P99222
-
|
Teplizumab
MGA-031; PRV-031
|
CD3
|
Metabolic Disease
|
|
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes.
|
-
- HY-19889
-
-
- HY-124711
-
|
TBOPP
|
Others
|
Cancer
|
|
TBOPP is a selective inhibitor of DOCK1 with an IC50 of 8.4 μM. TBOPP binds to the DOCK1 DHR-2 domain with high affinity (Kd of 7.1 μM), has anti-tumor activity for broader types of tumors.
|
-
- HY-N9172
-
|
Eupaglehnin C
|
Others
|
Cancer
|
|
Eupaglehnin C is a germacrane-type sesquiterpenoi. Eupaglehnin C can be isolated from the MeOH extract of Eupatorium glehni (Compositae). Eupaglehnin C has cytotoxic activity against HeLa-S3 cancer cell lines.
|
-
- HY-N3395
-
|
Leachianone G
|
HSV
|
Infection
|
|
Leachianone G is an antiviral flavonoid from the root bark of Morus alba L. Leachianone G shows potent antiviral activity against herpes simplex type 1 virus (HSV-1) with an IC50 value of 1.6 μg/mL.
|
-
- HY-P99183
-
|
Abituzumab
EMD 525797; DI17E6
|
Integrin
|
Cancer
|
|
Abituzumab (DI17E6) is a humanised anti-integrin αV monoclonal antibody (IgG2 type). Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer.
|
-
- HY-148610
-
|
LDH-IN-2
|
Others
|
Metabolic Disease
|
|
LDH-IN-2, a salicylic acid derivative, is an inhibitor of glycolate oxidase (GO). LDH-IN-2 decreases oxalate output in hyperoxaluric hepatocytes. LDH-IN-2 can be used for research of primary hyperoxaluria type 1 (PH1).
|
-
- HY-15497
-
|
AZD7687
|
Acyltransferase
|
Metabolic Disease
|
|
AZD7687 is a potent, selective, reversible and orally active diacylglycerol acyltransferase 1 (DGAT1) inhibitor with an IC50 of 80 nM for human DGAT1. AZD7687 can be used for type 2 diabetes mellitus and obesity research.
|
-
- HY-151452
-
-
- HY-B0285
-
-
- HY-128575
-
|
BNC375
|
nAChR
|
Neurological Disease
|
|
BNC375 is a potent, selective, and orally available type I positive allosteric modulator of α7 nAChRs with an EC50 of 1.9 μM. BNC375 exhibits good CNS-agent like properties and clinical candidate potential. .
|
-
- HY-111613
-
|
Pinaverium bromide
|
Calcium Channel
|
Others
|
|
Pinaverium bromide is an L-type calcium channel blocker with selectivity for the gastrointestinal tract, effectively relieves pain, diarrhea and intestinal discomfort, provides good therapeutic efficacies without significant adverse effects on Irritable bowel syndrome (IBS) patients.
|
-
- HY-105049
-
|
T-91825
PPI-0903M
|
Bacterial
|
Infection
|
|
T-91825 (PPI-0903M), an N-phosphono-type cephalosporin, is the active form of TAK-599. T-91825 is active against both gram-positive and gram-negative bacteria.
|
-
- HY-N7696
-
|
Physalin F
|
Apoptosis
|
Inflammation/Immunology
|
|
Physalin F is a secosteroid with potent anti-inflammatory and immunomodulatory activities. Physalin F induces apoptosis of PBMC, decreasing the spontaneous proliferation and cytokine production caused by Human T-lymphotropic virus type 1 (HTLV-1) infection.
|
-
- HY-B0285A
-
-
- HY-41076
-
-
- HY-N7887
-
-
- HY-114412
-
-
- HY-103309S
-
|
ML218-d9
|
Calcium Channel
|
Neurological Disease
|
|
ML218-d9 is the deuterium labeled ML218. ML218 is a potent, selective and orally active T-type Ca2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC50s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier[1].
|
-
- HY-136065
-
|
bpV(phen)
|
PTEN
Phosphatase
Parasite
Apoptosis
|
Cancer
Infection
Metabolic Disease
Inflammation/Immunology
|
|
bpV(phen), a insulin-mimetic agent, is a potent protein tyrosine phosphatase (PTP) and PTEN inhibitor with IC50s of 38 nM, 343 nM and 920 nM for PTEN, PTP-β and PTP-1B, respectively. bpV(phen) inhibits proliferation of the protozoan parasite Leishmania in vitro. bpV(phen) strongly induces the secretion of a large number of chemokines and pro-inflammatory cytokines, and it activates a Th1-type pathway (IL-12, IFNγ). bpV(phen) can also induce cell apoptosis, and has anti-angiogenic and anti-tumor activity.
|
-
- HY-B0517S
-
|
Mepivacaine-d3
|
Sodium Channel
|
Neurological Disease
|
|
Mepivacaine-d3 is the deuterium labeled Mepivacaine. Mepivacaine is an amide-type local anesthetic agent. Mepivacaine binds to specific voltage-gated sodium ion channels in neuronal cell membranes, which inhibits both sodium influx and membrane depolarization[1][2].
|
-
- HY-144105
-
|
NSC405640
|
MDM-2/p53
|
Cancer
|
|
NSC405640 is a potent inhibitor of the MDM2-p53 interaction. NSC405640 rescues structural p53 mutations. NSC405640 selectively inhibits the growth of cell lines with wild-type p53.
|
-
- HY-147988
-
-
- HY-136173
-
|
Batoprotafib
TNO155
|
SHP2
Phosphatase
|
Cancer
|
|
Batoprotafib (TNO155) is a potent selective and orally active allosteric inhibitor of wild-type SHP2 (IC50=0.011 µM). Batoprotafib has the potential for the study of RTK-dependent malignancies, especially advanced solid tumors.
|
-
- HY-148210
-
|
AMPK activator 9
|
AMPK
|
Metabolic Disease
|
|
AMPK activator 9 (ZM-6) is a potent AMPK (α2β1γ1) activator with an EC50 value of 1.1 µM. AMPK activator 9 has the potential for the research of type 2 diabetes.
|
-
- HY-N2590
-
|
Lupenone
|
Parasite
|
Cancer
Infection
Inflammation/Immunology
|
|
Lupenone, isolated from Musa basjoo, belongs to lupane type triterpenoids. Lupenone shows various pharmacological activities including anti-inflammatory, anti-virus, anti-diabetes, anti-cancer, improving Chagas disease without major toxicity.
|
-
- HY-A0057
-
|
Gabapentin
|
Calcium Channel
|
Neurological Disease
Cancer
|
|
Gabapentin is a potent, orally active P/Q type Ca 2+ channel blocker. Gabapentin inhibits neuronal Ca 2+ influx and reduction of neurotransmitter release. Gabapentin is a GABA analog that can be used to relieve neuropathic pain.
|
-
- HY-P2990
-
|
Enteropeptidase
TMPRSS15
|
Ser/Thr Protease
|
Metabolic Disease
|
|
Enteropeptidase (TMPRSS15), a type II transmembrane serine protease and a physiological activator of trypsinogen. Enteropeptidase is associated with the brush border membrane (BBM) of the enterocytes in the upper small intestine. Trypsinogen is the primary substrate for Enteropeptidase. Enteropeptidase is involved in digestion in humans and animals.
|
-
- HY-15162
-
|
Monomethyl auristatin E
MMAE; SGD-1010; Vedotin
|
Microtubule/Tubulin
ADC Cytotoxin
Apoptosis
|
Cancer
|
|
Monomethyl auristatin E (MMAE; SGD-1010) is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. MMAE is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) to treat several different cancer types.
|
-
- HY-123377A
-
-
- HY-134877
-
|
BAY 2476568
|
EGFR
|
Cancer
|
|
BAY 2476568 is a potent and selective EGFR inhibitor, with IC50s of < 0.2 nM for wild-type EGFR and several mutations (EGFRR ex20insSVD, EGFRR ex20insASV, EGFRR ex20insNPG).
|
-
- HY-151938
-
|
Reverse transcriptase-IN-3
|
HIV
|
Infection
|
|
Reverse transcriptase-IN-3 is a pyrimidine-5-carboxamide derivative, acts as an inhibitor of HIV-1. Reverse transcriptase-IN-3 shows potent activity against the HIV-1 wild-type and mutant strains.
|
-
- HY-117605S
-
-
- HY-129943
-
|
Benzothiohydrazide
|
Bacterial
|
Infection
|
|
Benzothiohydrazide is an analogue of anti–tubercular agent Isoniazid. Benzothiohydrazide exhibits anti–tubercular activity, with MICs of 132 μM and 264 μM for M. tuberculosis wild type (H37Rv) and clinical mutant strains (IC1 and IC2).
|
-
- HY-100164
-
|
SDZ-MKS 492
MKS 492
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
SDZ-MKS 492 (MKS 492) is a selective inhibitor of cyclic GMP-inhibited phosphodiesterase (type III PDE). SDZ-MKS 492 inhibits antigen- or platelet activating factor (PAF)-induced bronchoconstriction and allergic reactions in guinea pigs and rats.
|
-
- HY-B1072A
-
|
D-Phenothrin
(-)-trans-Phenothrin
|
Parasite
|
Infection
|
|
D-Phenothrin ((-)-trans-Phenothrin), an orally active Type II synthetic pyrethroid, is widely used to kill insects, mosquitoes, and human lice. D-Phenothrin is also used in veterinary medicine to control insect pests on animals and protect agricultural crops.
|
-
- HY-A0057A
-
|
Gabapentin hydrochloride
|
Calcium Channel
|
Neurological Disease
Cancer
|
|
Gabapentin hydrochloride is a potent, orally active P/Q type Ca 2+ channel blocker. Gabapentin hydrochloride inhibits neuronal Ca 2+ influx and reduction of neurotransmitter release. Gabapentin hydrochloride is a GABA analog that can be used to relieve neuropathic pain.
|
-
- HY-153113
-
|
Rongliflozin
DJT1116PG
|
SGLT
|
Endocrinology
|
|
Rongliflozin (DJT1116PG) is a selective and orally active inhibitor of sodium-glucose co-transporter-2 (SGLT-2). Rongliflozin can be used for the research of type 2 diabetes mellitus (T2DM).
|
-
- HY-109155
-
|
Paltusotine
CRN00808
|
Somatostatin Receptor
|
Endocrinology
|
|
Paltusotine (CRN00808) is an orally active, nonpeptide selective somatostatin type 2 (SST2) receptor agonist. Paltusotine has the potential for maintaining GH and IGF-1 levels after depot somatostatin receptor ligand therapy.
|
-
- HY-120088
-
|
PF-06446846
|
Ser/Thr Protease
|
Cardiovascular Disease
|
|
PF-06446846 is an orally active proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. PF-06446846 directly and selectively inhibits translation of PCSK9 by stalling the 80S ribosome in the proximity of codon region.
|
-
- HY-N2993
-
|
Polyporenic acid C
|
Apoptosis
|
Cancer
|
|
Polyporenic acid C is a lanostane-type triterpenoid isolated from P. cocos. Polyporenic acid C induces cell apoptosis through the death receptor-mediated apoptotic pathway without the involvement of the mitochondria. Polyporenic acid C is promising agent for lung cancer therapy.
|
-
- HY-P3821
-
|
PRMT5-IN-22
|
Histone Methyltransferase
|
Cancer
|
PRMT5-IN-22 (compound 53) is an inhibitor of protein arginine methyltransferase 5 (PRMT5) with anti-tumor activity. PRMT5 is a type of protein arginine methyltransferase, and is a new anti-tumor target related to epigenetic modification.
|
-
- HY-P3822
-
|
PRMT5-IN-23
|
Histone Methyltransferase
|
Cancer
|
PRMT5-IN-23 (compound 50) is an inhibitor of protein arginine methyltransferase 5 (PRMT5) with anti-tumor activity. PRMT5 is a type of protein arginine methyltransferase, and is a new anti-tumor target related to epigenetic modification.
|
-
- HY-N1034
-
|
12-Oxocalanolide A
(±)-12-Oxocalanolide A
|
HIV
|
Infection
|
|
12-Oxocalanolide A (compound 6) is a potent inhibitor of reverse transcriptase from human immunodeficiency virus type 1 (HIV-1) with an IC50 and EC50 of 2.8 and 12 μM, respectively. 12-Oxocalanolide A is the analogue of Calanolide.
|
-
- HY-B0632S
-
|
Diltiazem-d6
|
Calcium Channel
|
Cardiovascular Disease
|
|
Diltiazem-d6 is the deuterium labeled Diltiazem. Diltiazem is an orally active L-type Ca2+ channel blocker, with antihypertensive and antiarrhythmic effects. Diltiazem can be used for the research of cardiac arrhythmia, hypertension, and angina pectoris[1][2][3].
|
-
- HY-17445
-
|
Muraglitazar
BMS-298585
|
PPAR
|
Metabolic Disease
|
|
Muraglitazar is a PPAR α/γ dual agonist for the research of type 2 diabetes and associated dyslipidemia. Muraglitazar shows potent activity in vitro at human PPARα (EC50 = 320 nM) and PPARγ(EC50 = 110 nM).
|
-
- HY-151255
-
|
CDK8-IN-9
|
CDK
|
Cancer
|
|
CDK8-IN-9 (compound 22) is a potent type II CDK8 inhibitor with an IC50 value of 48.6 nM. CDK8-IN-9 can inhibit tumor growth and is used in colorectal cancer studies.
|
-
- HY-132179
-
-
- HY-148030
-
|
XL01126
|
PROTACs
LRRK2
|
Neurological Disease
|
|
XL01126 is a potent degrader of LRRK2 with DC50s of 14 nM (G2019S LRRK2) and 32 nM (WT LRRK2), respectively. XL01126 can cross blood-brain barrier and be used as a degrader probe in Parkinson’s disease research. XL01126 exerts function of study of non-catalytic and scaffolding functions of LRRK2.
|
-
- HY-141411
-
|
(Rac)-Zevaquenabant
(Rac)-MRI-1867
|
Cannabinoid Receptor
NO Synthase
|
Others
|
|
(Rac)-Zevaquenabant ((Rac)-MRI-1867, compound 6b) is a cannabinoid receptor type 1 (CB1R)/iNOS antagonist, with a Ki of 5.7 nM for CB1R. (Rac)-Zevaquenabant is potential for the research of liver fibrosis.
|
-
- HY-N2589
-
|
Isosaponarin
|
TGF-β Receptor
|
Others
|
|
Isosaponarin is a flavone glycoside isolated from wasabi leaves. Isosaponarin increases collagen synthesis, caused by up-regulated TGF-β type II receptor (TβR-II) and prolyl 4-hydroxylase (P4H) proteins production.
|
-
- HY-W008820S2
-
|
Glutaric acid-d2
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Glutaric acid-d2 is the deuterium labeled Glutaric acid. Glutaric acid, C5 dicarboxylic acid, is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I[1][2][3].
|
-
- HY-112598A
-
|
PF-06815345 hydrochloride
|
Ser/Thr Protease
|
Metabolic Disease
|
|
PF-06815345 hydrochloride is an orally active and potent inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) with an IC50 value of 13.4 μM. PF-06815345 hydrochloride significantly decreases the PCSK9 level in vivo in mouse.
|
-
- HY-120758
-
|
SEL24-B489
|
Pim
FLT3
Apoptosis
|
Cancer
|
SEL24-B489 is a potent, type I, orally active, dual PIM and FLT3-ITD inhibitor, with Kd values of 2 nM for PIM1, 2 nM for PIM2 and 3 nM for PIM3, respectively.
|
-
- HY-111396
-
|
PC58538
|
Bacterial
|
Infection
|
|
PC58538 is a cell division inhibitor, targeting to FtsZ. PC58538 shows moderate antibacterial activity, and inhibits cell division in vegetative cells of wild-type B. subtilis. PC58538 is also known to modulate the rate of GTP hydrolysis.
|
-
- HY-W004284S1
-
-
- HY-112598
-
|
PF-06815345
|
Ser/Thr Protease
|
Metabolic Disease
|
|
PF-06815345 is an orally active and potent inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) with an IC50 value of 13.4 μM. PF-06815345 significantly decreases the PCSK9 level in vivo in mouse.
|
-
- HY-18253S
-
|
Udenafil-d7
|
Phosphodiesterase (PDE)
|
Endocrinology
Others
|
|
Udenafil-d7 is the deuterium labeled Udenafil. Udenafil (DA8159) is a potent, selective and orally active phosphodiesterase type 5 (PDE5) inhibitor. Udenafil also inhibits cGMP hydrolysis and can be used for erectile dysfunction research[1][2].
|
-
- HY-N6697
-
|
Aflatoxin G1
|
Bacterial
Antibiotic
Parasite
|
Cancer
Infection
|
|
Aflatoxin G1 is one type of aflatoxins occuring in nature. It is produced by molds, such as Aspergillus flavus and Aspergillus parasiticus. Aflatoxins are hepatogenic, teratogenic, imunosuppressive, and carcinogenic fungal metabolites found in feeds, nuts, wine-grapes, spices, and other grain crops.
|
-
- HY-A0092
-
|
Trimethadione
3,5,5,-Trimethyloxazolidine-2,4-dione
|
Calcium Channel
|
Neurological Disease
|
|
Trimethadione (3,5,5,-Trimethyloxazolidine-2,4-dione) is an oxazolidinedione anticonvulsant agent widely used against absences seizures. Trimethadione also is a T-type calcium channel blocker which has antihyperalgesic effects.
|
-
- HY-N7757
-
|
Pedunculagin
|
5 alpha Reductase
|
Inflammation/Immunology
|
|
Pedunculagin is a potent 5α-reductase type 1 inhibitor. Pedunculagin inhibits nitric oxide (NO), IL-6, IL-8 production. Pedunculagin decreases the protein expression of 5α-reductase. Pedunculagin shows anti-inflammatory activity.
|
-
- HY-148235
-
|
TP-051
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
TP-051 is a potent FFAR1 agonist with an Ki value of 16 nM for human FFAR1. TP-051 can increase insulin secretion in rat insulinoma cells. TP-051 can be used to research type 2 diabetes.
|
-
- HY-N10640
-
|
Alismanol M
|
FXR
|
Inflammation/Immunology
|
|
Alismanol M is a farnesoid X receptor (FXR) agonist with an EC50 value of 50.25 μM. Alismanol M is a protostane-type triterpenoid that can be isolated from the rhizome of Alisma orientale. Alismanol M can be used for the research of cholestasis and nonalcoholic steatohepatitis.
|
-
- HY-W008820S1
-
|
Glutaric acid-d4
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Glutaric acid-d4 is the deuterium labeled Glutaric acid. Glutaric acid, C5 dicarboxylic acid, is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I[1][2][3].
|
-
- HY-113378S
-
|
3-Hydroxybutyric acid-d4 sodium
β-Hydroxybutyric acid-d4 (sodium)
|
Endogenous Metabolite
|
Metabolic Disease
|
|
3-Hydroxybutyric acid-d4 (sodium) is the deuterium labeled 3-Hydroxybutyric acid. 3-Hydroxybutyric acid (β-Hydroxybutyric acid) is a metabolite that is elevated in type I diabetes. 3-Hydroxybutyric acid can modulate the properties of membrane lipids[1].
|
-
- HY-P1201A
-
|
Cyclosomatostatin TFA
|
Somatostatin Receptor
|
Cancer
|
|
Cyclosomatostatin TFA is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin TFA can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells.
|
-
- HY-114489B
-
-
- HY-15461
-
|
Ertugliflozin
PF-04971729
|
SGLT
|
Metabolic Disease
|
|
Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2. Has the potential for the treatment of type 2 diabetes mellitus.
|
-
- HY-118091A
-
|
Bexlosteride
LY300502
|
Others
|
Cancer
|
|
Bexlosteride (LY300502) is a benzoquinolinone human type I 5α-reductase inhibitor. Bexlosteride shows metabolic inhibitory, antiproliferative, and antisecretory effects in LNCaP human prostatic adenocarcinoma cell cultures. Bexlosteride can be used for the research of prostatic cancer.
|
-
- HY-N6252
-
|
Gypenoside XLVI
|
Others
|
Cancer
|
|
Gypenoside XLVI is one of the major dammarane-type triterpenoid saponins from Gynostamma pentaphallum. Gypenoside XLVI has a tetracyclic triterpene structure and possess potent non-small cell lung carcinoma A549 cell inhibitory activity.
|
-
- HY-132609
-
-
- HY-114489A
-
|
Haemanthamine
|
Apoptosis
Influenza Virus
Parasite
|
Cancer
Infection
Neurological Disease
|
|
Haemanthamine is a crinine-type alkaloid isolated from the Amaryllidaceae plants with potent anticancer activity. Haemanthamine targets ribosomal that inhibits protein biosynthesis during the elongation stage of translation. Haemanthamine has pro-apoptotic, antioxidant, antiviral, antimalarial and anticonvulsant activities.
|
-
- HY-P99226
-
|
Daxdilimab
MEDI7734; VIB7734
|
SARS-CoV
|
Cancer
|
|
Daxdilimab is an anti-ILT7 monoclonal antibody, ILT7 is a cell surface molecule specific to the pDC type of dendritic cells. Daxdilimab can be used in acute lung injury (ALI) in patients with COVID-19 infection research.
|
-
- HY-153609
-
-
- HY-W004284S
-
-
- HY-N1493
-
|
14-Deoxycoleon U
6-Hydroxysalvinolone; 11-Hydroxymontbretol
|
Others
|
Cancer
|
|
14-Deoxycoleon U is a natural abietane-type diterpene. 14-Deoxycoleon U exerts an inhibitory effect on tumor cells proliferation. 14-Deoxycoleon U may be a potent anti-cancerous lead compound for lung cancer research.
|
-
- HY-N3522
-
|
Platycoside E
|
Others
|
Inflammation/Immunology
|
|
Platycoside E is a platycodigenin-type saponin isolated from the root of Platycodon grandiflorum with haemolytic activity and adjuvant potential. Platycoside E promotes the production of the sera OVA-specific IgG2a and IgG2b antibody in the ovalbumin (OVA)-immunized mice.
|
-
- HY-139884
-
|
EGFR-IN-18
|
EGFR
|
Cancer
|
|
EGFR-IN-18 potently inhibits enzymatic activity in L858R/T790M/C797S mutant EGFR (4.9 nM), with a significantly lower activity for wild-type EGFR (47 nM).
|
-
- HY-17404S
-
|
Cilnidipine-d7
FRC-8653-d7
|
Calcium Channel
|
Cardiovascular Disease
|
|
Cilnidipine-d7 is deuterium labeled Cilnidipine. Cilnidipine is a long-acting, second-generation dihydropyridine Ca2+-channel blocker on L and N-type Ca2+ channel[1][2][3][4]. Antihypertensive effects[5].
|
-
- HY-W032013
-
-
- HY-122818
-
|
bpV(phen) trihydrate
|
PTEN
Phosphatase
Parasite
Apoptosis
|
Cancer
Infection
Metabolic Disease
Inflammation/Immunology
|
|
bpV(phen) trihydrate, a insulin-mimetic agent, is a potent protein tyrosine phosphatase (PTP) and PTEN inhibitor with IC50s of 38 nM, 343 nM and 920 nM for PTEN, PTP-β and PTP-1B, respectively. bpV(phen) trihydrate inhibits proliferation of the protozoan parasite Leishmania in vitro. bpV(phen) trihydrate strongly induces the secretion of a large number of chemokines and pro-inflammatory cytokines, and it activates a Th1-type pathway (IL-12, IFNγ). bpV(phen) trihydrate can also induce cell apoptosis, and has anti-angiogenic and anti-tumor activity.
|
-
- HY-N6980
-
|
Licorice glycoside C2
|
HIV
|
Cancer
Infection
|
|
Licorice glycoside C2 is a oleanane-type triterpene oligoglycoside isolated from Glycyrrhiza uralensis. Various biological activities are associated with licorice extracts, such as anti-viral, anti-microbial, antioxidant, anti-inflammatory, anti-ulcer, anti-cancer and anti-HIV effects.
|
-
- HY-139077
-
-
- HY-103235
-
|
NPEC-caged-(S)-AMPA
|
iGluR
|
Neurological Disease
|
|
NPEC- caged-(S)-AMPA, a caged neurotransmitter analog, is a NPEC photoprotecting group caged the (S)-AMPA (HY-100815A) to make caged ligands specific for glutamate receptor sub-types. NPEC- caged-(S)-AMPA selectively activates AMPA receptor.
|
-
- HY-B0317
-
|
Amlodipine
|
Calcium Channel
|
Cancer
Cardiovascular Disease
|
|
Amlodipine, an antianginal agent and an orally active dihydropyridine calcium channel blocker, works by blocking the voltage-dependent L-type calcium channels, thereby inhibiting the initial influx of calcium. Amlodipine can be used for the research of high blood pressure and cancer.
|
-
- HY-B0317C
-
|
Amlodipine mesylate
|
Calcium Channel
|
Cancer
Cardiovascular Disease
|
|
Amlodipine mesylate, an antianginal agent and an orally active dihydropyridine calcium channel blocker, works by blocking the voltage-dependent L-type calcium channels, thereby inhibiting the initial influx of calcium. Amlodipine mesylate can be used for the research of high blood pressure and cancer.
|
-
- HY-19843
-
|
MK-0941
|
Glucokinase
|
Metabolic Disease
|
|
MK-0941 is a potent, orally active and allosteric glucokinase activator, with EC50s of 240 and 65 nM for recombinant human glucokinase in the presence of 2.5 and 10 mM glucose, respectively. MK-0941 has potential in the treatment of type 2 diabetes.
|
-
- HY-12585
-
-
- HY-10285A
-
|
Saxagliptin hydrate
BMS-477118 hydrate
|
Dipeptidyl Peptidase
|
Metabolic Disease
|
|
Saxagliptin hydrate (BMS-477118 hydrate) is a potent, selective, reversible, competitive and orally active dipeptidyl peptidase-4 (DPP-4) (Ki = 0.6-1.3 nM) inhibitor. Saxagliptin hydrate has the peotential for type 2 diabetes mellitus research.
|
-
- HY-W145497
-
|
D-(+)-Sorbose
|
Insulin Receptor
|
Metabolic Disease
|
|
D-(+)-Sorbose, an active enantiomer of D-Sorbose, which inhibits disaccharidase activity and demonstrates suppressive action on postprandial blood levels of glucose and insulin in the rat. D-sorbose acts as a sweetener may contribute to the prevention of lifestyle-related diseases, such as type 2 diabetes mellitus.
|
-
- HY-N5109
-
|
Cheilanthifoline
|
Parasite
|
Infection
|
|
Cheilanthifoline, an alkaloid, is isolated from Corydalis calliantha. Cheilanthifoline exhibits antiplasmodial activities against Plasmodium falciparum, with IC50s of 0.90 μg/mL and 1.22 μg/mL for wild type (TM4) and multidrug resistant (K1) strains, respectively.
|
-
- HY-144623
-
|
Antiviral agent 15
|
SARS-CoV
|
Infection
|
|
Antiviral agent 15 (Compound 15f) is a Clofazimine derivative with antiviral effects. Antiviral agent 15 inhibits both rabies virus and pseudo-typed SARS-CoV-2 with EC50 values of 1.45 μM and 14.6 μM, respectively.
|
-
- HY-10285
-
|
Saxagliptin
BMS-477118
|
Dipeptidyl Peptidase
|
Metabolic Disease
|
|
Saxagliptin (BMS-477118) is a potent, selective, reversible, competitive and orally active dipeptidyl peptidase-4 (DPP-4) (Ki = 0.6-1.3 nM) inhibitor. Saxagliptin has the peotential for type 2 diabetes mellitus research.
|
-
- HY-14655S
-
-
- HY-P1074
-
|
SNX-482
|
Calcium Channel
|
Neurological Disease
|
|
SNX-482, a peptidyl toxin of the spider Hysterocrates gigas, is a potent, high affinity, selective and voltage-dependent R-type CaV2.3 channel blocker with an IC50 of 30 nM. SNX-482 has antinociceptive effect.
|
-
- HY-146560
-
-
- HY-B0285B
-
-
- HY-W010320
-
|
Ethyl maltol
2-Ethyl-3-hydroxy-4H-pyran-4-one
|
Biochemical Assay Reagents
|
Others
|
|
Ethyl maltol (2-Ethyl-3-hydroxy-4H-pyran-4-one), an odor-active (OA) compound, is an important food additive and the main component of a type of incense added to food.
|
-
- HY-16448
-
|
Saxagliptin hydrochloride
BMS-477118 hydrochloride
|
Dipeptidyl Peptidase
|
Metabolic Disease
|
|
Saxagliptin hydrochloride (BMS-477118 hydrochloride) is a potent, selective, reversible, competitive and orally active dipeptidyl peptidase-4 (DPP-4) (Ki = 0.6-1.3 nM) inhibitor. Saxagliptin hydrochloride has the peotential for type 2 diabetes mellitus research.
|
-
- HY-131055
-
|
Mytoxin B
|
ADC Cytotoxin
PI3K
Apoptosis
|
Cancer
|
|
Mytoxin B is an ADC cytotoxin. Mytoxin B is a satratoxin-type trichothecene macrolide and is similar to the effect of LY294002 (HY-10108). Mytoxin B induces cell apoptosis via PI3K/Akt pathway.
|
-
- HY-P3137
-
|
TRV056
|
Angiotensin Receptor
|
Cardiovascular Disease
|
|
TRV056 is a Gq-biased ligand of the angiotensin II receptor type 1 (AT1R). TRV056 is efficacious in stimulating cellular Gq-mediated signaling. TRV056 can be used to develop the Gq-biased AT1R agonists.
|
-
- HY-16755
-
|
Solcitinib
GSK-2586184; GLPG-0778
|
JAK
|
Inflammation/Immunology
|
|
Solcitinib is an orally active, competitive, potent, selective JAK1 inhibitor, with an IC50 of 9.8 nM, and 11-, 55- and 23-fold selectivity over JAK2, JAK3 and TYK2, respectively; Solcitinib is used in the research of moderate-to-severe plaque-type psoriasis.
|
-
- HY-103247
-
|
EMD 66684
|
Angiotensin Receptor
|
Cardiovascular Disease
|
|
EMD 66684 is an antagonist of Angiotensin II Type 1 (AT1) receptor. EMD 66684 shows potent binding affinities for the AT1 subtype Ang II receptor with an IC50 value of 0.7 nM. EMD 66684 also serves as an antiischemic cytoprotectant -.
|
-
- HY-N7433
-
-
- HY-121835
-
|
GLP-1R agonist 2
|
GCGR
|
Metabolic Disease
|
|
GLP-1R agonist 2 (compound 2) is a potent GLP-1R agonist. GLP-1R agonist 2 has the potential for the research of metabolic diseases like Type2 Diabetes and Obesity.
|
-
- HY-10432A
-
|
A 83-01 sodium
|
TGF-β Receptor
|
Cancer
|
|
A 83-01 sodium is a potent inhibitor of TGF-β type I receptor ALK5 kinase, ALK4 and ALK7, with IC50s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively.
|
-
- HY-P99192
-
|
Emibetuzumab
LY2875358
|
c-Met/HGFR
|
Cancer
|
|
Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer.
|
-
- HY-148687
-
|
SPC5001
|
Others
|
Cardiovascular Disease
|
|
SPC5001 is a locked nucleic acid (LNA)-modifed antisense oligonucleotide (ASO) complementary to human PCSK9 (proprotein convertase subtilisin/kexin type 9) mRNA. SPC5001 can be used for the research of hypercholesterolemia. SPC5001 sequence: 5′-TGmCTACAAAACmCmCA-3′.
|
-
- HY-130136
-
|
TMPRSS6-IN-1
|
Ser/Thr Protease
|
Others
|
|
TMPRSS6-IN-1 (compound 8) is a potent inhibitor of TMPRSS6 (Matriptase-2), belonging to TTSPs (transmembrane serine protease). TMPRSS6, is a type II TTSP, the genetic reduction of which will improve symptoms of hemochromatosis and beta thalassemia in mice.
|
-
- HY-15408
-
|
Trelagliptin
SYR-472
|
Dipeptidyl Peptidase
|
Metabolic Disease
|
|
Trelagliptin (SYR-472) is a potent, orally active and highly selective DPP-4 inhibitor with an IC50 of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM).
|
-
- HY-B1464
-
|
Cetylpyridinium chloride
|
Bacterial
HBV
|
Infection
Inflammation/Immunology
|
|
Cetylpyridinium chloride, a cationic quaternary ammonium compound, is an anti-bacterial agent with broad-spectrum activity. Cetylpyridinium chloride is an effective anti-HBV capsid assembly inhibitor with an IC50 of 2.5 μM. Cetylpyridinium chloride is used in pesticides and various types of mouthwashes, and other personal care products.
|
-
- HY-P2910
-
|
Galactose oxidase
GOase
|
Endogenous Metabolite
|
Others
|
|
Galactose oxidase (GOase) from fungus is often used in biochemical studies. Galactose oxidase is a type II copper metalloenzyme, and it containing a single polypeptide. Galactose oxidase catalyzes two-electron oxidation of primary alcohols to their corresponding aldehydes, coupling with the reduction of dioxygen to hydrogen peroxide.
|
-
- HY-P0190
-
|
Iberiotoxin
|
Potassium Channel
|
Cardiovascular Disease
|
|
Iberiotoxin is a toxin isolated from Buthus tamulus scorpion venom. Iberiotoxin is a selective high conductance high conductance Ca 2+-activated K + channel inhibitor with a Kd of ~1 nM. Iberiotoxin does not block other types of voltage-dependent ion channels.
|
-
- HY-119691
-
|
Alamifovir
LY582563; MCC-478
|
HBV
|
Infection
|
|
Alamifovir (LY582563; MCC-478), a purine nucleotide analogue proagent, shows potent activity against wild type and lamivudine resistant hepatitis B virus (HBV). Alamifovir has high activity against HBV replication and sustained antiviral effect.
|
-
- HY-114334
-
|
Glutaminase-IN-1
CB839 derivative
|
Glutaminase
|
Cancer
|
|
Glutaminase-IN-1 (CB839 derivative), a CB839 derivative, is an allosteric inhibitor of 1,3,4-selenadiazole-containing kidney-type glutaminase (KGA), with an IC50 of 1 nM. Glutaminase-IN-1 (CB839 derivative) shows improved cellular uptake and antitumor activity.
|
-
- HY-P1753
-
|
VIR-165
|
HIV
|
Infection
|
|
VIR-165 is a modified form of virus inhibitory peptide (VIRIP) that binds the fusion peptide of the gp41 subunit and prevents its insertion into the target membrane. VIRIP inhibits a wide variety of human immunodeficiency virus type 1 (HIV-1) strains.
|
-
- HY-13459
-
|
PF-5274857
|
Smo
|
Cancer
|
|
PF-5274857 is a potent, selective, orally active and brain-penetrant antagonist of Smo, with an IC50 of 5.8 nM and Ki of 4.6 nM. PF-5274857 has potential for research of tumor types including brain tumors and brain metastasis driven by an activated Hh pathway.
|
-
- HY-130994
-
|
Aeruginosin 865
|
NF-κB
ADC Cytotoxin
|
Cancer
Inflammation/Immunology
|
|
Aeruginosin 865, isolated from terrestrial cyanobacterium Nostoc sp. Lukešová 30/93, is the first aeruginosin-type peptide containing both a fatty acid and a carbohydrate moiety. Aeruginosin 865 inhibits translocation of NF-kB to the nucleus. Aeruginosin 865 has anti-inflammatory effect
|
-
- HY-125443
-
|
Lucialdehyde A
|
Others
|
Cancer
|
|
Lucialdehydes A is a lanostante-type triterpene aldehydes, isolated from the fruiting bodies of Ganoderma lucidum. Lucialdehydes A shows cytotoxic effects on tumor cells, including Lewis lung carcinoma (LLC), T-47D, Sarcoma 180, and Meth-A tumor cell lines.
|
-
- HY-N10486
-
|
BChE-IN-10
|
Cholinesterase (ChE)
|
Neurological Disease
|
|
BChE-IN-10 (compound 6) is a potent butyrylcholinesterase (BChE) mixed-type inhibitor with an IC50 value of 6.4 μM. BChE-IN-10 can be isolated from Bletilla striata. BChE-IN-10 can be used for the research of Alzheimer's disease (AD).
|
-
- HY-B0317A
-
|
Amlodipine maleate
|
Calcium Channel
|
Cancer
Cardiovascular Disease
|
|
Amlodipine maleate is a dihydropyridine calcium channel blocker, acts as an orally active antianginal agent. Amlodipine maleate blocks the voltage-dependent L-type calcium channels, thereby inhibiting the initial influx of calcium. Amlodipine maleate can be used for the research of high blood pressure and cancer.
|
-
- HY-123956
-
|
HG-12-6
|
IRAK
|
Inflammation/Immunology
|
|
HG-12-6 is a type II inhibitor of IRAK4. HG-12-6 shows preferential binding to unphosphorylated inactive IRAK4 with an IC50 of 165 nM. HG-12-6 can modulate IRAK4 activity in autoimmunity and inflammation.
|
-
- HY-103021
-
|
LY3200882
|
TGF-β Receptor
|
Cancer
Inflammation/Immunology
|
|
LY3200882 is a potent, highly selective, ATP-competitive and orally active TGF-β receptor type 1 (ALK5) inhibitor with an IC50 of 38.2 nM. LY3200882 inhibits various pro-tumorigenic activities and is also used as an immune modulatory agent.
|
-
- HY-13459A
-
|
PF-5274857 hydrochloride
|
Smo
|
Cancer
|
|
PF-5274857 hydrochloride is a potent, selective, orally active and brain-penetrant antagonist of Smo, with an IC50 of 5.8 nM and Ki of 4.6 nM. PF-5274857 hydrochloride has potential for research of tumor types including brain tumors and brain metastasis driven by an activated Hh pathway.
|
-
- HY-N10959
-
|
4,15-Isoatriplicolide methylacrylate
|
Others
|
Cancer
|
|
4,15-Isoatriplicolide methylacrylate is a germacrane-type sesquiterpene lactone. 4,15-Isoatriplicolide methylacrylate also is a cytotoxic agent. 4,15-Isoatriplicolide methylacrylate has cytotoxic activity for MCF-7 human breast cancer cell line.
|
-
- HY-108022
-
|
Azemiglitazone
MSDC-0602
|
Mitochondrial Metabolism
|
Metabolic Disease
|
|
Azemiglitazone (MSDC-0602), a PPARγ-sparing thiazolidinedione (TZD), interacts with the mitochondrial pyruvate carrier (MPC) and inhibits its activity and has the potential for type 2 diabetes study with reducing risk of PPARγ-mediated side effects.
|
-
- HY-114308
-
|
SGL5213
|
SGLT
|
Metabolic Disease
|
|
SGL5213 is a potent, oral active and low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor, with IC50 values of 29 nM and 20 nM for hSGLT1 and hSGLT2, respectively. SGL5213 has potential to treat type 2 diabetes treatment.
|
-
- HY-B0233
-
|
Isradipine
PN 200-110
|
Calcium Channel
Autophagy
|
Neurological Disease
Cardiovascular Disease
|
|
Isradipine (PN 200-110) is an orally active L-type calcium channel blocker. Isradipine, as a powerful peripheral vasodilator, is a dihydropyridine calcium antagonist with selective actions on the heart as well as the peripheral circulation. Isradipine is a potentially viable neuroprotective agent for Parkinson's disease.
|
-
- HY-N1638
-
|
1-Methyl-2-undecyl-4(1H)-quinolone
|
Monoamine Oxidase
|
Neurological Disease
|
|
1-Methyl-2-undecyl-4(1H)-quinolone is a potent, irreversible and selective inhibitor of type B monoamine oxidase (MAO-B). 1-Methyl-2-undecyl-4(1H)-quinolone shows a selective inhibition of MAO-B activity with the IC50 and Ki values of 15.3 μM and 9.91 μM, respectively, but did not inhibit type A MAO (MAO-A) activity. Methyl-2-undecyl-4(1H)-quinolone, as a quinolone alkaloid, is isolated from fresh leaves and fruits of Evodia rutaecarpa HOOK. f. et THOMS.
|
-
- HY-N2920
-
|
β-Amyrenonol
11-Oxo-β-amyrin
|
Cytochrome P450
|
Cancer
Inflammation/Immunology
|
|
β-Amyrenonol (11-Oxo-β-amyrin), an oleanolic-type triterpenoid in licorice roots, is a precursor of Glycyrrhetinic acid. β-Amyrenonol has anti-proliferative and anti-inflammatory activities, and β-Amyrenonol could function as the skeleton for the synthesis of many triterpenoids.
|
-
- HY-101329
-
|
Anthracene-9-carboxylic acid
9-Anthracenecarboxylic acid
|
Chloride Channel
|
Others
|
|
Anthracene-9-carboxylic acid (9-Anthracenecarboxylic acid) is an anthracene derivative traditionally used to block and identify Ca 2+-activated Cl - currents (CaCCs) in various cell types, like diverse smooth muscle cells, epithelial cells and salivary gland cells.
|
-
- HY-12071G
-
|
LDN193189
DM-3189
|
TGF-β Receptor
|
Cancer
|
|
LDN193189 (DM-3189) (GMP) is LDN193189 (HY-12071) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. LDN193189 is selective BMP type I receptor inhibitor.
|
-
- HY-12436
-
|
NTRC-824
|
Neurotensin Receptor
|
Neurological Disease
|
|
NTRC-824 (Compound 5) is a potent, selective and neurotensin-like nonpeptide neurotensin receptor type 2 (NTS2) antagonist with an IC50 of 38 nM and a Ki of 202 nM. NTRC-824 is >150-fold selectivity for NTS2 over NTS1 (Ki >30 μM).
|
-
- HY-113377A
-
|
L-Glyceric acid sodium
|
Endogenous Metabolite
|
Metabolic Disease
|
|
L-Glyceric acid sodium is a mainly urinary metabolite accumulating in rare inherited metabolic disease L-glyceric aciduria. L-Glyceric acid sodium can be used to diagnose primary hyperoxaluria type 2 (PH2). L-Glyceric acid sodium excretion to distinguish PH1 from PH2.
|
-
- HY-W010452S
-
|
3-Hydroxybutyric acid-d2 sodium
β-Hydroxybutyric acid-d2 sodium
|
Endogenous Metabolite
|
Metabolic Disease
|
|
3-Hydroxybutyric acid-d2 (sodium) is the deuterium labeled 3-Hydroxybutyric acid sodium[1]. 3-Hydroxybutyric acid sodium (β-Hydroxybutyric acid sodium) is a metabolite that is elevated in type I diabetes. 3-Hydroxybutyric acid sodium can modulate the properties of membrane lipids[2].
|
-
- HY-16743
-
|
Ibiglustat
Venglustat; SAR402671; GZ402671
|
Glucosylceramide Synthase (GCS)
|
Metabolic Disease
|
|
Ibiglustat (Venglustat) is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease.
|
-
- HY-W040127
-
-
- HY-B1448A
-
|
Benidipine
KW-3049 free base
|
Apoptosis
Calcium Channel
|
Cardiovascular Disease
|
|
Benidipine is a potent and orally active calcium channel antagonist. Benidipine shows anti-apoptosis effects in ischaemic/reperfused myocardial cells. Benidipine increases the activity of endothelial cell-type nitric oxide synthase and improves coronary circulation in hypertensive rats.
|
-
- HY-13213
-
-
- HY-15408A
-
|
Trelagliptin succinate
SYR-472 succinate
|
Dipeptidyl Peptidase
|
Metabolic Disease
|
|
Trelagliptin (SYR-472) succinate is a potent, orally active and highly selective DPP-4 inhibitor with an IC50 of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM).
|
-
- HY-13955S1
-
-
- HY-145411
-
|
PEG2000-C-DMG
|
Liposome
|
Endocrinology
|
|
PEG2000-C-DMG, a pegylated lipid, can be used for the preparation of Onpattro. Onpattro, a hepatically directed investigational RNAi therapeutic agent, harnesses this process to reduce the production of mutant and wild-type transthyretin by targeting the 3′ untranslated region of transthyretin mRNA.
|
-
- HY-103682A
-
|
PF-06726304 acetate
|
Histone Methyltransferase
|
Cancer
|
|
PF-06726304 acetate is a potent and selective EZH2 inhibitor. PF-06726304 acetate inhibits wild-type and Y641N mutant EZH2 with Kis of 0.7 and 3.0 nM, respectively. PF-06726304 acetate displays robust antitumor growth activity.
|
-
- HY-112233
-
|
O-304
|
AMPK
|
Metabolic Disease
Cardiovascular Disease
|
|
O-304 is a first-in-class, orally available pan-AMPK activator, which increases AMPK activity by suppressing the dephosphorylation of pAMPK. O-304 exhibits a great potential as a agent to treat type 2 diabetes (T2D) and associated cardiovascular complications .
|
-
- HY-135815
-
|
Mobocertinib
TAK-788; AP32788
|
EGFR
|
Cancer
|
|
Mobocertinib (TAK-788) is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib can be used in NSCLC research.
|
-
- HY-113377
-
|
L-Glyceric acid
|
Endogenous Metabolite
|
Metabolic Disease
|
|
L-Glyceric acid is a mainly urinary metabolite accumulating in rare inherited metabolic disease L-glyceric aciduria. L-Glyceric acid can be used to diagnose primary hyperoxaluria type 2 (PH2). L-Glyceric acid excretion to distinguish PH1 from PH2.
|
-
- HY-113603
-
|
Tildacerfont
|
CRFR
|
Cancer
|
|
Tildacerfont is a potent and orally active corticotrophin-releasing factor type 1 (CRF1) receptort antagonis. Tildacerfont effectively reduces adrenocorticotropic hormone (ACTH) and adrenal androgen levels. Tildacerfont has favourable safety profile. Tildacerfont can be used for researching congenital adrenal hyperplasia.
|
-
- HY-103682
-
|
PF-06726304
|
Histone Methyltransferase
|
Cancer
|
|
PF-06726304 is a potent and selective EZH2 inhibitor. PF-06726304 inhibits wild-type and Y641N mutant EZH2 with Kis of 0.7 and 3.0 nM, respectively. PF-06726304 displays robust antitumor growth activity.
|
-
- HY-135815B
-
|
Mobocertinib mesylate
TAK-788 mesylate; AP32788 mesylate
|
EGFR
|
Cancer
|
|
Mobocertinib (TAK-788) mesylate is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib mesylate potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib mesylate can be used in NSCLC research.
|
-
- HY-N1622
-
|
1-Dehydroxy-23-deoxojessic acid
|
Others
|
Cancer
|
|
1-Dehydroxy-23-deoxojessic acid (compound 10) is a cycloartane-type triterpene. 1-Dehydroxy-23-deoxojessic acid exhibits cytotoxicity against murine colon 26-L5 carcinoma cells, with an EC50 of 62.38 μM.
|
-
- HY-P1840
-
-
- HY-128849
-
|
Eprodisate
|
Others
|
Inflammation/Immunology
|
|
Eprodisate is a new compound designed to interfere with interactions between amyloidogenic proteins and glycosaminoglycans and thereby inhibit polymerization of amyloid fibrils and deposition of the fibrils in tissues.
Eprodisate slow the progression of AA amyloidosis-related renal disease |
